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SUMMARY
Perfusion of the rat isolated small intestine via the mesenteric artery liberates a 
hypotensive oxytocic principle (Gaddum’s substance R) which is detectable in 
perfusate after 30 min and is present in samples collected 8 hours later. The 
oxytocic activity of substance R is lost after boiling, but is unaffected by treatment 
with thioglycolate. Furthermore, atropine, methysergide and indomethacin failed to 
antagonize uterine contractions to substance R. The pharmacological properties of 
substance R were compared to those of an oxytocic tissue kallikrein. Urinary 
kallikrein and substance R liberate a kinin from kininogen and share other 
pharmacological characteristics. The oxytocic and kininogenase properties of both 
substance R and urinary kallikrein are inhibited by Trasylol. In contrast, SBTI 
selectively inhibited the oxytocic and kininogenase activities of substance R, but not 
those of urinary kallikrein. D-Arg-[Hyp3,Thi5>8,D-Phe7]-bradykinin, a selective BK2 
bradykinin receptor antagonist inhibited the oxytocic responses of substance R and 
urinary kallikrein. Gel filtration of substance R resolved a single peak of oxytocic 
and kininogenase activities with an estimated molecular mass of 40 kDa which was 
confirmed by SDS-PAGE analysis. A specific radioimmunoassay clearly demonstr­
ated that substance R shares immunological identity with rat tissue kallikrein. 
Western blot analysis of substance R revealed a single band with a molecular mass 
of 39 kDa. It is concluded that substance R is a tissue kallikrein which may be 
distinguished from urinary and other rat tissue kallikreins by its susceptibility to 
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Throughout his career Gaddum maintained an interest in naturally-occuring 
substances and was responsible for a number of important discoveries in the study 
of neurotransmitters and autacoids and some of his first publications were concerned 
with their measurement (see Feldberg, 1967). In 1931, together with U.S. von Euler, 
Gaddum showed that extracts of brain and intestine contained a principle which 
stimulated smooth muscle (von Euler & Gaddum, 1931). This was identified as a 
polypeptide and named substance P. Substance P has since been demonstrated to be 
a neurotransmitter in peptidergic neurones with important central and peripheral 
actions (see Pemow, 1983). Gaddum and Feldberg (1934) showed that acetylcholine 
was the neurotransmitter at ganglionic synapses. Throughout the early 1950’s the 
research carried out by Gaddum and his co-workers led to a fundemental 
understanding of the distribution and function of 5-hydroxytryptamine (5-HT) in the 
brain (see Feldberg, 1967).
Gaddum also had an enormous impact on the development of modem techniques of 
bioassay. He applied his interest in mathematics and statistics to the conventional 
methods of pharmacological research and designed the principles of quantitative 
bioassay. This work was instrumental in the acceptance of a mathematical approach 
with the result that pharmacology became a quantitative science in its own right. 
One of the many techniques which Gaddum refined or introduced was that of 
superfusion. In 1953 he published a method and an apparatus for its application in 
what has become a much cited paper entitled The Technique o f Superfusion 
(Gaddum, 1953). In addition to his refinements and innovations of experimental 
bioassay techniques, Gaddum invented a number of pieces of equipment and utilised 
several unusual tissue preparations in his bioassays. Together with his textbook 
simply entitled Pharmacology, which was first published in 1940 and continues to 
be updated and reprinted, Gaddum’s experimental work and the application of his 
approach has had a lasting influence on the discipline of pharmacology.
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1.1 SUPERFUSION
The Oxford English Dictionary (O.E.D.) (1989) gives several definitions of 
superfusion, but in medical terms it is defined thus:
The technique of causing a stream of liquid to run over the surface of a piece of suspended tissue, 
keeping it viable and allowing the interchange of substances between it and the fluid to be observed.
The Dictionary credits Gaddum with its first use, quoting from his 1953 paper The 
Technique o f Superfusion,
A piece of tissue may be suspended in air and kept in good condition by a stream of a suitable 
solution running over its surface... This technique may be called superfiision, since the fluid runs 
over the tissue, by analogy with perfusion, in which the fluid runs through the tissue.
Although this was the first time that the term superfusion had been used to describe 
the technique, it was not the first time that the technique itself had been used. 
Gaddum acknowleged this fact himself, but the O.E.D. omits his reference to 
Finkleman’s experiments (Finkleman, 1930) in the above quotation.
1.2 THE DEVELOPMENT OF THE TECHNIQUE OF SUPERFUSION
Experiments where fluid from an electrically-stimulated nerve or muscle was 
utilised to prove the transmitter theory of nerve action required a significant 
reappraisal of modifications to the classical technique of Magnus (1904). The 
technique of superfusion was first used in 1930 by Finkleman in experiments 
demonstrating the release of a substance from one tissue to act on a second tissue, 
so-called “humoral transferance”. However, similar experiments had been used 
before to show the phenomenon of humoral transferance of vagusstoff and 
acceleranstoff between frog and later mammalian hearts. Loewi (1921) took the 
fluid from a frog heart that had been electrically stimulated by the vagus, and stored 
it. When this fluid was reapplied to the heart in an unstimulated state Loewi found 
that a decrease in its activity was seen. He concluded that stimulation of the vagus 
resulted in the generation of a humoral factor which when transfered back to the
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unstimulated heart inhibited The inhibitory substance was named vagusstoff which 
was later identified as acetylcholine. Loewi’s observations were found by some to 
be unrepeatable (see Bain, 1932a) and controversy raged for several years (see 
Macintosh, 1986) before an elegant modification was made to the method by ten 
Cate (1924), where perfusion fluid from a stimulated heart passed directly to the 
second, unstimulated, heart and humoral transferance of Loewi’s vagusstoff was 
demonstrated conclusively.
Jendrassik (1924) applied the effluent from stimulated perfused rabbit hearts to 
isolated intestine. However, he too collected the perfusate before adding it to the 
conventional isolated intestinal preparation.
In 1930 Finkleman described experiments which showed that inhibition of the rabbit 
isolated duodenum occured after stimulation of the sympathetic innervation of the 
mesentery. Use of conventional gut bath techniques did not allow Finkleman to 
prove that the inhibition was due to the release of a humoral factor, there being too 
much dilution of the inhibitory substance to demonstrate its activity on a second 
duodenum preparation. In solving this problem Finkleman developed a technique 
which used the minimum amount of fluid possible to prevent dilution of the 
inhibitory factor. Finkleman suspended two lengths of duodenum in a warmed, 
moist chamber and superfused them in series with Ringer’s solution. Thus the fluid 
passed directly from the first, stimulated length of gut to the second test piece of 
gut. Hence, Finkleman was able to demonstrate the humoral transferance of the 
inhibitory substance which he concluded was of an “adrenaline-like character”.
A method based on that devised by ten Cate (1924) was soon utilised in conjunction 
with superfusion to demonstrate the release and action of vagus substance on tissues 
other than the heart. Bain (1932a) showed that vagal stimulation of one frog heart 
released vagus substance which passed directly to and inhibited a second heart. Bain 
modified his apparatus to show that when the fluid perfusing a stimulated heart 
flowed over a length of frog stomach muscle, this contracted. This was the first use 
of superfusion to demonstrate the action of a substance released from one tissue on
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a second, different preparation, a technique which has resulted in a number of 
important discoveries in recent years. Bain (1932b) used the technique of 
superfusion succesfully a second time to demonstrate the release and humoral 
transmission of neurotransmitter from the dog tongue.
Gaddum himself used the superfusion technique prior to 1953 to show the action of 
a substance named sympathin on hen’s caecum foil wing its release from the 
perfused rabbits ear by stimulation of the “adrenergic” nerves (Gaddum et al., 
1939). Gaddum’s apparatus differed somewhat to that of Finkleman, requiring as it 
did only a single piece of gut, but appears to be more practical. Despite being 
essentially the same as the apparatus described in the 1953 paper, Gaddum used no 
term to describe the method used.
Kwiatkowski (1941), a co-author on Gaddum’s 1939 paper, used the superfused 
guinea-pig ileum as a “new technique for assaying histamine”. The apparatus and 
method used were referred to as being “based on the principle used for the detection 
of sympathin”, used by Gaddum et al. (1939) but gave no further details.
Despite these previous publications, it was not until the appearance of Gaddum’s 
paper The Technique o f Superfusion in 1953 (figure 1) that superfusion became 
widely used and the paper has become widely cited. However, less well known is 
that Gaddum used this publication to report the production by the perfused rat 
intestine of a factor with potent oxytocic activity which he named substance R.
1.3.0 GADDUM’S “TECHNIQUE OF SUPERFUSION” PAPER
1.3.1 The discovery of substance R
Gaddum appears to have returned to the use of the superfusion technique for the 
same reason that saw its innovation by Finkleman, that is, the problem of dilution of 
biologically active samples when using conventional methods of bioassay.
Gaddum began his paper by defining superfusion and making reference to the
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earlier papers of Finkleman (1930), Gaddum et al. (1939) and Kwiatkowski (1941). 
The apparatus required was then described in detail and the methods and principles 
of its use, something which Kwiatkowski (1941) omitted to do.
The initial discovery of substance R was made whilst Gaddum was performing an 
experiment similar in design to that of Finkleman (1930) with modified apparatus, 
where “two tissues were suspended above one the other and the same fluid was 
superfused over them both in series”. In experiments where a length of rat’s small 
intestine was superfused above a rat’s uterus Gaddum observed that
...a substance was sometimes liberated from rat’s small intestine which caused a contraction of rat’s 
uterus.
This original finding led to experiments where the whole of the small intestine was 
isolated and perfused with Tyrode’s solution through the mesenteric vasculature. 
Samples of this perfusate were found to be oxytocic, causing a volume-dependent 
slow, delayed contraction of the superfused rat uterus.
In the results section Gaddum once again gave details of the superfusion technique 
before briefly describing the assay of histamine. Gaddum claimed that his technique 
provided a more sensitive assay than that of Kwiatkowski (1941) because Gaddum 
recommended the application of assay samples directly onto the tissue by pipette 
whereas Kwiatkowski injected the sample into the stream of superfusate above the 
tissue. It is interesting to note that the method which has become widely used is the 
more convenient, the latter rather than the former.
The remainder of the paper is devoted to the results of investigations into the natun. 
of the oxytocic principle present in intestinal perfusate which Gaddum named 
“substance R”. Gaddum demonstrated that the oxytocic activity could not be due to 
a number of known pharmacologically active substances, including acetylcholine, 
5-HT, oxytocin or substance P. Substance R could be precipitated with acetone and 
crude preparations were made in this way. The oxytocic activity was not lost on 
dialysis of the perfusate, but it was destroyed by boiling. Gaddum did not consider
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that either trypsin or chymotrypsin were present in and responsible for the activity 
of preparations of substance R, but he could not conclusively prove so. Study of the 
content of substance R in the gut led Gaddum to suggest that it may be secreted into 
the intestine by “some gland”.
Despite his inability to positively identify substance R with any known substance, 
Gaddum noted at the end of his discussion that the known properties of substance R 
were similar to those then recently reviewed by Werle and Berek (1950) for 
kallikrein. Gaddum finished by stating that this possibility had not been fully 
explored and that substance R...
may appear as a complication of experiments on the pharmacological activity of extracts of the 
intestine, or of experiments designed to detect the release of active substances by the intestine under 
various experimental conditions.
1.3.2 Subsequent developments to the method
After the publication of Gaddum’s paper in 1953, the technique of superfusion 
became more widely used. Indeed, a modification to the technique, used for the 
detection of low concentrations of histamine in plasma on the guinea-pig ileum, was 
published the following year (Adam et al., 1954). Other minor changes in protocol 
have been made over the years, but the principle remains the same. Some major, if 
little used, changes have also been made, for example, the sensitivity of the 
technique can be greatly increased if the tissue is immersed in a bath of oil to 
minimise the flow rate and volume of superfusate which bathes the tissue in a 
laminar flow (Ferreira & de Souza Costa, 1976).
Other modifications to the technique have led to important discoveries. Vane (1958, 
1964, 1966), using the so-called blood bathed organ technique, developed an on-line 
method of detection of substances liberated into the circulation. A simple extension 
of Feldberg’s and Gaddum’s methods devised by Vane and his colleagues was to 
contribute to his Nobel laureate (see Vane, 1983). The superfusion of generally up 
to six different tissues in a cascade system allowed the differentiation of various
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endogenous mediators to be made by a characteristic pattern of responses.
Vane’s use and various adaptations of superfusion, including the perfusion of an 
organ such as the lung above the assay tissues, was responsible for the original 
detections of what were later identified as thromboxane A2 (Piper & Vane, 1969) 
and prostacyclin (PGI2) (Moncada et al., 1976). Such experiments also led to the 
formation of Vane’s hypothesis of the mechanism of action of aspirin (see Vane, 
1983). The discovery of lipocortins (Flower & Blackwell, 1979) and the subsequent 
explanation of steroid action (see Flower, 1984) were also made possible by the use 
of this technique.
More recently superfusion of a column of cultured endothelial cells above a cascade 
of vascular tissue has been used for the bioassay of PGI2 and endothelium-derived 
relaxing factor (EDRF) (Gryglewski et al., 1986). This method has enabled the 
half-life of EDRF to be calculated accurately and has contributed to the attempts at 
identification of the substance responsible for the actions of EDRF.
Today superfusion remains the technique of choice to the pharmacologist where 
either little of an active substance is available, or a high concentration is required. 
Whilst the number and complexity of chemical methods of assay has continued to 
increase, the technique of bioassay of which Gaddum was a great proponent, still 
provides a valuable and simple tool for the quantification and even discovery of 
biologically active substances.
1.4.0 THE FATE OF SUBSTANCE R
Gaddum appears to have desisted from further investigation of substance R after 
1953 despite maintaining an interest in kallikreins and kinins (Horton & Gaddum, 
1958; Gaddum & Guth 1960). In September of that year a symposium was held in 
Montreal which was attended by many of the leading authorities of what may be 
called autocoids, including Gaddum himself. The work presented at this symposium 
dealt with the isolation and characterisation of substances which stimulated smooth
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muscle, most of which had been found to be polypeptides. Gaddum edited the 
volume of papers presented at Montreal under the title of Polypeptides which 
stimulate plain muscle (Gaddum, 1955). It includes an introduction and a chapter on 
“The pharmacological analysis of tissue extracts” written by Gaddum but contains 
no reference to substance R, despite the fact that it provided an ideal illustration of a 
recent identfication of an unkown substance. A chapter by E. Werle on the 
chemistry and pharmacology of kallikrein makes no mention of either substance R 
or any kallikrein present in intestine. Perhaps discussions with his contemporaries at 
this symposium left Gaddum convinced that substance R was a kallikrein and 
further characterization by him was needless. The content of two similar volumes 
published soon after (Schachter, 1960; Erdos et al., 1966) reflected the growing 
interest in substance P and the kallikrein-kinin system but in niether is there any 
mention of substance R. Throughout the 1950’s, Gaddum’s interest was also 
increasingly turning toward 5-HT and other centrally acting neurotransmitters (see 
Feldberg, 1967). Whatever the reason, Gaddum himself made no further mention of 
substance R in any of his published scientific writings and its discovery was not 
even acknowleged by Gaddum’s own biographers (von Euler, 1966; Feldberg, 1967; 
Vogt, 1970; Holmstedt & Liljestrand, 1981).
A search of the literature revealed that substance R has continued to be neglected to 
the present time. The true identity of substance R was therefore unkown at the 
begining of the present study. Gaddum’s own intuition suggested that substance R 
and kallikrein were similar, if not identical (Gaddum, 1953). Once the presence of 
substance R in intestinal perfusate was confirmed, a comparison of substance R and 
kallikrein was therefore made.
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1.5.0 THE KALLIKREIN-KININ SYSTEM
1.5.1 Nomenclature of the components of the kallikrein-kinin system
There have been many names given to the various components of the 
kallikrein-kinin system since its discovery in Germany in the 1920’s and of the 
bradykinin-bradykininogen system in Brazil in the late 1940’s. Kallikrein itself has 
probably had the most pseudonyms, perhaps the most outrageous being the “Munich 
kid” (Fritz, 1981). With different groups working simultaneously on the 
characterization of these substances in different parts of the world at various times, 
it was perhaps inevitable that some confusion of the nomenclature would occur. In 
order to clarify and simplify the terminology in use, a meeting was held in Florence 
in 1965 (Webster, 1966). The background to many of the names currendy in use has 
been described by Webster (1966, 1970b) and Hamburg (1978).
The term kininogenase, e.g. kallikreins, trypsin, pepsin, snake venoms, certain 
bacterial proteases etc, may be applied in a general sense to any enzyme which 
forms a kinin from an inactive precursor protein substrate (Webster, 1966).
Kallikreins (E.C. 3.4.21.8) belong to a large generic group of proteins, the serine 
proteases. Kallikrein was defined as an endogenous enzyme which rapidly and 
specifically liberates a kinin from kininogen (Webster, 1966, 1970b). The inactive 
zymogen of kallikrein is known as prekallikrein. In mammals there are two distinct 
kallikrein systems, those of plasma kallikrein and tissue kallikrein. Although the end 
products of these two systems are essentially similar and produce the same 
biological effects, each system fulfils specific physiological roles.
Kininogen is a term first introduced by Schachter and his colleagues (1962) for the 
stable substrate of kallikrein which was originally crudely prepared by Werle’s 
group in 1937. There are two types of kininogen in human plasma, distinguished by 
their different molecular masses: low molecular weight (LMW) kininogen and high 
molecular weight (HMW) kininogen.
10
Schachter and Thain (1954) introduced the term kinin. Kinins are hypotensive 
polypeptides which contract most isolated smooth muscle preparations, but relax the 
rat duodenum (Webster, 1966, 1970b). Kinins also cause bronchconstriction in the 
guinea-pig, increase microvascular permeability, and produce pain when applied to 
the base of a skin blister. These low molecular weight polypeptides belong to a 
closely-related group which are present naturally in wasp and other insect venoms, 
or are released from a plasma substrate by the actions of kininogenases (Schachter 
1980a). Kinins are acted upon by enzymes called kininases ultimately producing 
inactive peptide fragments.
A simplified scheme demonstrating the interactions of the major components of the 
kallikrein-kinin system is shown in figure 2.
1.5.2 The discovery of kallikrein
The hypotensive action of urine was first noted during the nineteenth century (see 
Erdos, 1970). Later, in 1909 Abelous and Bardier confirmed the presence of a 
hypotensive component of urine which was later partially purified by Pribtan and 
Hermheiser in 1920 (see Werle, 1976). However, little attention was immediately 
paid to this work and it is not until the mid 1920’s that the discovery of kallikrein 
can truly be considered to have taken place.
Whilst investigating post-operative reflex anuria in 1925, the Munich surgeon E.K. 
Frey found that prolonged hypotension followed intravenous injection of normal dog 
urine into the anaesthetised dog (Frey, 1926). Frey (1926) also observed that normal 
human urine produced a similar dose-dependent fall in arterial blood pressure but 
that this was less potent than dog urine. Frey firmly believed that he had discovered 
a novel hypotensive agent, despite the assurances of others that this activity was 
probably due to a number of pharmacologically active substances, amongst which 
histamine was a prime candidate. Frey followed his conviction however, and 
demonstrated that since his hypotensive agent remained after dialysis but not after 
boiling it could not be the low molecular weight, thermostable substance histamine.
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Seeking help to isolate the active substance from urine Frey contacted the Nobel 
laureate R. Willstatter who suggested that Frey collaborate with his fellow worker
H. Kraut. Being a chemist with experience in the isolation of high molecular weight, 
thermolabile substances, Kraut was able to prepare a stable standard preparation of 
the active hypotensive principle which was then named Frey-stoff (or F-stoff) and 
considered to be a circulating hormone (see Werle, 1976). Soon after it was shown 
that F-stoff was inactivated by blood, a process reversible by mild acidification 
(Frey and Kraut, 1928; Frey et al., 1928). A number of other tissues, in several 
species, were also found to contain inhibitors of F-stoff (Kraut et al., 1930b). If 
F-stoff was a hormone, some organ was producing it and the source of F-stoff was 
therefore sought. It was soon found that pancreatic juice from the fistulae of dogs 
and men and the content of a human pancreatic cyst produced hypotension in the 
dog (Kraut et al., 1930a; Frey et al., 1930). Extracts from the normal pancreas of 
several species, including man, were found to contain considerable amounts of 
F-stoff (Kraut et al., 1930a). Hence, the decision was made to rename F-stofJ 
“kallikrein” after the Greek synonym for pancreas, kallikreas (Kraut et al., 1930a).
Kallikrein was not unique to the pancreas however, and was soon found in other 
glands and fluids. Just as the inactivation of F-stoff by blood could be reversed by 
mild acidification, acidification of serum alone was found to activate a substance 
with the same characteristics as F-stoff (Kraut et al., 1928). This kallikrein in 
plasma was later assumed to be pancreatic kalllikrein, secreted into the blood and 
circulating in an inactive form, being activated before excretion in the urine. 
However, it is now known that urinary kallikrein is produced in the kidneys. 
Salivary glands were also shown to produce a kallikrein. The hypotension which 
was known to follow intravenous injection of saliva was found to be caused mainly 
by kallikrein and not acetylcholine as had been assumed previously (Werle & von 
Roden, 1936). By the late 1930’s many other tissues were also found to contain 
kallikrein activity (see Webster, 1970a; Schachter, 1980a).
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1.5.3 The enzymatic nature of kallikrein
That kallikrein was an enzyme rather than a circulating hormone was first 
recognized in the late 1930’s when Werle and his colleagues were investigating its 
pharmacological actions. In 1928 Frey and Kraut had shown that kallikrein was not 
responsible for the dilatation of blood vessels which led to its hypotensive activity 
and another explanation was required (see Werle, 1976). The large size of the 
kallikrein molecule, coupled with its chemical nature, suggested to Werle that it 
may be an enzyme (Werle, 1976). Werle (1936c) found that the dog isolated gut 
was extaordinarily sensitve to kallikrein. However, incubation of the kallikrein with 
serum for 30 minutes abolished its spasmogenic and hypotensive activities. In 
contrast, incubation lasting only 2 minutes markedly increased the activity of the 
mixture (Werle et al., 1936). In addition, this mixture stimulated the guinea-pig 
isolated ileum whereas neither kallikrein nor serum alone did. Werle concluded that 
kallikrein was acting as an enzyme, releasing the pharmacologically active Substanz 
DK (darmkontrahiernde substanz) from an inactive precursor present in plasma 
(Werle et al., 1936; see Werle, 1976). Werle (1936b) considered that kallikrein itself 
circulated in a complex with an inactivator and was freed by another protease which 
itself was prevented from activating kallikrein by an inhibitor. In 1939 Werle and 
Grunz showed that Substanz DK  markedly lowered blood pressure after intravenous 
injection and its enzymatic breakdown in plasma could be inhibited by cystein (see 
Werle, 1976; Webster, 1970a). When, in 1948 Werle and Berek suggested that 
Substanz DK  be changed to “kallidin”, being released from its precursor 
“kallidinogen” by the action of kallikrein on serum, the basic components of the 
kallikrein-kinin system were known to exist, and most had been named.
1.5.4 The discovery of bradykinin
In Brazil at this time, research was being carried out into the role of the venom from 
the snake Bothrops jararaca and of trypsin in the release of histamine and 
circulatory shock in the dog. This led to an important discovery of relevance to the 
established work in Germany. In 1948 a substance was identified in the blood of
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one of the Brazilian group’s experimental dogs which produced a slow contraction 
of the guinea-pig isolated ileum which was not acetylcholine or histamine (Rocha e 
Silva et al., 1949). This substance was given the name “bradykinin” from the idea 
of a “slowly acting substance” from the Greek brady (slowly) and kinin (movement) 
(Rocha e Silva, 1976a, 1976b). This group also found that the physicochemical 
properties of bradykinin suggested that it was a polypeptide of low molecular 
weight, released from the globulin fraction of plasma from an inactive precursor 
which they named “bradykininogen”, and that it could be destroyed by plasma 
enzymes (Rocha e Silva et al., 1949). However, because of the apparently confusing 
nature of the literature at this time, bradykinin was not linked immediately with 
kallidin (Rocha e Silva, 1976a, 1976b).
1.5.5 The structure of kinins
Bradykinin was the first kinin to be purified and synthesized (see Elliott, 1970). 
After perfecting the isolation of bradykinin from ox blood, in 1959 Elliott and his 
colleagues deduced its amino acid composition (Elliott et al., 1960). The following 
year two independent groups synthesized bradykinin and deduced its structure as 
H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH (Elliott et al., 1960; Boissonnas, 
1962; Boissonnas et al., 1963). By 1962 bradykinin had been characterized using 
bioassays by comparison with synthetic analogues (see Elliott, 1970).
Soon after the characterization of bradykinin, kallidin was identified as the closely 
related decapeptide lysyl-bradykinin (Webster & Pierce, 1963). Bradykinin and 
Lys-bradykinin were shown to be two of the components of the so-called substance 
Z (see Gaddum & Horton, 1958) found in urine, together with a third, 
undecapeptide kinin, methionyl-lysyl-bradykinin (Miwa et al., 1969). Met- 
Lys-bradykinin is thought to be formed by the action of pepsin on kininogen in 
acidified urine (see Pisano, 1979).
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1.5.6 Soruces of other kinins
Several kinins have been identified which are generated as a result of the action of a 
kininogenase contained in leukocytes (Greenbaum et al., 1978; Greenbaum, 1979). 
These “leukokinins” range from 21-25 amino acid residues in length but are thought 
not to contain the bradykinin moiety per se since peptide analysis has revealed they 
contain only one phenylalanine residue whereas bradykinin contains two (Green­
baum, 1979). Okamoto and Greenbaum (1983) discovered an additional kinin, 
“T-kinin” (Ile-Ser-bradykinin) which is liberated from rat plasma in the presence of 
high concentrations of trypsin, and more recently Met-Ile-Ser-bradykinin (Met- 
T-kinin) was discovered (Sakamoto et al., 1989).
Other kinins of mammalian origin have been isolated containing as many as sixteen 
amino acid residues, but all are very weak agonists compared to bradykinin and 
there has been some doubt as to their authenticity and physiological relevance (see 
Pisano, 1970).
Schachter and Thain (1954) were the first to characterize a kinin from 
non-mammalian sources. The venom of the common European wasp, Vespa 
vulgaris, yielded kinin-like activity which was later shown to be due to the presence 
of three separate kinins (Mathias & Schachter, 1958). Since these original 
observations, the structure of the kinins in wasp and several other insect venoms and 
also kinins from amphibian tissues have been determined. These may have up to 
eighteen peptide residues in total, built around a bradykinin core, sometimes with 
substitutions to the bradykinin moiety (see Pisano, 1970, 1979; Bertaccini, 1976).
Kallikrein was found in hen excreta in 1936 (Werle et al., 1936) which was 
hypotensive only in the hen and not in mammals (Werle & Hiirter, 1936). The 
generation of an “omithokinin” from bird plasma was later demonstrated by Werle 
et al. (1966). This differed from mammalian kinin in terms of its amino acid 
composition, molecular weight and pharmacological activity. Omithokinin was not 
hypotensive in mammals and it was therefore assumed that omithokinin was not
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closely related structurally to bradykinin (Werle et al., 1966). However, the 
structure of omithokinin has recently been reported as [Thr6,Leu8]-bradykinin 
(Kimura et al., 1989). This group confirmed Werle’s finding that the pharmacology 
is markedly different to bradykinin and concluded from these structural and 
pharmacological differences that residue 8 in the kinin sequence is of critical 
importance in the specific interaction of kinins with their receptors.
1.5.7 Kinin receptors and antagonists
As early as 1960 Collier and his colleagues (Collier & Shorley, 1960) proposed the 
existence of more than one bradykinin receptor. Several aspirin-like compounds 
specifically antagonized the bronchoconstrictor activity of bradykinin in vivo in the 
guinea-pig, but did not specifically antagonize the increased vascular permeability in 
guinea-pig skin, nor bradykinin’s action in vitro on the guinea-pig ileum or rat 
duodenum (Collier & Shorley, 1960). Collier therefore concluded that there were 
two types of bradykinin receptor, by analogy with the two types of acetylcholine 
receptor which are antagonized by two different antagonists acting at separate sites 
(Collier & Shorley, 1960).
Whilst studying the inflammatory action of bradykinin in 1970, Rocha e Silva 
hypothesised that there were two bradykinin receptors. One bradykinin receptor 
mediated pain (P receptor) whilst the second (S receptor) which mediated plasma 
extravasation also appeared to be present in the guinea-pig ileum and some vascular 
tissues (see Barabe et al., 1977). It had also been suggested that there were 
structural differences between bradykinin receptors in vascular and visceral smooth 
muscle (Edery & Grunfeld, 1969). Other evidence gained from electrophysiological 
and empirical studies supported this idea of two types of bradykinin receptor (see 
Boschcov et al., 1984).
These distinctions of receptors however, were not based on any sound 
pharmacological criteria such as those proposed by Schild (Regoli et al., 1978), the 
most important criterion of which is the demonstration of competitive antagonism.
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However, researchers in this field had to await the synthesis of effective competitive 
antagonists. The analysis of the structure-activity relationship of hundreds of 
bradykinin analogues over the last 25-30 years has recently led to the development 
of effective receptor antagonists (see Schroder, 1970; Stewart, 1979; Regoli & 
Barabe, 1980, 1988; Vavrek & Stewart, 1989; Regoli et al., 1990). Two bradykinin 
receptor subtypes (BR^ and BK2) have been identified in accordance with Schild’s 
recommendations using competitive antagonists and more rigorous criteria (Regoli 
& Barabe, 1988).
The order of potency of bradykinin, kallidin and their kininase I (see below) 
metabolites, des-Arg9-bradykinin and des-Arg10-kallidin was shown to vary between 
several isolated organs. Thus, it was found that des-Arg9-bradykinin and 
des-Arg10-kallidin were more potent in the rabbit aorta than their native precursors 
(Regoli et al., 1977). This was in contrast to other isolated preparations such as the 
cat ileum and rat uterus, where the native kinins were more potent than their 
kininase I metabolites (Barabe et al., 1977). These contradicting results suggested to 
these authors the presence of two kinin receptors which were named Bj for those in 
the rabbit aorta and mesenteric vein, and B2 for those in the rat uterus, cat ileum 
and rabbit jugular vein (Regoli et al., 1978).
Bradykinin receptors have since been identified and defined in a number of different 
tissues (see Regoli et al., 1988). The identification of the two forms of receptor gave 
further impetus to research into the structure-activity relationship of kinins and soon 
antagonists were being synthesized and evaluated in bioassays (Regoli & Barabe, 
1980), although the development of more specific and potent antagonists was to 
take several more years.
Study of BKj receptor systems revealed that an increase in sensitivity of the rabbit 
aorta and mesenteric vein preparations occurred gradually during in vitro incubation 
of these tissues (Regoli et al., 1978). This was found to be the result of a de novo 
synthesis of the BKj receptors, and could be blocked by the protein synthesis 
inhibitors actinomycin D and cycloheximide (Regoli et al., 1978). This phenomenon
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occurred in all preparations containing BK^ receptors studied (Regoli & Barabe, 
1980). In contrast to these results it has recently been reported that cultured rat 
aortic vascular smooth muscle cells possess only BK2 receptors (Hirata et al., 1989). 
This may be a species difference or may reflect functional changes of cell 
membranes during culture leading to loss of BKj receptors (Hirata et al., 1989). The 
de novo synthesis of BKj receptors has also been demonstrated in vivo, following 
intravenous injection of endotoxin into rabbits (Marceau et al., 1983).
The use of competitive antagonists has confirmed the two-receptor hypothesis of 
Regoli and colleagues (1978). BKj bradykinin receptor antagonists, for example, 
[Leu8],des-Arg9-bradykinin (Regoli & Barabe, 1980), are active only in tissues 
possessing BKj receptors and are completely inactive in BK2 receptor systems 
(Regoli et al., 1989). On the other hand, BK2 receptor antagonists are non-selective. 
These antagonists such as the prototype [Thi5’8,D-Phe7]-bradykinin (Regoli et al., 
1986a) are active on both BKj and BK2 receptor systems (Regoli et al., 1989). It is 
thought that the BK2 receptor antagonists are converted by kininase I and other 
carboxypeptidases to metabolites devoid of the C-terminal Arg which are active as 
BKX receptor antagonists (Regoli et al., 1986b; Regoli et al., 1989), an action that is 
significantly reduced by inhibition of kininase I (Regoli et al., 1986b). Boschcov 
and colleagues (1984) demonstrated that the relaxant and contractile effects of 
bradykinin in the rat isolated duodenum are mediated by different sites which are 
further distinguished by their apparent affinities for agonists and potentiating 
peptides.
A number of other bradykinin analogues have been synthesized which are specific 
antagonists of BK2 bradykinin receptors, one of which, D-Arg-[Hyp3,Thi5*8,D- 
Phe7]-bradykinin (Regoli et al., 1986a; Schachter et al., 1987), blocks bradykinin- 
induced vascular permeability in rabbit skin as well as inhibiting responses to 
bradykinin in vitro (Schachter et al., 1987).
More recently three bradykinin analogues have been synthesized which are 
extremely potent long-acting specific antagonists of bradykinin in a number of
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different preparations, in vitro and in vivo (Lembeck et al., 1991). The most active 
of these was D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]-bradykinin. All three of these 
compounds had a long duration of action and it was suggested that they therefore 
have a high affinity for bradykinin receptors. However, the receptor subtype 
specificity of these antagonists was not investigated.
Farmer et al. (1989) have suggested the presence of a third subtype of bradykinin 
receptor in lung tissues, the B3 receptor. BK2 receptor antagonists were not effective 
against bradykinin-induced bronchoconstriction in the guinea-pig. It had previously 
been reported that in vitro, BK2 receptor antagonists were inactive against 
contraction of airway smooth muscle induced by bradykinin (see Farmer et al., 
1989). In addition responses to bradykinin in lung tissues were not inhibited by BKj 
receptor antagonists and thus the effects of bradykinin in this organ are mediated by 
specific bradykinin receptors which are of neither the BKj nor BK2 subtype (Farmer 
et al., 1989). Interestingly the new long-acting bradykinin receptor antagonists 
described by Lembeck et al. (1991) were effective inhibitors of bradykinin-induced 
bronchoconstriction in the guinea-pig.
Recently a study of the vascular actions of bradykinin in the guinea-pig isolated 
hind brain has also revealed the presence of a third type of bradykinin receptor 
(Cohen-Laroque et al., 1990). Both selective BKj and BK2 receptor antagonists had 
similar activities against bradykinin-induced vasoconstriction in this preparation. 
The receptor mediating this response had other pharmacological characteristics 
which do not match those previously described for BKX or BK2 receptors and it was 
concluded it may be of a novel third subtype.
The receptors which mediate the biological responses of bradykinin have as yet not 
been isolated and characterized as others have, e.g. the nicotinic acetylcholine 
receptor. However, binding sites for radiolabelled bradykinin and analogues have 
been identified in a number of tissues, although early studies were complicated by 
binding to kininase enzymes. Odya et al. (1980) demonstrated high and low affinity, 
specific, saturable binding sites for bradykinin and related peptides in the
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myometrium of bovine uterus. The affinities were similar to those reported in a 
previous publication for rat uterus (see Odya et al., 1980). This group considered 
that the properties of these binding sites were consistent with those expected of 
receptors (Odya et al., 1980). Binding sites were also found in guinea-pig ileum, 
colon, duodenum, heart, and kidney, and rat uterus (Innis et al., 1981). The relative 
potencies of bradykinin analogues at binding sites in guinea-pig ileum correlated 
well with their potencies in contracting smooth muscle (Innis et al., 1981). There 
was not, however, such good correlation in the rat uterus, but it was thought that 
this may be explained by discrepancies in the contractile potencies of peptides in 
ileal and uterine tissues which may be due to a difference in recognition sites (Innis 
et al., 1981). Manning et al. (1982) further investigated the binding sites in 
guinea-pig ileum and found that specific bradykinin receptor binding sites occur in 
the mucosa as well as the muscle region. Localization of receptors was 
demonstrated by light microscopic autoradiography, and these results correlated well 
with the biological sites of action of bradykinin (Manning et al., 1982). The 
medullary interstitium of the kidney also contains bradykinin binding sites (Manning 
& Snyder, 1986). Bradykinin binding sites with low and high affinities were 
demonstrated on cultured rat aortic vascular smooth muscle cells (Hirata et al., 
1989) and human fibroblasts (Roscher et al., 1983).
The pharmacological evidence for the existence of a BK3 receptor subtype in 
guinea-pig lung was corroborated by binding studies carried out on displacement of 
radiolabelled bradykinin by BKj and BK2 antagonists. In lung parenchyma 40% of 
the binding sites were of neither the BKX nor BK2 subtype, whilst in tracheal tissue 
binding of labelled bradykinin was not displaced by either type of antagonist and 
thus these sites appeared to be exclusively of the BK3 subtype (Farmer et al., 1989).
In summary, three different bradykinin receptors, BKj, BK2 and BK3 have been 
identified and characterized by use of synthetic agonists and antagonists. Membrane 
binding sites for bradykinin have also been identified in a number of tissues and 
species and binding studies have corroborated the biological evidence . The location
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of the BKi and BK2 receptor subtypes and ther implication in a variety of biological 
activities has recently been reviewed (Regoli et al., 1989, 1990).
1.5.8 Kininogens
Kininogens are single chain acid glycoproteins synthsised and secreted by the liver, 
which reside in the alpha-2-globulin fraction of normal plasma. Kininogens are the 
high molecular weight precursors of kinins and have been purified from a number 
of species (see Movat, 1979). Crude preparations of kininogen were prepared by 
early investigators by heating plasma to 60°C for 1-3 hours, but later improved 
methods were employed and more purified samples were prepared (see Schachter, 
1969).
Studies carried out in the 1960’s by the groups of Margolis and Vogt (see Movat, 
1979) indicated that plasma contains more than one form of substrate for kallikrein. 
Following on from the work of Margolis, Vogt (1966) postulated that there are two 
kinin-forming systems in plasma, each containing a separate kininogen and 
kininogenase. Jacobsen (1966a, 1966b) used gel filtration chromatography to resolve 
for the first time, two plasma kininogens of different molecular weight which he 
referred to as substrates 1 and 2. In plasma from a number of species the HMW 
form of kininogen acted as a substrate for both plasma and glandular kallikreins 
whereas the LMW form was only a good substrate for glandular kallikreins and not 
plasma kallikrein (Jacobsen, 1966a, 1966b).
These two forms of kininogen have been extensively studied in a number of species, 
especially in man. However, there are large species differences in the size of HMW 
kininogen (see Movat, 1978, 1979; Kato et al., 1981; Miiller-Esterl & Fritz, 1984). 
For a time the presence of HMW kininogen in human plasma was disputed until a 
condition known as Williams or Fitzgerald trait was described in which there is a 
deficieny of HMW kininogen (see Movat, 1979). Human HMW kininogen was 
shown to have a molecular mass of 114 kDa by SDS-electrophoresis, and to consist 
of a heavy chain of 63 kDa and a light chain of 58 kDa. HMW kininogen circulates
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in normal plasma as a complex with prekallikrein, attached to the heavy chain of the 
kininogen (see Silverberg and Kaplan, 1988). This chain also contains regions 
which bind to Hageman factor and subendothelial sufaces (Sugo et al., 1980). LMW 
kininogen was similarly comprised of two chains, of 62 and 5.4 kDa, with the 
native protein having a molecular weight of 68 kDa (Miiller-Esterl & Fritz, 1984). 
In both kininogens the heavy chain contains the kinin sequence (Miiller-Esterl et al.,
1986).
A third kininogen has more recently been described in rat plasma. It differs 
markedly from HMW and LMW kininogen in that it is not susceptible to proteolytic 
cleavage by kallikreins (Okamoto & Greenbaum, 1984). Trypsin and cathepsin D 
act on this “T-kininogen” to release Ile-Ser-bradykinin (Okamoto & Greenbaum, 
1983) and Met-He-Ser-bradykinin is released by an acid protease (Sakamoto et al., 
1989). Two forms of T-kininogen have been isolated by gel filtration chromatog­
raphy and SDS-PAGE with a molecular weight of 69 kDa (Okamoto & Greenbaum, 
1984; Greenbaum & Okamoto, 1988).
1.5.9.0 Kinin-forming pathways
Kallikreins can be divided into two classes: plasma kallikreins and tissue (or 
glandular) kallikreins. The observation by early investigators that F-stoff was 
present in the pancreas led them to believe that it was synthesized there prior to its 
release into the circulation and subsequent renal excretion (see Werle, 1976). 
However, it is now known that plasma, pancreatic and urinary kallikreins all differ 
from one another.
The differences between kallikreins from various sources first became apparent to 
the original workers in this field, but the significance of their observations was not 
recognized. It was known, for example, that plasma kallikrein required activation 
whereas the kallikrein present in urine was already in an active form (Kraut et a i, 
1928; Werle, 1936b).
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In 1955 Werle and his colleagues showed that kallikrein from plasma exists as an 
inactive precursor, prekallikrein or prokallikrein, which may be activated by 
enzymatic processes (Werle, 1976). Pancreatic kallikrein was likewise demonstrated 
to exist in an inactive form, relying on contact with gastric juices for its activation 
(Fielder & Werle, 1967). Kallikreins from most other glandular sources appear not 
to require activation (Webster, 1970a), although prokallikrein is also found in the 
kidney and in urine and some other tissues (Spragg, 1983, 1988; Yakada et al., 
1985).
The first known inhibitor of kallikrein was found in human blood by Frey and Kraut 
(1928). After further investigation it was assumed that the inactive kallikrein in 
human plasma was formed by a complex of pancreatic kallikrein and the circulating 
inhibitor. It is now clear, however, that plasma kallikrein circulates as an inactive 
precursor of kallikrein which is activated by Hageman factor (factor XII) (Werle, 
1955; Colman & Bagdasarian, 1976). Thus, plasma prekallikrein is a proenzyme in 
a cascade system analagous to other zymogens such as prothrombin.
Later, studies of various inhibitors of kallikrein revealed other differences between 
kallikreins derived from several sources and species which were supported by 
immunochemical evidence (see Webster & Pierce, 1963; Webster, 1970a). All 
plasma kallikreins which were studied were found to be inhibited by soy bean 
trypsin inhibitor (SBTI) whereas those kallikreins derived from other sources were 
not (see Webster, 1970a).
The two types of kallikrein also liberated different kinins from plasma. Separation 
of kallidin and bradykinin by chromatography enabled Webster and Pierce (1963) to 
show that glandular kallikreins generated only kallidin whereas plasma kallikrein 
liberated only bradykinin from plasma kininogen. These findings were soon 
confirmed by others (Habermann, 1966; see Webster, 1970a) and further 
biochemical distinctions were made shortly after.
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1.5.9.1 Plasma kallikrein
Using ion-exchange chromatography plasma kallikrein was first separated by Becker 
and his colleagues (Kagen et a l, 1963; Becker & Kagen, 1964). Improvements in 
biochemical separation procedures have since enabled a greater purification of 
activated plasma kallikrein and its precursor prekallikrein.
A number of authors, utilizing a variety of techniques, have attributed different 
molecular weights to human plasma prekallikrein and kallikrein. Gel filtration 
chromatography of prekallikrein in normal plasma and in a complex with HMW 
kininogen gave a molecular mass of 285 kDa whereas prekallikrein from HMW 
kininogen-deficient plasma was isolated with a molecular weight of 115 kDa 
(Mandle et a l, 1976). The following year however, the same group reported two 
molecular weight variants of prekallikrein, of 85 kDa and 88 kDa using 
SDS-electrophoresis (Mandle & Kaplan, 1977).
There are several enzymes which may catalyse the activation of prekallikrein. These 
include trypsin, factor XII, factor Xlla and factor XII fragments (see Heimark & 
Davie, 1981). Following activation with activated Hageman factor (factor Xlla), and 
under reducing conditions, SDS-electrophoresis revealed two disulphide-linked, 
“kallikrein-light” and “kallikrein-heavy” chains of 33 kDa or 36 kDa and 52 kDa 
respectively (Mandle & Kaplan, 1977). Using radiolabelled inhibitor, the active site 
of kallikrein was found to reside in the light chain of the molecule (Mandle & 
Kaplan, 1977), the heavy chain containing a region which binds to the heavy chain 
of HMW kininogen (see Silverberg and Kaplan, 1988). Other reports have estimated 
the molecular weight of human prekallikrein to be approximately 100 kDa and both 
bovine and rabbit prekallikreins are of similar sizes (see Movat, 1979; Schachter, 
1980a).
A number of workers have reported that neither bovine, human (see Movat, 1978, 
1979) nor hog (see Schachter, 1980a) plasma prekallikrein undergoes a significant 
change in molecular weight upon activation by Hageman factor. Mandle and Kaplan
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(1977) found that there was no difference in either molecular weight or charge 
between the active kallikrein and proenzyme. It has been assumed therefore that 
only limited proteolysis occurs to the prekallikrein during activation. On the other 
hand, activation of rabbit prekallikrein by factor Xllf (see Movat, 1979) and 
activation of human prekallikrein by kallikrein itself (Mandle & Kaplan, 1977) 
resulted in cleavage of a fragment of approximately 10 kDa from prekallikrein in 
both cases.
Circulating kallikrein may be inhibited by a number of plasma-borne inhibitors; Q  
inactivator, alpha-2-macroglobulin, alpha-1-antitrypsin and antithrombin III, but the 
former two are considered to be the major inhibitors (see Harpel et al., 1975; 
Schachter, 1980a). To summarise, plasma prekallikrein, the form of kallikrein 
normally found in plasma, has a molecular weight of approximately 90-100 kDa and 
consists of two disulphide-linked chains of approximately 35 kDa and 55 kDa. This 
molecule appears to undergo no significant change in molecular weight or other 
properties on activation to kallikrein by its normal activator, Hageman factor. The 
light chain contains the enzymatic active site whilst the heavy chain interacts with 
HMW kininogen. Plasma kallikrein is inactivated by a number of circulating 
inhibitors.
The amino acid sequence of human prekallikrein is now known (Chung et al., 1986) 
and is highly homologous with that of human factor XI (Fujikawa et al., 1986). 
Chung et al. (1986) reported no heterogeneity of the sequence, and the two variants 
of the light chain reported by Mandle and Kaplan (1977) may be due to differences 
in carbohydrate content.
1.5.9.2 Tissue kallikrein
Tissue kallikreins have been isolated from a wide variety of species and tissues over 
recent years. Immunocytochemical studies have revealed that tissue kallikreins are 
also present in exocrine secretions and in low concentration in plasma (Rabito et al., 
1980, 1982; Woodley et al., 1985). Active tissue kallikrein circulating in plasma is
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bound to a “kallikrein-binding protein”, distinct from the circulating plasma 
kallikrein inhibitors, which has recently been isolated and characterized (Chao et al., 
1986b; Chao et al., 1990).
Tissue kallikreins differ from plasma kallikrein in both physical and chemical 
properties and are clearly distinctly different enzymes (MacDonald et al., 1988). As 
one reviewer commented, the relationships between these two groups is not closer 
than, e.g., those between trypsin and thrombin (Fielder, 1979).
Kallikreins from glandular or tissue sources differ from plasma kallikreins in their 
substrate specificities and the kinins which they release from kininogens. Bradykinin 
is liberated from kininogen by plasma kallikrein whereas tissue kallikrein releases 
kallidin (Webster & Pierce, 1963; Habermann, 1966). Plasma kallikrein acts only on 
the HMW form of kininogen whilst LMW kininogen is the primary substrate of 
tissue kallikrein (Jacobsen, 1966a, 1966b).
The two groups of enzymes also differ in their susceptibility to inhibitors. The 
polyvalent trypsin inhibitor aprotinin (Trasylol), isolated from bovine pancreas and 
lung, inhibits both plasma and tissue forms of kallikrein (Trautschold et al., 1967), 
whilst other enzyme inhibitors are more selective (Back & Steger, 1968). It is well 
documented that plasma kallikreins are inhibited by soy bean trypsin inhibitor 
(SBTI) whereas all tissue kallikreins tested were not (Werle & Maier, 1952; Werle 
& Trautschold, 1963; Back & Steger, 1968; Webster, 1970a; Vogel, 1979).
The kallikrein present in most tissues is usually in an active form, whereas that in 
plasma exists as an inactive proenzyme. However, an inactive precursor of 
kallikrein has been noted in colon, kidney, urine and other tissues as well as 
pancreas where the proenzyme was discovered in 1930. Extracts of colon, intestine, 
lymph nodes brain and nerves of several species have also been found to contain a 
trypsin-activated tissue kallikrein-like enzyme (Werle & Vogel, 1961).
The inactive form of pancreatic kallikrein is rapidly converted to active kallikrein by
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trypsin and this form of enzyme has been extensively studied (see Webster, 1970a; 
Fielder, 1979). Trypsin also activates the prokallikrein or “latent kallikrein” found in 
human urine and kidney (see Spragg, 1983 & 1988; Yakada et al., 1985). Whilst 
Spragg (1988) reported isolation of latent kallikrein with a molecular weight of 
55-60 kDa by electrophoresis, Yakada et al. (1985) found a molecular mass of 48 
kDa by the same method. Other differences appear in these reports. Activation of 
the proenzyme cleaved a heptapeptide activation fragment and resulted in a drop in 
molecular weight to 46 kDa (Yakada et al., 1985). Spragg (1983), however, 
reported the loss of a 10 kDa fragment on activation by trypsin and molecular 
weight estimation by chromatography, in agreement with a previous report. Yakada 
et al. (1985) found that the most efficient activator of prokallikrein was the 
metalloprotease thermolysin, with trypsin being more active than plasma kallikrein.
Whilst the above reports differ in some details, both authors concluded that the 
isolated kallikrein was of a tissue type, the molecular weights, for example, being 
much lower than expected for a plasma kallikrein.
Recently, human urinary kalikrein was isolated with a molecular weight of 45 kDa 
by gel filtration which corresponded to that of 45 kDa for the trypsin-activated 48 
kDa inactive kallikrein also isolated (Kizuki et al., 1986). Similar results were 
obtained in the rat where inactive urinary kallikrein was found with a molecular 
weight of 44 kDa, both urinary kallikrein and trypsin-activated inactive kallikrein 
being 38 kDa (Takaoka et al., 1986).
Another kallikrein, found in the wall of the colon, however, appears to be a plasma 
kallikrein. This enzyme was isolated in an inactive form which was activated by 
trypsin and resembled plasma kallikrein in its molecular weight and inhibition 
pattern (Seki et al., 1972).
Some tissue kallikreins then, are released in an inactive form, but generally tissue 
kallikreins appear not to require a proper process of activation (Webster, 1970a). 
Tissue kallikreins have now been identified in a great many tissues. By the late
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1930’s Werle and his colleagues had demonstrated the presence of kallikrein not 
only in blood, urine and pancreas, but also in extracts of salivary glands, intestine, 
lung and neuronal tissues (see Schachter, 1980a). Urinary, kidney, submandibular 
salivary gland, salivary and pancreatic kallikreins of many mammalian species have 
been the most extensively studied (see Schachter, 1966, 1980a; Webster, 1970a; 
Nustad et a l, 1976; Fielder, 1979) whilst the presence of kallikrein in guinea-pig 
coagulating and prostate glands is well established (Bhoola et a l, 1961, 1962). 
More recently tissue kallikreins have been discovered in a wide variety of tissues 
(see table 1). However, tissue kallikreins may be even more widely distributed, as 
recent evidence from the identification of kallikrein genes suggests (MacDonald et 
al., 1988; Margolius, 1989).
The localization of kallikreins in many tissues has been visualised by immunoche­
mical methods (see Berg-0stravik et al., 1980; Schachter, 1979, 1980b; Schachter et 
al., 1986; Berg, 1988). Like other secretory proteins, kallikrein is synthesized on the 
rough endoplasmic reticulum and then glycosylated in the Golgi apparatus. A signal 
peptide of 17 amino acids is believed to be cleaved from the N-terminal of the 
newly synthesized molecule, leaving prokallikrein with a short 7 amino acid 
activation peptide which may then be removed by one of a number of possible 
proteases (see MacDonald et al., 1988). Granular intracellular stores of tissue 
kallikrein have been reported (Bhoola et al., 1979). Kallikreins from tissue sources 
are also of a markedly different molecular weight when compared to plasma 
kallikreins. Fielder (1979) produced a comprehensive survey of the literature to that 
date, and despite differences in species and tissue type and techniques, the various 
estimates of molecular weight were between 25-45 kDa. All the tissue kallikreins 
isolated were inhibited by aprotinin but were unaffected by SBTI. More recently 
monoclonal antibodies against a number of tissue kallikreins have been developed. 
These have enabled highly purified preparations of several tissue kallikreins to be 
obtained.
The primary structures of some tissue kallikreins are now known, either from amino
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acid sequencing of the purified protein, or being deduced from the mRNA sequence 
where this has been identified.
Porcine pancreatic kallikrein has been purified and sequenced. There are two known 
forms of this kallikrein, but the amino acid sequence was identical for both 
(Tschesche et al., 1979). It was reported that there are some slight changes in the 
amino acid sequences between pancreatic and other tissue kallikreins in the pig, 
however, the major differences in molecular weights and charge were accounted for 
by differences in glycosylation (Tschesche et al., 1979).
Some evidence suggested heterogeneity of human tissue kallikreins, including 
multiple forms of urinary kallikrein. However, Lu et al. (1989) showed from 
sequence data that human urinary kallikrein consists of a single polypeptide chain. 
The theoretical molecular mass of 26.4 kDa from amino acid composition differed 
markedly from the two forms isolated by electrophoresis with masses of 38 kDa and 
42.5 kDa (Lu et al., 1989). These and other different forms previously reported are 
due to heterogeneity in glycosylation rather than the primary protein structure.
The sequencing of tissue kallikreins has enabled cDNA libraries to be probed and a 
kallikrein gene family has now been identified (Gerald et al., 1986; Chao & Chao, 
1987). The number of genes encoding the kallikrein gene family is dependant on 
species, ranging from 4 in man to 27 in mouse (see MacDonald et al., 1988). The 
kallikrein gene family encodes for serine proteases other than tissue kallikreins per 
se which often differ from kallikrein at key amino acid residues that are responsible 
for cleavage specificity, but some of these may act as kininogenases. Analysis of the 
mRNA within species reveals a very high homology (74-89%) between members of 
the family. Determination of gene structure shows that the tissue kallikrein of 
different species is very similar, with 59-70% homology, whilst within species all 
tissue kallikreins share the same gene (see MacDonald et al., 1988). As yet the 
biological function of all the members of the kallikrein gene family remain to be 
elucidated, and it is thought that some genes may be redundant.
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Tissue kallikreins are also differentiated from plasma kallikrein in that they have 
little or no proteolytic activity on proteins other than kininogens (Erdos, 1979) 
whilst plasma kallikrein has a wider spectrum of substrates. This lower substrate 
specificity of plasma kallikrein is thought to explain its greater susceptibility to 
inhibitors (Schachter, 1980a).
1.5.9.3 Other kinin-generating systems
An alternative kinin generating system exists in a number of types of leukocytes 
(Greenbaum, 1979). The acid protease which releases leukokinins is bound within 
the cell rather than present in plasma and is released to act on the substrate. This is 
now identified as a cathepsin D-like enzyme (Greenbaum, 1984). The kininogen 
from which leukokinins are released has a molecular mass of 100 kDa (Roffman & 
Greenbaum, 1979) and differs from normal HMW kininogen in that it is not acted 
upon by kallikreins. More recently, the study of leukokininogen levels in human 
and animal plasmas uncovered a hitherto unknown pathway of kinin generation. The 
total kininogen content of 1.0 ml plasma was classically measured by kinin 
liberation by 0.1 mg trypsin (Greenbaum, 1984). However, when a much increased 
concentration of trypsin was used (up to 1.5 mg mb1), an unexpected rise in kinin 
release was seen (Okamoto & Greenbaum, 1983). This additional kinin was found 
to chromatograph differently from bradykinin, Lys-bradykinin and Met-Lys- 
bradykinin. The structure of this “T-kinin” (“T” from trypsin) was shown to be 
Ile-Ser-bradykinin (Okamoto and Greenbaum, 1983). It appears that another 
enzyme, from granulatomous tissues of rats, may act on T-kininogen to release 
Met-T-kinin (Sakamoto et al., 1989). The supposed existence of a T-kininogenase 
has been confirmed by experimental results. The rat and mouse submandibular 
glands contain a 28 kDa enzyme which is activated by thiol (Barlas et. al., 1987). A 
very similar protease of 27 kDa was found in rat submandibular gland by another 
group (Gutman et al., 1988), but they did not comment on its activation by thiol. 
Other enzymes such as cathepsin D may also release T-kinin (see Barlas et al.,
1987).
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1.5.10 Inactivation of kinins
Enzymes which inactivate kinins act at both the N-terminal and the C-terminal of 
the bradykinin chain. The most important of these inactivators are the kininases I 
and II which cleave the molecule at the C-terminal. Peptides such as bradykinin and 
kallidin are highly charged and it is unlikely that they can cross the cell membrane. 
Intracellular proteases therefore probably have little influence over the metabolic 
fate of kinins, and the most important proteases are located extracellularly. None of 
the enzymes which act on kinins are substrate specific, but may act on other 
peptides with susceptible bonds. Thus, there is an interaction between the kinin 
systems and others such as the complement and renin-angiotensin systems.
The conversion of kallidin to bradykinin was originally observed in human plasma 
(Webster & Pierce, 1963) and in horse plasma (Erdos et al., 1963). An arginine 
aminopeptidase present in blood has been isolated which cleaves the N-terminal 
Lys1 residue from kallidin and the N-terminal dipeptide Me^-Lys2 from 
Met-Lys-bradykinin, yielding bradykinin (Guimaraes et al, 1973). Trypsin is also 
able to cleave Lys1 from kallidin, but this is probably unimportant since trypsin is 
only active in the circulation in certain pathological conditions (see Regoli & 
Barab6, 1980). There are other enzymes capable of acting at the N-terminal of 
kinins, iminopeptidase and prolidase, but these are found intracellularly and so are 
probably of limited importance. It is also generally accepted that enzymes acting at 
the N-terminal of kinins play a limited role, if any, in their inactivation (Regoli & 
Barabe, 1980). Thus, cleavage of Lys1 from kallidin by aminopeptidase merely 
liberates bradykinin which requires further degradation by other enzymes to render 
it inactive.
Enzymes which act at the C-terminal of kinins are, however, more important in 
kinin inactivation. Kininase I (carboxypeptidase N) was first discovered in human 
plasma (Erdos & Sloane, 1962). This exopeptidase removes the C-terminal Arg 
from bradykinin and kallidin and is responsible for 90% of the destruction of kinins 
in plasma, the remainder being destroyed by kininase II (angiotensin converting
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enzyme) (see Regoli & Barabe, 1980). Removal of the C-terminal Arg by kininase I 
reduces the activity of bradykinin proportionally more than that of kallidin.
Pancreatic carboxypeptidase B and chymotrypsin may also inactivate kinins by 
removing the C-terminal Arg, but the former is far more effective (Erdos, 1979). 
The plasma concentration of carboxypeptidase B is too low for it to be of any 
importance in the inactivation of circulating kinins.
There has been another carboxypeptidase-like kininase described which is of 
unknown origin but which differs in its molecular weight from kininase I and other 
carboxypeptidases (Erdos, 1979). Erdos (1979) also mentioned a number of other 
reputed kininases present in a variety of tissues which were presumed to be either 
kininase I or II.
Both des-Arg9-bradykinin and des-Arg10-kallidin which are liberated by carboxy­
peptidase type enzymes are potent stimulants of BK^ receptor systems. This would 
suggest that inactivation of kinins by carboxypeptidases (e.g. kininase I) is less 
efficient than that by kininase II.
Kininase II cleaves the C-terminal dipeptide Phe-Arg from kinins (Yang & Erdos, 
1967) before releasing a second dipeptide, Ser-Pro (Dorer et al., 1974a). Bradykinin 
is the preferred substrate of kininase II, kallidin and other higher homologues of 
bradykinin being less susceptible, and degraded at a much reduced rate or not at all 
(Dorer et al., 1974b). This enzyme is located mainly on the cell membrane of 
endothelial cells, being closely associated with the lungs, kidneys and liver (Ferreira 
& Vane, 1967; Vane, 1969) and is present in many other vascular beds (Vane, 1969; 
Erdos, 1979; Regoli & Barabe, 1980). Kininase II provides the complete catabolism 
of bradykinin; des-Phe8,des-Arg9-bradykinin being almost totally inactive both in 
vitro and in vivo (as is des-Phe9,des-Arg10-kallidin) and the shorter peptides having 
no activity (see Regoli & Barabe, 1980).
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1.5.11 Physiological roles of kallikrein-kinin systems
Plasma kallikrein participates in the surface-dependent activation of blood 
coagulation, fibrinolysis, kinin generation and inflammation. Of these, the 
involvement of plasma kallikrein in blood clotting following contact activation and 
subsequent tissue repair is well documented and this is now generally accepted as 
its primary physiological role (see Pisano, 1975; Movat, 1979; Schachter, 1980a; 
Miiller-Esterl & Fritz, 1984).
HMW kininogen is thought to be an essential component of the intrinsic coagulation 
cascade. Those patients suffering from Fitzgerald trait, having a deficiency of HMW 
kininogen, have an extreme prolongation of kaolin-activated clotting time whereas 
LMW kininogen deficiency has no effect on the clotting time (see Movat, 1979).
The larger plasma kallikreins have less specific substrate requirements than do 
tissue kallikreins, but the existence of a physiological role for the plasma 
kallikrein-HMW kininogen system is now considered well established (Miiller- 
Esterl & Fritz, 1984). This function is believed to be an important factor in the 
intrinsic blood coagulation cascade and fibrinolysis and has been fully discussed 
elsewhere (Pisano, 1975; Movat, 1979; Miiller-Esterl and Fritz, 1984), but will be 
described brifely. A summary appears in figure 3.
Injury to blood vessels leads to exposure of the negatively charged surfaces of the 
basement membrane lying beneath endothelial cells. These strongly anionic surfaces 
rapidly bind to highly cationic sections of both circulating HMW kininogen- 
prekallikrein complex and Hageman factor. A histidine-rich segment of HMW 
kininogen (Han et al., 1975) anchors the molecule to the affected site whilst 
reciprocal activation of prekallikrein and Hageman factor takes place when active 
kallikrein is the major activator of Hageman factor, and active Hageman factor is 
the major activator of prekallikrein. Activated Hageman factor (factor Xlla) in turn 
activates factor XI and so triggers the coagulation cascade. Parallel with this, HMW 
kininogen undergoes limited proteolysis by activated kallikrein which liberates
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bradykinin and a fragment of HMW kininogen. This so-called called “kinin-free 
HMW kininogen” is more than twice as efficient as a cofactor of the contact phase 
than is native HMW kininogen and so acts to augment the cascade. The bradykinin 
liberated by the degradation of kininogen then increases microvascular permeability, 
and allows blood proteins to pass to the site of injury and so facilitates tissue repair.
Plasma kallikrein has been implicated in the activation of several other regulatory 
systems: prorenin activation initiates the renin-angiotensin system and thus liberates 
angiotensin II; activation of plasminogen triggers the fibrinolytic cascade; 
complement activation (see Movat, 1979; Silverberg & Kaplan, 1987); and is 
involved in the defence mechanisms against infectious diseases (Colman, 1989).
Both kininase I and II interact intimately with other blood-borne systems. Kininase I 
has also been referred to as anaphylatoxin inactivator, cleaving the C-terminal Arg 
from complement fragments C3a and Csa (Erdos, 1979). However, this does not 
render them totally inactive, e.g., despite being unable to release histamine from 
mast cells, C 5a des-Arg possesses potent inflammatory activity (Jose et al., 1981).
As may be apparent from its pseudonym, kininase II is an integral component of the 
renin-angiotensin system, but cleaves bradykinin in preference to angiotensin I. This 
enzyme is involved directly in the regulation of blood pressure by determining the 
conversion of angiotensin I to the hypertensive peptide angiotensin II. Kininase II 
also serves to eliminate the hypotensive peptide bradykinin from the circulation. 
Thus, inhibition of kininase II reduces the plasma level of angiotensin II and 
prevents bradykinin breakdown.
Tissue kallikreins are known to be present in a large number of tissues and like 
plasma kallikrein are thought to be implicated in a number of physiological roles. 
Both tissue and plasma kallikreins are known to be involved in the acute and 
chronic inflammatory response (see Kaplan & Silverberg, 1988; Kaplan et al., 
1989). Kallikrein and bradykinin exert a number of other actions: release of 
prostaglandins (Terragno & Terragno, 1979) and EDRF (Gryglewski et al., 1986)
34
from endothelial cells; production of functional vasodilatation in exocrine glands 
(Gautvik et al., 1976; Bhoola et al., 1979); regulation of systemic arterial blood 
pressure by prorenin activation (Ward & Margolius, 1979; Sealy, 1980); renal 
sodium and water balance (Nasjletti & Malik, 1980); and ion transport in the gut 
(Cuthbert & MacVinish, 1989).
1.6.0 SUMMARY
The kallikrein-kinin systems are thus implicated in many important roles, both 
physiological and pathological, with many of the components playing an essential 
part. The plasma kallikrein system interacts closely with other humoral systems, 
notably that of blood coagulation where its role is considered vital, and others such 
as the liberation of angiotensin II, activation of plasminogen and initiation of the 
fibrinolytic cascade, and the activation of the complement system where its 
physiological relevance has been questioned (Miiller-Esterl & Fritz, 1984).
A more complete understanding of the kallikrein-kinin system and its interrelations­
hips with other local mechanisms would therefore be an important step in the 
understanding of physiological processes and the treatment of pathologiocal states. 
The recent development of bradykinin receptor antagonists may help in this, but 
there is still no specific and selective tissue kallikrein inhibitor available.
The identity of an oxytocic principle derived from the isolated small intestine of rat 
described by Gaddum (1953) remained unkown until the present study. A search of 
the literature revealed that neither Gaddum nor any of his colleagues pursued the 
identity of substance R. However, Gaddum (1953) himself suggested that the 
properties of substance R and kallikrein were similar. Gaddum’s original 
observations have therefore been repeated and extended. His conclusions have been 
re-evaluated by a comparison of substance R with kallikrein. This has been made 
possible by the use of biochemical and pharmacological tools and techniques which 
were unavailabe to Gaddum when he wrote his paper of 1953, The Technique of 






Male Wistar rats (200-300 g), female Wistar rats (150-200 g), male Dunkin-Hartley 
guinea-pigs (500-900 g) and New Zealand White rabbits (2.5-3.0 kg) were all 
supplied by the University of Bath Animal House.
2.2 MATERIALS
Drugs and reagents were obtained from the following sources:
Amersham International, Amersham, Bucks:
125I-human serum albumin, 50 pCi per ml in sterile isotonic saline.
Bayer UK Ltd, Newbury, Berkshire:
Trasylol (aprotinin).
Janssen Pharmaceutical Ltd, Oxford:
Hypnorm (fentanyl citrate, 0.315 mg ml-1 and fluanison, 10 mg ml-1).
Kabi Yitrum Ltd, Uxbridge, Middlesex:
H-D-Val-L-Leu-L-Arg-p-nitroanilide hydrochloride (S-2266).
Novabiochem (UK) Ltd, Nottingham:
D-Arg- [Hyp3 ,Thi5*8,D-Phe7] -bradykinin.
May and Baker Ltd, Dagenham, Essex:
Pentabarbitone sodium as a 60 mg ml-1 solution in ethanol (Sagatal and Expiral).
37





Roche Products Ltd, Welwyn Garden City, Hertfordshire:
Midazolam hydrochloride, 5 mg ml-1 (Hypnovel).
Sandoz Products Ltd, Hounslow, Middlesex:
Methysergide hydrogen maleate.
Sigma Chemical Company, Poole, Dorset: 
atropine sulphate 
blue dextran
bovine serum albumin (Cohn fraction V, essentially fatty acid free) (BSA) 
bradykinin triacetate
carbamylcholine carbonic anhydrase (EC.4.2.1.1) from bovine erythrocytes 
alpha- and delta-chymotrypsin (EC.3.4.21.1) from bovine pancreas 




Folin and Ciocalteu’s phenol reagent
heparin sulphate
indomethacin
kallikrein (EC.3.4.21.35) from porcine pancreas 
lima bean trypsin inhibitor
molecular weight marker kit MW-SDS-70L: alpha-lactabumin, soy bean trypsin 
inhibitor PMSF-treated trypsinogen, carbonic anhydrase, glyceraldehyde-3-phosp- 
hate dehydrogenase, egg albumin and bovine albumin.
molecular weight marker kit MW-SDS-BLUE: (prestained markers) lactic dehydro­
genase, fumarase, pyruvate kinase, fructose-6-phosphate kinase, beta-galactosidase 
and alpha-2-macroglobulin
ovomucoid (partially purified from chicken egg white)
papain (EC.3.4.22.2) (insoluble, attached to beaded agarose) from Papaya latex 
soy bean trypsin inhibitor (SBTI) 
thioglycolic acid (as the sodium salt)
Trizma base 
Trizma hydrochloride
trypsin (EC.3.4.21.4) and insoluble trypsin (attached to cross-linked beaded agarose) 
from bovine pancreas.
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General laboratory grade chemicals were purchased from British Drug Houses 
(BDH), Poole; Fisons, FSA Laboratory Supplies, Loughborough; and Sigma 
Chemical Company, Poole.
The following were gifts. A sample of human plasma kininogen was kindly donated 
by Dr K.D. Bhoola, University of Bristol. Captopril was kindly donated by E.R. 
Squibb & Sons Ltd, London. Expired human plasma was given by Dr T. 
Wallington, Regional Blood Transfusion Centre, Southmead Hospital, Bristol.
2.3 BUFFERS, PHYSIOLOGICAL SALT SOLUTIONS AND
ANAESTHETICS
Tris buffer. A stock of 500 mM, pH 7.5 tris buffer was prepared at room 
temperature with 400 mM Trizma hydrochloride and 100 mM Trizma base 
dissolved in deionized water. The stock was stored at 4°C and working strength 
buffer (50 mM, pH 7.5) was prepared by dilution in deionized water.
Phosphate buffered saline (50 mM, pH 7.5) (PBS) was made with 12.5 mM 
Na2H2P 0 4.2H20 , 37.4 mM Na2H P04.2H20  and with and 154 mM NaCl in 
deionized water.
Physiological salt solutuions were prepared with the following compositions:
Tyrode’s solution: 137.0 mM NaCl, 5.5 mM D(+)-glucose, 12.0 mM NaHC03, 2.7 
mM KC1, 1.05 mM MgCl2.6H20 , 0.42 mM NaH2P 0 4.2H20  and 1.84 mM 
CaCl2.6H20 .
De Jalon’s solution: 154.0 mM NaCl, 2.8 mM D(+)-glucose, 5.9 mM NaHC03, 5.6 
mM KC1 and 0.55 mM CaCl2.6H20 .
Hypnorm-midazolam cocktail anaesthetic was prepared by mixing 1 part Hypnorm 
with 2 parts sterile water and this mixture with 1 part Hypnovel.
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Sterile PBS and water were prepared with filtered (0.22 pm) polished deionized 
water and autoclaved.
2.4.0 METHODS
2.4.1 Collection of substance R
The perfused isolated small intestines of male Wistar rats were used for the 
collection of substance R. Initially in this study rats were anaesthetised with ether. 
However, subcutaneous administration of the Hypnorm-midazolam cocktail (0.5 ml 
per 300 g) was found to be more convenient. Anaesthetised rats were then given 
heparin (1000 u) via a tail vein to prevent blood clotting during the perfusion. Later 
it was found that the same results could be obtained if animals were killed by 
cervical dislocation and the use of anaesthetics was abandoned. The bulk of the 
results presented here were obtained from preparations of substance R prepared 
without the use of anaesthetics.
Following laparotomy the small intestine was ligated at the duodenal level, distal to 
the pancreas and also at the ileo-caecal junction (figure 4). The superior mesenteric 
artery was cannulated and all other vessels, with the exception of the hepatic portal 
vein, were tied off. The mesenteric vasculature was flushed through slowly with 2 
ml of Tyrode’s solution containing heparin (200 u). The intestine was sectioned 
anterior to the duodenal ligature and distal to the caecal ligature, and the mesenteric 
vasculature was isolated. The intact mesenteric bed was then removed, care being 
taken to exclude all pancreatic tissue, suspended in a heated jacket (37°C) and 
perfused through the mesenteric artery with oxygenated (95% 0 2, 5% C 02) 
Tyrode’s solution (0.4 m lm hr1) supplied by a peristaltic pump (Watson-Marlow 
502S) (figure 5). Effluent from the hepatic portal vein was either collected for 
consecutive 20 min periods by a fraction collector (LKB Bromma 2212 Helirac or 
2112 Redirac) or, after a 30 min equilibration period, perfusate was pooled and used 
as starting material for the isolation of substance R by the methods described below.
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2.4.2 Preparation of substance R
Initially samples of intestinal perfusate were simply dialysed overnight against PBS 
at 4°C. Small volumes of intestinal perfusate were also desalted using PD-10 
columns (Sephadex G-25M). Later, larger volumes were used to isolate the oxytocic 
principle by chromatographic techniques to obtain purified samples for use in the 
laboratory. Figure 6 summarises the steps in the purification of substance R.
For preparative purposes pooled perfusates from three intestinal perfusions were 
used. The pooled perfusates from three such preparations were then dialysed 
overnight against 10 volumes of ammonium bicarbonate (50 mM, pH 7.8, 4°C). The 
high molecular weight residue was filtered, freeze-dried and stored at -20°C. 
Generally the lyophylised perfusate from nine intestinal preparations was 
redissolved in tris buffer and filtered before application to the ion-exchange column. 
Substance R eluted from the ion-exchange column was then subjected to gel 
filtration chromatography.
2.4.3 Anion-exchange chromatography
Anion-exchange chromatography of the soluble lyophyllised intestinal extract 
(section 2.4.2) was performed using DEAE-sepharose. The sample (15-30 ml) was 
applied to the column (2.6 x 30 cm) equilibrated in tris buffer at 4°C and washed 
with 50-150 ml tris. 5.0 ml fractions of eluate were collected (Gilson model 203 
fraction collector) at a flow rate of 0.4 ml m in1 (Gilson Minipuls 312 peristaltic 
pump) by a linear salt gradient of 0-1.0 M sodium chloride. Fractions were assayed 
for oxytocic activity on the superfused rat uterus before measuring absorbance at 
280 nm to obtain the elution profile. The fractions containing oxytocic activity were 
then pooled, dialysed against 50 volumes of ammonium bicarbonate (50 mM, pH 
7.8, 4°C) for 12-18 hours and lyophyllised.
2.4.4 Gel-filtration chromatography
Gel-filtration chromatography of the oxytocic principle was carried out routinely on
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a calibrated column of Sephacryl S-300 (2.6 x 90 cm) to prepare samples of 
substance R for use in the laboratory. The column was equilibrated with PBS at 4°C 
and 5.0 ml of soluble intestinal extract eluted from the ion-exchange column was 
applied to the column. The sample was eluted at a flow rate of 0.4 ml min-1 and 5.0 
ml fractions were collected. The oxytocic activty of each fraction was determined 
by assay on the superfused rat uterus and an elution profile was obtained by 
measuring each samples absorbance at 280 nm.
Estimation of the molecular weight of the oxytocic principle was made on a 
Sephacryl S-200 column (2.6 x 90 cm), calibrated with molecular weight markers, 
using the conditions described above. The fraction containing the peak oxytocic 
activity (in terms of the per cent maximal contraction per pi of fraction) was 
determined by assay on the superfused isolated rat uterus.
2.4.5 Calibration of Sephacryl columns
The columns were equilibrated with PBS at 4°C for calibration. Blue dextran or the 
calibrating proteins, at a concentration of 2.5-5.0 mg mb1, were loaded onto the 
column in a volume of 5.0 ml. Fractions of 5.0 ml were eluted from the column at a 
flow rate of 0.4 ml m in 1. The elution profiles of the calibrating proteins and blue 
dextran were determined spectrophotometrically at 280nm.
The void volume (V0) of the column was determined with blue dextran. The elution 
volumes (Ve) of the calibrating proteins (bovine serum albumin (66 kD), carbonic 
anhydrase (29 kD), cytochrome-C (12.5 kD) and aprotinin (6.5 kD) were then 
determined. The ratio Ve/V0 was calculated for each of the calibrating proteins and 
this was plotted against their molecular weights on semi-log paper.
The approximate molecular weight of substance R was determined by comparing 
the value of V /V 0 obtained for the fraction containing peak oxytocic activity 
against the calibration curve.
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2.4.6.0 Isolated smooth muscle preparations
Tissues were generally superfused by a modification of the method of Gaddum 
(1953). Tissues were suspended from isotonic transducers (Ealing) in heated jackets 
and were superfused with heated oxygenated (95% 0 2, 5% C 02) Tyrode’s or de 
Jalon’s solutions supplied by a pump (Watson-Marlow MHRE 22) at a flow rate of 
5 ml min-1. Contractions were recorded on a linear pen recorder (JJ Instruments 
CR650 or CR650S). A cascade system was sometimes employed, where superfusion 
fluid passed over two tissues in series. Reagents were prepared such that between 10 
and 100 pi volumes were injected into the stream of heated superfusion fluid 
proximal to the tissues. However, sometimes larger volumes of reagent were 
required and, when this exceeded 250 pi, the pump was stopped and the sample was 
injected into the injection port at a rate equivalent to that of the superfusion. 
Antagonists and inhibitors were added to the reservoir of superfusate.
2.4.6.1 The rat isolated uterus
Rat uteri in oestrus were used for the assay of oxytocic activity of samples. Rats 
were primed 18-24 hours before the experiment by subcutaneous administration of 
stilboestrol (0.1 mg kg '1) to virgin female rats. The uteri were then prepared 
according to the method of de Jalon, a thread tied around each end, and mounted in 
the heated superfusion jacket (30-32°C) under 0.5 g tension. Uteri were superfused 
with de Jalon’s solution (30-32°C, 5 ml min*1) (Gaddum, 1953).
In experiments investigating the effect of inhibitors and antagonists on oxytocic 
agents, a dose of agonist giving 70-90% of the maximum contraction was used.
2.4.6.2 The rat isolated fundus strip
A strip of rat fundus 4 cm long was prepared from male rats by the method of Vane 
(1957) and superfused with Tyrode’s solution (37°C, 5 ml min-1) under 1.0 g 
tension.
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2.4.6.3 The rat isolated duodenum
The rat isolated duodenum was either prepared by the method of Horton (1959) or 
the proximal 3 cm of duodenum was removed and was mounted in the superfusion 
apparatus under 1.0 g tension and superfused with de Jalon’s solution (37°C, 5 ml 
min-1).
2.4.6.4 The guinea-pig isolated ileum
Male guinea-pigs were killed by cervical dislocation and the abdomen opened. A 
short section of terminal ileum was removed and placed in oxygenated Tyrode’s 
solution. 2 cm lengths of ileum were selected and threads were attached to either 
end. The isolated ileum was then either superfused with Tyrode’s solution (37°C, 5 
ml min-1) or was mounted in a standard organ bath in Tyrode’s solution (37°C) 
under 1.0 g tension.
2.4.6.5 Assay of kinin-releasing activity
The kinin-releasing activity of substance R and kallikrein was assayed on the 
isolated guinea-pig ileum. In these experiments a 2 cm length of ileum was 
suspended in an 8 ml organ bath and bathed in oxygenated Tyrode’s solution 
containing captopril (4.6 x 104 M). The bath was washed out by upward 
displacement overflow. Bradykinin was used as a standard reference agonist.
2.4.7 Measurement of arterial blood pressure
Guinea-pigs were anaesthetised with phenobarbitone (100 mg kg-1, i.p.) and 
pentabarbitone (30 mg kg-1, i.p.) and paralysed with gallamine (10 mg kg'1, i.m.). 
Animals were ventilated (8 ml k g 1, 1 Hz) via a tracheal cannula using a mixture of 
air and oxygen (50:50, v/v). Blood pressure and heart rate were recorded from the 
carotid artery using a transducer (type P23Dd, Gould). Agents were injected as a 
bolus into the jugular vein via an indwelling canula.
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2.4.8 Measurement of local plasma protein leakage in rabbit skin
Plasma protein extravasation was measured as the local accumulation of 125I-HSA 
as described previously (Williams, 1979), with several minor modifications (see 
figure 7). Rabbits were anaesthetised by an intravenous injection of sodium 
pentobarbitone (Sagatal), 30 mg k g 1 via an indwelling cannula in the marginal ear 
vein. The hair of the back and flanks was closely clipped and a fixed, balanced site 
pattern was marked either side of the midline. 125I-HSA (5 pCi) was mixed with 1.0 
ml sterile Evans blue dye (2.5% in saline) and was administered 10-15 minutes prior 
to intradermal injections. Solutions of agents for intradermal injection were prepared 
beforehand in sterile saline or PBS, and kept on ice until required. Test and control 
sites were injected in six replicates (0.1 ml), using 1.0 ml syringes fitted with 27g 
(0.4 x 12 mm) sterile needles. Thirty minutes after the intradermal injections, a 
blood sample was taken by cardiac puncture into heparin (10 u ml*1) and the animal 
was killed with an overdose of barbiturate (Expiral).
Skin samples for estimation of plasma leakage were prepared in the following 
manner. The rabbit was skinned and the skin laid outside-down, blood was 
expressed from the larger vessels, and excess fat was removed from the skin. Skin 
sites were excised using a 17 mm steel punch and were placed in polycarbonate 
tubes ready for counting. Plasma samples were prepared by centrifugation of the 
heparinised blood at 1,500 g, 10 min. Three 1.0 ml plasma samples in polycarbonate 
tubes were taken as standards, and together with the skin samples, were counted in a 
gamma-counter (LKB 1275 Multigamma). Exudate volumes are expressed in terms 
of plasma volume per skin site, calculated by dividing the count from each skin site 
by the count for 1 pi of plasma.
Prostaglandin E2  (PGE2 ) was used at a concentration of 3 x 10_1° moles per site in 
all experiments.
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2.4.9 Chromogenic assay of kininogenase activity
Hydrolysis of the chromogenic substrate S-2266 was used to assay the tissue 
kallikrein content of samples (Amundsen et al., 1979). The endpoint method for the 
determination of kallikrein in urine as described in the Kabi Vitrum Laboratory 
Instruction booklet was used.
2.4.10 Immunodiffusion assay
In collaboration with Mr Carlos Figueroa at the University of Bristol a double 
diffusion immunoassay was carried out. Samples of substance R and rat urinary 
kallikrein prepared in our laboratory were tested against rabbit anti-rat tissue 
kallikrein antiserum (Rabito et al., 1980).
2.4.11 Radioimmunoassy for tissue kallikrein
Radioimmunoassay for rat tissue kallikrein was performed in Professor Chao’s 
laboratory by a previously published method (Shimamoto et al., 1979: see Chao and 
Chao, 1988).
2.4.12 Preparation of urinary kallikrein
Initially, crude preparations of rat urinary kallikrein were made by desalting rat 
urine on a Sephadex-G25M (PD-10) column equilibrated with PBS. Later, for 
comparative purposes, rat urinary kallikrein was prepared from urine collected 
overnight from male rats. The urine from individual rats was pooled and filtered 
before an overnight dialysis against 20 volumes of PBS. The dialysed sample was 
stored frozen at -20°C. A partially purified preparation of urinary kallikrein was 
obtained using the same preparative and assay techniques used in the isolation of 
substance R.
2.4.13 Kininogen preparations
Crude rat kininogen was prepared from blood collected by cardiac puncture from
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anaesthetised rats. Plasma was prepared by centrifugation of heparinised blood (10 u 
ml-1) at 1500 g for 10 min. Serum was prepared by centrifugation of coagulated 
blood (3,000 g, 15 min). Plasma or serum was heated at 56°C for 3 hours. After 
centrifugation (3,000g, 15 min) the supernatant was used as a crude preparation of 
kininogen.
Human plasma kininogen was prepared according to a method modified from that of 
Bhoola and Lemon (unpublished). Expired anticoagulated human plasma was heated 
at 56°C for 3 hours. An equal volume of cold (4°C) saturated ammonium sulphate 
solution was added slowly whilst stirring. The mixture was stored at 4°C for 24 
hours and then centrifuged at 1,750 g, 4°C for 20 minutes. The supernatant was 
decanted and discarded and the pellet was resuspended in a volume of cold 0.9% 
saline equal to half the original volume of plasma. The material was dialysed 
against 3 x 10 volumes of deionised water at 4°C over 48 hours. The dialysed 
sample was centrifuged at 1,750 g, 4°C for 20 minutes. The supernatant was 
decanted, freeze-dried and stored dessicated at -20°C.
2.4.14 Determination of protein concentration
A modification of the method of Lowry et al. (1951) was used to determine the 
protein concentration of samples. Standard curves were constructed using BSA as 
the standard.
2.4.15 SDS-polyacrylamide gel electrophoreseis
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out in our 
laboratory by Miss Amber Elderfield using an adaptation of the method of Laemmili 
(1970). Briefly, 20pl aliquots of substance R preparations, containing 10 or 5 pg 
protein were applied to SDS/polyacrylamide gels and constituent proteins were 
separated by electrophoresis using a 'Mighty Small II' vertical slab gel unit (Hoefer 
Scientific Instruments). Gels were stained with 0.2% PAGE blue 83 (BDH) to 
visualise individual bands.
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2.4.16 Western blot analysis
Western blot analysis of substance R was carried out in collaboration with 
Professors Henry Margolius and Julie Chao at their laboratories at the Medical 
University of South Carolina, USA.
An antigen overlay method was used for Western blot analysis of substance R and 
rat tissue kallikrein. Electrophoresis was performed on a 7.1-15% linear gradient 
SDS-PAGE under reducing conditions and the proteins were electrotransferred onto 
nitrocellulose. The nitrocellulose sheet was incubated with sheep anti-rat tissue 
kallikrein antiserum (1:500 dilution) followed by 125I-rat tissue kallikrein. The 
antibody binding sites were visualised by autoradiography.
2.4.17 Statistical analysis
Where necessary data are expressed as mean ± standard error of the mean (mean ± 
s.e. mean). Statistical significance was computed using the paired r-test or analysis 





3.1.0 PROPERTIES OF AN OXYTOCIC PRINCPLE FROM THE RAT 
INTESTINE
3.1.1 Release of an oxytocic princple from rat intestine
Experiments were carried out where lengths of rat isolated small intestine were 
introduced into the stream of superfusion fluid above the rat uterus in a cascade 
system. This resulted in the uterus undergoing a series of slow and prolonged 
contractions (figure 8). In four such experiments the series of contractions began 
immediately following the introduction of the intestine and lasted between 5 and 20 
minutes. In each experiment the uterus did not contract at all spontaneously after the 
initial series of contractions and each was stable for at least 30 minutes, one uterus 
being stable for 150 minutes.
Figure 8 also shows that the same phenomenom was observed when a length of 
guinea-pig ileum was placed above the rat uterus in the cascade system.
Neither a “sham” disturbance of the superfusate flow where a length of cotton 
thread replaced the intestine, nor the introduction of another uterus in place of the 
intestine resulted in contraction of the uterus.
The motility of the gut appeared to have no relation to the contractions of the 
superfused uterus below.
3.1.2 Intestinal perfusion
Perfusion of the rat isolated small intestine resulted in the elution of a light yellow 
perfusate, tinted red in the first two or three fractions by the presence of 
erythrocytes. Fractions collected after several hours of perfusion were markedly 
darker in colour than the earlier ones. A small increase in volume with time was 
also noted.
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3.1.3 Oxytocic activity of intestinal perfusate
The effluent from perfused small intestines was found to contract the rat isolated 
superfused uterus in a dose-dependent manner (figure 9). In contrast to uterine 
contractions induced by either carbachol or bradykinin, those to intestinal perfusate 
were delayed in onset (from 30-60 seconds) (figure 10). Contractions of the uterus 
to intestinal perfusate resembled those to bradykinin in that they reached a 
maximum slowly compared with responses to carbachol.
3.1.4 Time-course of release of oxytocic activity from perfused rat small 
intestine
Figure 11 shows the time-course of release of oxytocic activity from an intestinal 
perfusion. When consecutive fractions of perfusate from isolated intestines were 
collected, at least 30 minutes elapsed before oxytocic activity was detectable. 
However, oxytocic activity was released in increasing amounts thereafter. A 
maximum concentration of oxytocic activity was reached after 3-4 hours, and this 
was sustained for at least a further 2-3 hours. In three such preparations the protein 
concentration of the eluate remained between 1-2 mg ml-1 throughout the period of 
perfusion. Although there was a slight rise observed at the begining of perfusion, 
there appeared to be no correlation between protein concentration and oxytocic 
activity. In a number of perfusion experiments carried out at the begining of this 
study, oxcytocic activity always appeared in the eluate within 20-60 minutes.
Fasting animals overnight prior to isolation and perfusion of their intestines had no 
influence on the time-course of release of oxytocic activity.
In the first few experiments the isolated gut was supported in the heated jacket by a 
guaze hammock (Gaddum, 1953). Removal of this accelerated the isolation and 
perfusion procedure and did not affect the results obtained. Therefore use of the 
hammock was dispensed with.
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3.1.5 Physical properties of the oxytocic principle
The oxytocic principle from the intestinal perfusate was non-dialysable (m.w. cut 
off 10-15 kDa). Oxytocic samples of perfusate were applied to Sephadex G-25M 
(PD-10) columns equilibrated with PBS. The eluate from the PD-10 columns 
contained oxytocic acivity. This provided a reliable method for rapidly desalting 
oxytocic samples of intestinal perfusate. This material was found to be stable for at 
least 8 weeks when stored frozen at -20°C.
When oxytocic samples were mixed with 4 volumes of cold (4°C) acetone a white 
precipitate was formed. After drying off under nitrogen, and redissolving in PBS, 
the precipitate was found to posess oxytocic acivity.
Heating oxytocic samples of intestinal perfusate in a boiling water bath for 10-15 
minutes resulted in a substantial loss of acitvity on the uterus preparation. This was 
further investigated using purified samples. Boiled samples retained only 5-20% of 
their preboiled activity.
Thioglycolic acid was used to determine whether oxytocin was responsible for 
oxytocic acitvty in intestinal perfusate. Samples were incubated at room temperature 
with a mixture of thioglycolate (0.01M) and sodium bicabonate (0.01M) at pH 7.5 
for 30 minutes (Walker, 1967) before assay on the isolated uterus. Treatment of 
samples containing oxytocic activity with thiogycolate did not result in any loss of 
activity (figure 12).
Incubation with either insoluble trypsin or insoluble papain (10 enzyme units per 
ml, pH 7.5, 30 minutes, 37°C) did not result in any change in oxytocic activity of 
the samples (figure 13).
3.1.6 Pharmacology of the oxytocic principle
Oxytocic activity of samples of intestinal perfusate was not inhibited by addition of 
atropine (10 6M), methysergide (5.7 x 10'7M) or indomethacin (10_5M) to the
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superfusate.
3.2.0 COMPARISON OF THE PHARMACOLOGY OF SUBSTANCE R AND 
RAT URINARY KALLIKREIN
The results presented in section 3.1 are very similar to the characteristics of 
“substance R” reported by Gaddum in 1953. As Gaddum himself observed, these 
properties resemble those of the then recently described kallikrein. To compare the 
activities of the two substances further, rat urine was utilized as a readily available 
source of kallikrein. A commercial preparation of porcine pancreatic kallikrein was 
also used in some experiments.
Where “substance R” is used in the following sections discussing results, it denotes 
that results were obtained using a sample of the oxytocic principle from intestinal 
perfusate which had been purified using chromatographic techniques.
3.2.1 Oxytocic activity
Rat urinary kallikrein induced contraction of the superfused rat isolated utreus. The 
contractions resembled those produced by substance R, being delayed in onset and 
slow to reach a maximum. Up to 500 pg of porcine pancreatic kallikrein was found 
to be inactive on the uterus in an experiment where 40 pi of intestinal perfusate 
(50-100 pg protein) produced a maximal contraction.
3.2.2 Pharmacological distinction of substance R from trypsin and chymotryp- 
sin
Trypsin, alpha- and delta-chymotrypsin were all found to cause contractions of the 
rat uterus that were similar to those produced by intestinal perfusate and kallikrein. 
An attempt was therefore made to distinguish the oxytocic activty in intestinal 
perfusate.
Figure 14 shows the responses of sections of superfused rat uterus. A supramaximal
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dose of substance R had no effect on the sensitivity of the tissue to bradykinin 
(figure 14a). Trypsin (100 pg) did not induce a contraction of the uterus. A higher 
dose of trypsin (1 mg) induced a contraction and sensitization of the tissue to 
bradykinin (figure 14a). The same piece of tissue however, then contracted to and 
was sensitized by trypsin (1 mg). A supramaximal dose of urinary kallikrein did not 
induce a sensitization of the uterus to bradykinin (figure 14b).
Like trypsin, both alpha- and delta-chymotrypsin sensitized the rat uterus to 
bradykinin (figure 15a & b) at similar doses.
3.2.3 Action on other isolated smooth muscle preparations
Neither substance R nor urinary kallikrein contracted the superfused guinea-pig 
ileum, rat fundic strip or rat ileum at doses up to 10-fold those which were oxytocic. 
The superfused rat duodenum relaxed to both substance R and urinary kallikrein at 
doses coparable to those which were oxytocic. However, whilst consistently relaxing 
to bradykinin, duodenal preparations rapidly became insensitve to both substances.
3.2.4 Cardiovascular actions of substance R
Substance R was hypotensive in the anaesthetised rat and guinea-pig. Figure 16 
shows the recording of the arterial blood pressure of an anaesthetised guinea-pig. 
Intravenous injection of substance R (10, 20 and 50 pi) caused a dose-related 
reduction in arterial blood pressure. No action on the heart rate or lung function was 
observed at these doses. At similar doses, substance R did not relax a rat aorta 
contracted to phenylephrine (endothelium intact) or have any effect on the perfusion 
pressure or rate of a Langendorf perfused rat heart.
3.2.5 Effect of trypsin inhibitors on oxytocic activity
In each of six experiments, addition of aprotinin (Trasylol) (100 KIU m l1; 2.2 x 
10'6M) to the fluid superfusing the isolated uterus completely inhibited the oxytocic 
activity of both substance R and urinary kallikrein (figure 17).
55
Soy bean trypsin inhibitor (SBTI) (100 pg m l'1; 5 x 10'7M) completely inhibited the 
action of substance R on the isolated rat uterus (99.4 ± 0.3%) whereas the oxytocic 
acitvity of urinary kallikrein was only reduced by 12.6 ± 2.5% (n=6) (figure 18). 
Responses to bradykinin and carbachol were reduced by 9.9 ± 1.8% and 3.0 ± 0.8% 
respectively. Inhibition of uterine responses to substance R by SBTI was significant 
(P<0.01, ANOVAR). SBTI was found to be effective against substance R at a 
concentration of 50 pg ml; 2.5 x 10'7M (n=3).
The trypsin inhibitors ovomucoid trypsin inhibitor (100 pg ml-1) and lima bean 
trypsin inhibitor (100 pg m l'1) were ineffective against the oxytocic activity of 
substance R and urinary kallikrein.
3.2.6 Effect of D-Arg-[Hyp3,Thi5>8,D-Phe7]-bradykinin on oxytocic activity
Figure 19 shows the inhibition of kinin-dependent oxytocic responses by the BK2 
antagonist D-Arg-[Hyp3,Thi5>8,D-Phe7]-bradykinin. Addition of D-Arg- 
[Hyp3,Thi5’8,D-Phe7]-bradykinin (10'7M) to the superfusate reduced oxytocic 
responses to bradykinin, kallikrein and substance R by 63.8 ± 10.7%, 69.5 ± 11.8% 
and 85.9 ± 8.6% respectively (PcO.Ol, ANOVAR) («=8). Responses to carbachol 
were not reduced in the presence of the kinin antagonist, on the contrary, they were 
enhanced in all experiments (increasing by 17.9 ± 4.6%, n=6).
3.2.7 Kinin-releasing activity
When desalted intestinal perfusate and desalted rat urine were incubated with rat 
heat inactivated plasma or serum in the presence of captopril (4.6 x 10'4M) (37°C, 
30 min), a substance was released which contracted the guinea-pig isolated ileum.
Figure 20 shows responses of a length of guinea-pig ileum to desalted samples of 
intestinal perfusate and rat urine. Addition of these alone had little or no effect on 
the ileum. However, when added to the bath in the presence of heat inactivated 
plasma, addition of either substance brought about an immediate contraction of the 
tissue.
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Further experiments were carried out with purified preparations of substance R and 
urinary kallikrein using human plasma kininogen as the substrate. The kinin- 
releasing activity was assayed on the guinea-pig isolated ileum preparation in the 
presence of captopril (4.6 x 10'4M). The ileum was unresponsive to either kallikrein, 
substance R or kininogen alone. However, when kininogen was first added to the 
bath, subsequent addition of kallikrein or substance R resulted in contraction of the 
ileum which was inhibited by the kinin receptor antagonist D-Arg-[Hyp3,Thi5«8,D- 
Phe7]-bradykinin (107M). Complete inhibition of these contractions was obtained 
when aprotinin (100 KIU ml'1, 2.2 x 10'6M) was added to the bath (n=3). In 
contrast, figure 21 shows that SBTI (5 x 10'7M) produced a small inhibition of the 
kinin liberation by urinary kallikrein (13.2 ± 6.3%) but significantly (PcO.OOl, 
paired f-test) reduced the release of kinin by substance R by 80.4 ± 5.0%, as 
measured by contraction of the ileum {n-6) (figure 21).
3.2.8 Oedema formation in rabbit skin
Figure 22 shows that intradermal injection of substance R + PGE2 into rabbit skin 
resulted in dose dependent microvascular leakage. A 20 pi volume of the 
preparation of substance R used produced a maximal contraction of the uterus. In a 
preliminary experiment substance R alone (20 pi) produced a substantial 
inflammatory response (64 pi extravasation). PGE2 alone produced 20 pi of leakage. 
PGE2 potentiated the response to substance R, giving 201 pi of plasma leakage.
Maximum plasma leakage was obtained to 10 pi of substance R. A 10 pi sample of 
boiled substance R injected together with PGE2 gave a response equivalent to a 2 pi 
volume of unboiled substance R + PGE2 (figure 22).
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3.3.0 BIOCHEMICAL ANALYSIS OF SUBSTANCE R
3.3.1 Anion-exchange chromotography of intestinal perfusate
An elution profile of ion-exchange chromatography (DEAE-Sepharose) of intestinal 
perfusate is shown in figure 23. Freeze-dried pooled oxytocic fractions of intestinal 
perfusate were dissolved in tris buffer, loaded onto the column and washed with 100 
ml of buffer. A single peak of oxytocic activity was eluted by a linear salt gradient 
at approximately 0.2M NaCl.
3.3.2 Gel-filtration chromatography of partially purified substance R
During routine preparation of substance R gel filtration of pooled and lyophylised 
oxytocic fractions eluted from the ion-exchange column was performed on 
Sephacryl S-300. A single peak of oxytocic activity was eluted.
Determination of the molecular weight of substance R by gel filtration was carried 
out on Sephacryl S-200. A single peak of oxytocic activity was resolved, with the 
peak fraction having a molecular weight of 40,000 Daltons (figure 24). There was 
no detectable oxytocic activity in 200 pi samples of fractions either side of this 
peak.
3.3.3 Kininogenase activity
The fractions containing the peak of oxytocic activity from a molecular weight 
determination were assayed for kininogenase activity using the specific tissue 
kallikrein chromogenic substrate S-2266. A single peak of kininogenase activity 
coinciding with that of the oxytocic activity was found (figure 25). Very low levels 
of activity (3-20 nkat I-1) were present in the fractions immediately adjacent to the 
oxytocic peak, compared with 5.3 x 103 nkat l '1 in the peak fraction.
Kininogenase activity of samples of substance R was also studied, in the laboratory 
of professor Julie Chao, using two other assay techniques. Substance R posessed
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kininogenase activity assessed by the method of Shimamoto et al (1979) where 
kinin production from purified bovine kininogen was measured by radioim­
munoassay (Shimamoto et al, 1979). Substance R also hydrolysed the synthetic 
substrate 3H-Tos-Arg-OMe (Chao, personal communication).
3.3.4 Immunodiffusion study
Figure 26 shows the result of a double immunodiffusion assay using the technique 
of Ouchterlony. The assay was carried out on chromatographed samples of 
substance R and urinary kallikrein that were approximately equipotent on the rat 
uterus. A strong immunoprecipitate band was formed by the reaction of the 
antiserum with the urinary kallikrein. Another, weaker immunoprcipitate band was 
formed between the antiserum and substance R. A sample of a non-oxytocic fraction 
of eluate from the chromatography of substance R did not react with the antiserum.
3.3.5 SDS-PAGE analysis
The result of SDS-PAGE analysis of substance R is shown in figure 27. A number 
of protein bands were seperated, the major bands having molecular weights of 
approximately 62,000, 39,000, 26,000 and 21,000 Da. The 39 kDa band was well 
separated from the others, this band is thought to represent the protein which elutes 
with a molecular weight of 40 kDa from the gel-Sephacryl S-200 column, i.e. 
substance R.
3.3.6 Western blot analysis
In Western blot analysis using a highly sensitive and specific antigen overlay 
method, substance R was recognised by antibody against rat tissue kallikrein as a 
single polypeptide with a molecular mass of 39,000 Da, under reducing conditions 
(figure 28). The molecular weight of substance R was slightly larger than that of
38,000 Da tissue kallikrein purified from rat submandibular gland (figure 28).
The molecluar weight of substance R differed markedly from those obtained for
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tonin, argenine esterase A or T-kininogenase under identical conditions.
3.3.7 Radioimmunoassay for tissue kallikrein
Serial dilutions of substance R showed complete parallelism to the standard curve of 
tissue kallikrein in a direct radioimmunoassay (figure 29).
3.3.8 The effect of inhibitors on hydrolysis of S-2266
The results of a study of the effects of various inhibitors on the hydrolysis of the 
chromogenic substrate S-2266 are summarised in table 2. Aprotinin, SBTI, sheep 
anti-rat urinary kallikrein antibody, and the monoclonal antibody V4D11 all 
produced a concentration dependent inhibition of hydrolysis of S-2266. Substance R 
appeared to be more susceptible to inhibition by SBTI and aprotinin than was 







In 1953 Gaddum made a little-known discovery of an oxytocic principle from the 
rat small intestine which he named substance R. The results obtained in the present 
study confirm and extend those reported by Gaddum nearly 40 years ago. Initially 
an attempt was made to repeat Gaddum’s first observation of the detection of 
substance R. It was found that when a length of rat ileum was superfused in series 
above the rat uterus, the latter underwent a series of slow and prolonged 
contractions. This result is similar to Gaddum’s report that a substance was 
sometimes liberated from the superfused rat intestine which caused a contraction of 
the rat’s uterus, the principle he named substance R.
The slow, delayed contraction of the rat uterus by intestinal perfusate reported in the 
present study is similar to that described by Gaddum (1953) for substance R. 
Release of this oxytocic principle from the rat perfused small intestine increases 
with time from 30 minutes to approximately 3 hours after which the oxytocic 
activity of the perfusate remains high. The oxytocic activity of intestinal perfusate 
was unaffected by atropine or methysergide. Thioglycolate inactivates oxytocin (van 
Dyke et al., 1942; Ames et al., 1950), yet treatment of intestinal perfusate with this 
substance did not diminish its oxytocic activity. However, boiling samples of 
substance R resulted in a substantial loss of activity. Substance R was found to be 
non-dialysable (molecular weight cut off 10-15 kDa) and an acetone precipitate of 
preparations contained the oxytocic activity. These results are in agreement with 
those of Gaddum (1953). In addition substance P could not account for the oxytocic 
activity of substance R (Gaddum, 1953). Thus, the possibility that the oxytocic 
principle in intestinal perfusate is one of a number of pharmacologically-active 
substances such as acetylcholine, 5-HT, histamine, substance P and oxytocin was 
eliminated. In contrast, substance R is a high molecular weight and thermolabile 
substance.
As previously reported (Douglas et al., 1988, 1989) these results confirm the release 
of an oxytocic principle from rat intestine which shares the properties described by
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Gaddum (1953) for substance R. The nature of substance R has remained 
unidentified since Gaddum’s first report (1953) and was therefore further 
investigated.
As Gaddum (1953) himself remarked, substance R and kallikrein share a number of 
properties. In addtion to being of a high molecular weight and thermolabile, neither 
substance R or kallikrein contract the isolated guinea-pig ileum, rat fundic strip or 
rat ileum, both relax the rat duodenum and are both hypotensive. To explore this 
similarity further, desalted rat urine was used as a source of authentic 
kallikrein. Demonstration of the release of a kinin from its plasma substrate by a 
substance indicates that it may be a kallikrein (Webster, 1970a). Kinin generation 
from kininogen preparations was assayed on the guinea-pig ileum. Neither rat serum 
or plasma, nor the crude preparations of substance R or kallikrein, caused 
contraction of the guinea-pig ileum when added to the bath alone. However, when 
kallikrein or substance R were added to the bathing fluid in the presence of plasma 
or serum, the muscle contracted. Further experiments carried out with purified 
urinary kallikrein and substance R preparations confirmed the release of a kinin-like 
substance from human, rat and bovine plasma kininogen. The rate of generation of 
kinin-like activity by substance R was similar to that by urinary kallikrein. The 
competitive bradykinin antagonist D-Arg-[Hyp3,Thi5-8,D-Phe7]-bradykinin (Regoli 
et al., 1986a; Schachter et al., 1987) inhibited such contractions and it was 
concluded that a kinin was indeed released by substance R from kininogen 
preparations. Other evidence of the kininogenase activity of substance R was 
obtained from the fact that it hydrolysed the synthetic tissue kallikrein substrates 
S-2266 (Douglas et al., 1991) and 3H-Tos-Arg-OMe (Chao, personal communic­
ation).
The proteolytic enzymes trypsin and chymotrypsin contract the rat uterus in a 
similar way to substance R (Rocha e Silva, 1939; Gaddum, 1953). Gaddum (1953) 
explored the possibility that substance R was identical to either of these enzymes. 
He found that crude acetone precipitations of intestinal perfusate were more active
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on a weight for weight basis than crystalline preparations of either trypsin or 
chymotrypsin. Gaddum deduced, therefore, that neither enzyme was likely to be 
responsible for the oxytocic activity of substance R, but recognized that this 
possibility could not be discounted. The pharmacological actions of trypsin and 
chymotrypsin were therefore compared with those of substance R and kallikrein in 
the present study. Both trypsin and two forms of chymotrypsin, alpha- and delta-, 
caused a similar delayed, slow contraction of the superfused uterus to that induced 
by substance R or kallikrein. However, as reported by Gaddum (1953), it was noted 
that on a weight for weight basis they were considerably less potent than eithet 
kallikrein or substance R. It has been reported that trypsin, chymotrypsin and other 
proteases can sensitize certain smooth muscle preparations to the agonist bradykinin 
(Edery, 1964, 1965; Gilfoil & Kelly, 1966; Edery & Grunfield, 1969). It is not 
known why this sensitzation occurs, but several explanations have been put forward, 
such as a proteolytic action on the bonds between smooth muscle cells, allowing 
greater penetration of bradykinin (Edery, 1965); a direct action on the muscle fibres 
(Gilfoil & Kelly, 1966); and exposure of a greater number of bradykinin receptors 
(Edery & Grunfield, 1969).
Trypsin, alpha- and delta-chymotrypsin induced a specific sensitization of the tissue 
to bradykinin, at or below oxytocic doses. On the other hand, supramaximal doses 
of either kallikrein or substance R failed to produce any such sensitization. In 
addition, enzyme inhibitors such as ovomucoid trypsin inhibitor and lima bean 
trypsin inhibitor which inhibit the actions of trypsin and chymotrypsin were without 
effect on the oxytocic activity of substance R. These results strongly suggest that 
substance R is not identical to either trypsin or chymotrypsin.
The actions of various trypsin inhibitors on oxytocic responses to substance R and 
kallikrein were investigated. Ovomucoid trypsin inhibitor and lima bean trypsin 
inhibitor were inactive against either urinary kallikrein or substance R. These results 
are in agreement with previously reported inhibitory activities against tissue 
kallikreins (see Vogel & Werle, 1970; Vogel, 1979).
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The polyvalent trypsin inhibitor aprotinin (Trautschold et al., 1967) has been shown 
to inhibit most kallikreins (see Vogel, 1979). Aprotinin inhibited oxytocic responses 
of the rat uterus to both substance R and urinary kallikrein. However, SBTI, which 
selectively inhibits plasma kallikreins (Werle & Berek, 1952; Back & Steger, 1968; 
Vogel, 1979) blocked responses of the rat uterus to substance R without causing a 
significant reduction in those to urinary kallikrein. The release of kinin from 
kininogen by substance R was likewise inhibited by SBTI and aprotinin. Kinin 
liberation from kininogen by urinary kallikrein, however, was inhibited only by 
aprotinin. These results, summarised in figure 30, suggest that substance R posesses 
kininogenase activity but was unlikely to be a tissue kallikrein. An attempt was 
therefore made to purify and characterize substance R further.
Initial results from gel filtration chromatography of the soluble extract from 
intestinal perfusate suggested the molecular weight of substance R was approxim­
ately 21 kDa (Douglas et al., 1989). However, a large number of contaminating 
proteins, as revealed by SDS-PAGE may have affected this estimate. The number of 
contaminating proteins were reduced by anion-exchange chromatography prior to 
gel filtration. A single peak of biological activity with a molecular mass of 40 kDa 
was then resolved. This estimate was confirmed by SDS-PAGE in our laboratory 
and by Western blot analysis by Professor Chao. This peak of oxytocic activity also 
corresponded to another of kininogenase activity. This demonstrates that a single 
substance is responsible for these two biological activities.
This molecular weight estimation suggests that substance R is unlikely to be a 
plasma kallikrein since these have been reported to have masses of 90 kDa or more 
(see Movat, 1979; Schachter, 1980a). The possibility that substance R was a tissue 
kallikrein was investigated. Using an immunodiffusion assay, it was established that 
substance R preparations share immunological epitopes with rat tissue kallikrein 
(Douglas et al., 1989), a finding later confirmed by Western blot analysis and 
radioimmmunoassay.
Further evidence was obtained that substance R is very similar to rat tissue
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kallikrein with respect to its enzymatic properties. Substance R releases kinins from 
rat and bovine kininogens, hydrolyses the specific tissue kallikrein synthetic 
substrate S-2266, which is inhibited by aprotinin, and also hydrolyses 3H- 
Tos-Arg-OMe (Chao, personal communication). In addition, hydrolysis of S-2266 
by substance R is inhibited by both affinity-purified polyclonal anti-rat tissue 
kallikrein antibody, and the monoclonal antibody to rat tissue kallikrein, V4D11 
(Chao, personal communication). However, substance R was more susceptible to 
SBTI inhibition of S-2266 hydrolysis than was tissue kallikrein, thus confirming the 
original findings on the rat uterus (Chao, personal communication).
Substance R also shares other immunological properties with rat tissue kallikrein. 
Serial dilutions of substance R show complete parallelism to the standard curve of 
tissue kallikrein in a radioimmunoassay. Other purified members of the kallikrein 
gene family such as tonin, arginine esterase A and T-kininogenase share 80-85% 
sequence homology with tissue kallikrein but clearly display non-parallel curves to 
tissue kallikrein standard in the radioimmunoassay (Chao, personal communication). 
A number of cDNA clones encoding kallikrein gene family members have been 
sequenced by the groups of Chao and MacDonald (see MacDonald et al. 1989). 
These kallikrein-related cDNAs share 75-90% sequence homology and are 
indistinguishable in Northern or Southern blot analysis. The direct radioim­
munoassay for tissue kallikrein is therefore regarded as an extremely specific and 
powerful technique in distinguishing tissue kallikrein per se from other kallikrein 
gene family members (Chao, personal communication). In Western blot analysis of 
substance R, the antibody to rat tissue kallikrein recognizes only a single band with 
a molecular mass of 39 kDa. There was a slight difference in molecular weight 
between substance R (39 kDa) and rat submandibular kallikrein (38 kDa). However, 
the size of substance R is markedly different from tonin, arginine esterase A or 
T-kininogenase under identical conditions (Chao & Chao, 1987; Chao, personal 
communication).
Previous reports have given markedly differing estimates of molecular weight for
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tissue kallikrein (between 25-45 kDa). It has long been known that within the same 
tissue source there may be different forms of the enzyme which are distinguishable 
by their molecular mass or isoelectric point (see Fielder, 1979). These multiple 
forms of kallikrein could be the result of differences in the genetic expression of the 
enzyme. Alternatively, another explanation may be that kallikreins of pancreatic or 
sublingual origin are absorbed from the intestine into the blood and are excreted by 
the kidneys (Nustad et al., 1980). This appeared to be confirmed by evidence that 
the primary structure of human urinary and pancreatic kallikreins are identical 
(Fukushima et al., 1985). It has been shown, however, that whilst sharing the same 
primary protein structure such isoforms may be glycosylated differently. This was 
first demonstrated in pancreatic kallikrein. The two (or more) forms of porcine 
pancreatic kallikrein share the same amino acid sequence but differ in their 
carbohydrate content (Tschesche et al., 1979; Moriya et al., 1983). Urinary 
kallikrein has been intensively studied and multiple forms of this enzyme have also 
been described. Morichi et al. (1984) ascribed the microheterogeneity of human 
urinary kallikrein to variations in sialic acid and carbohydrate content. These authors 
suggested this may result in conformational changes within the molecule. Nustad 
and Pierce (1974), on the other hand, found no variation in the sialic acid residues 
of the isoforms of rat urinary kallikrein. The many different pi forms of human 
urinary kallikreins contain just a single polypeptide chain (Lu et al., 1989). The 
heterogeneity is not the result of multiple forms of kallikrein gene product, but 
rather a result of variations in the extent of glycosylation (Lu et al., 1989). These 
authors discussed the possible glycosylation sites within the molecule, deduced from 
experimental results and amino acid sequence data. It was their conclusion that the 
two molecular weight isoforms of the enzyme (38 and 42.5 kDa) and minor 
heterogeneity in isoelectric points, resulted from varying degrees of glycosylation of 
the Asn-141 residue.
It thus appears that the multiplicity of tissue kallikrein molecules is not derived 
from expression of various kallikrein gene family products, but is controlled by 
post-translational modification by events such as glycosylation. Such heterogeneity
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of processing would account for the slight difference in molecular mass between 
substance R and rat submandibular kallikrein as revealed by Western blot analysis. 
Given that there are a number of potential sites of glycosylation in the tissue 
kallikrein molecule (Lu et al., 1989), these differences may possibly occur at 
different residues in kallikreins from various tissue sources which may infer slight 
conformational changes and tertiary stuctural differences.
It is known that within the same species the same gene controls expression of tissue 
kallikrein throughout all tissues (see MacDonald et al., 1988). Thus, Chao et al. 
(1986), found that rat kallikreins from brain, spleen, kidney, pancreas, submandibu­
lar gland and urine were indistinguishable in their properties of mass, charge and 
immunoreactivity. Western blot analysis using a monoclonal antibody demonstrated 
a molecular mass for these kallikreins of 38 kDa (Chao et al., 1986). Key amino 
acid residues which are conserved through different species are thought to be the 
primary determinants of the proteolytic cleavage specificity of tissue kallikreins 
(MacDonald et al., 1988).
The results presented here from Western blot analysis and radioimmunoassay clearly 
demonstrate that substance R is a tissue kallikrein. The susceptibility to inhibition 
by SBTT is apparently its only distinguishing feature. There have been many reports 
in the past of kallikreins in the gastrointestinal tract, but none of those described is 
identical to substance R.
Werle and Vogel (1961) described a trypsin-activated SBTI-resistant substance in 
homogenates of colon wall which posessed hypotensive activity. Saline homo- 
genates of duodenal, jejunal, ileal and colonic tissues of rat and rabbit contained an 
acid-activated kinin-forming activity (Amundsen & Nustad, 1965). Amundsen 
(1966) demonstrated the release of kinin, kinin precursor, kininase and kinin- 
forming activity during the early phase of strangulated terminal ileum in rat. The 
kinin-forming activity was only present in samples which were acidified. However, 
none of these authors tested enzyme inhibitors on this mucosal tissue extract.
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Release of a 'kallikrein-like amidase’ from rat colon which hydrolysed a synthetic 
substrate of kallikrein has been demonstrated. Either incubation of tissue segments 
with bile salts, or perfusion of the colon with bile salts resulted in liberation of this 
enzyme, the activity of which was inhibited by aprotinin but not SBTI (Al-Dhahir & 
Zeitlin, 1983). Cat colon kallikrein has been isolated as a 40 kDa protein with 
several isoforms, inhibited partially by SBTI but not by aprotinin and is similar to 
other tissue kallikreins from cat in this respect (Fujimori et al., 1986a, 1986b). A 
trypsin-activated prekallikrein with a high molecular weight and other properties 
suggesting it is a plasma kallikrein has also been isolated from human, monkey and 
dog colon tissue (Seki et al., 1972).
It is possible that substance R may be derived from a source other than the ileum. 
Stomach kallikrein has been purified from rat and human tissues with molecular 
weights of 29 and 38 kDa respectively. The hydrolysis of a synthetic substrate by 
both stomach kallikreins was inhibited by aprotinin and DFP but no inhibition was 
seen with SBTI, LBTI or OMTI (Uchida et al., 1976; Uetsuji et al., 1981). The 
pancreas is another possible source of substance R, but unlike substance R, rat 
pancreatic kallikreins described so far have not been inhibited by SBTI (Vogel & 
Werle, 1970; Hojima et al., 1975; Vogel, 1979).
Of perhaps more relevance to the present study are reports of a tissue kallikrein 
from rat small intestine. This is a tissue kallikrein distinct from plasma kallikein as 
defined by its molecular weight of 33 kDa (Zeitlin et al., 1976), its hydrolysis of 
synthetic substrates (Zeitlin, 1971, 1972), and the action of inhibitors upon it 
(Zeitlin, 1971, 1972; Moriwaki et al., 1977b; Frankish & Zeitlin, 1980).
Aqueous extracts of rat homogenized intestinal tissue contained a kinin-forming 
enzyme (KFE) (Zeitlin, 1971). Incubation of these extracts with a stable kininogen 
preparation liberated kinin. Activation of this enzyme was demonstrated when 
incubation of the soluble extract at room temperature for 18 hours or at 55°C for 10 
minutes increased the KFE activity more than 5-fold. The kinin-releasing activity 
was inhibited by aprotinin but was not significantly reduced by SBTI (Zeitlin,
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1971). Zeitlin (1972) assessed the actvity of the KFE on synthetic substrates of 
tissue kallikrein and the effect of inhibitors on this hydrolysis. The effect of 
inhibitors on the KFE was the same as previously reported for their actions on rat 
salivary and urinary kallikrein. Zeitlin (1972) concluded that rat intestinal kallikrein 
is a tissue kallikrein and is present as an inactive precursor, located in the intestinal 
wall.
The kallikrein content of the gut wall along the length of the gastrointestinal tract of 
the rat was examined by Frankish and Zeitlin (1977a, 1980). There was little 
variation in the tissue content of kallikrein between different regions except for a 
peak of activity found in the caecum, which contained more than 5 times that of any 
other segment. The kallikrein content of the caecum was found to be directly related 
to the degree of luminal filling. Fasting for 24 hours had little effect on the 
kallikrein content of most tissues other than the duodenum and the caecum, where it 
was doubled and halved respectively. In the present study fasting appeared to have 
no effect on the amount of substance R released into the perfusate, as would be 
expected from the results of Frankish and Zeitlin (1980) who found little difference 
in the kallikrein content of the ileum between fasted and fed rats. Frankish and 
Zeitlin (1980) also noted that 17% of the kinin-forming activity in the caecum was 
inhibited by SBTI, and suggested this may have been kallikrein derived from 
plasma, like that described previously by Seki et al., (1972). However, it is 
interesting to speculate on the possibility that this may have been substance R 
derived from intestinal tissue.
The site of release of substance R from the perfused intestine is at present unknown. 
The presence of kininogenase in rat vascular tissues has previously been reported 
(Nolly & Lama, 1982; Nolly et al., 1985, 1986). However, in the present study, 
when the arterial vasculature of the mesentery alone was perfused, none of the 20 
minute fractions collected over 6 hours contained oxytocic activity. The 
kininogenase reported by Nolly and his colleagues was not inhibited by SBTI. It 
thus seems probable that substance R is released from the intestinal tissue during
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perfusion, rather than the arterial vasculature. This would be in agreement with the 
reports of Zeitlin that intestinal kallikrein is present in the mucosal tissue.
As discussed above, kallikreins have been isolated from tissues throughout the 
gastrointestinal tract in a number of species. Most previous reports on the 
immunocytochemical localization of tissue kallikreins have concentrated on the 
cellular localization within exocrine glands such as the submandibular gland, 
pancreas and guinea-pig coagulating gland. These reports have shown that 
kallikreins are present in the secretory cells of the coagulating gland and pancreas, 
and in the duct cells of the salivary gland (see Schachter, 1980b). These kallikreins 
were found in both secretory granules and free within the cytoplasm, depending on 
the cell type.
Recently Schachter and his colleagues (1980b, 1983) localized colonic kallikrein in 
cat, rat and man to the goblet cells alone in this tissue. It was also reported that 
kallikrein-like enzymes were present in the lamina propria and submucosa of the 
colon and other regions of the gastrointestinal tract (Schachter et al., 1980b). In a 
histochemical study of human colonic tissues, Garrett et al. (1982) reported that 
active kallikrein was seen only in the mast cells of the lamina propria. The 
immumocytochemical techniques utilized by Schachter et al. (1980b) may have 
identified the inactive proenzyme inaccessible to the visualization technique used by 
Garrett et al. (1982). These results are similar to those reported for the localization 
of a serine protease in the rat small intestine, which was located in the same tissue 
regions and also in mast cells (Woodbury et al., 1978).
Tissues of the gastrointestinal tract contain all the components of the kallikrein- 
kinin system, i.e. kininogen (Geiger et al., 1977), kallikrein (Zeitlin, 1971, 1972; 
Moriwaki et al., 1977b), kinins, and kininases (see Johnson, 1979). The true 
physiological function of tissue kallikrein within the gut is unknown but has been 
the subject of some speculation.
The stimulatory action of kinins on isolated intestinal smooth muscle preparations
70
was one of their first recognized properties, but whether this is an important 
physiological function of the kallikrein-kinin system is uncertain (see Johnson, 
1979; Bertacinni, 1982). However, stimulation of the pelvic nerves of the cat results 
in contraction of the colon and an associated reduction in the mucosal kallikrein and 
plasma kininogen contents (Fatsch et a l , 1978). The development of kinin receptor 
antagonists may now make an accurate assessment of the involvement of kinins in 
gastrointestinal motility possible.
Production and secretion of kallikreins by cells of exocrine glands is well 
established (see Gautvik et al., 1976; Bhoola et al., 1979). In addition to being 
secreted into exocrine fluids, it is thought that kallikreins act as mediators of 
functional vasodilatation within these glands, a role also proposed for the kallikreins 
of the gastrointestinal tract (Gautvik et al., 1976). Despite the many vasoactive 
neuropeptides (see Forssmann, 1980) and other vasoactive autocoids present in gut 
tissues, kallikreins may act in a similar way to that envisaged in exocrine glands. 
The rapid initial increase in blood flow is probably mediated by vasodilator nerves, 
whilst the formation of kinins may more closely adjust the blood flow according to 
the functional and metabolic requirements of the secretory tissues (Gautvik et al., 
1976).
Possibly the major physiological function of the kallikrein-kinin system in the 
gastrointestinal tract is in the regulation of transepithelial transport and intestinal 
absorption. Kallikrein itself appears to be absorbed from the gut. This was first 
recognized when oral administration of kallikrein was used clinically in the 
treatment of several conditions (see Fink et al., 1980). Later intestinal absorption of 
kallikrein was confirmed experimentally, and active tissue kallikrein absorbed 
through the gut wall has been detected in the circulation, bound to some plasma 
components (Moriwaki et al., 1977a; Overlack et al., 1983; Fink et al., 1989). 
Intestinal absorption of kallikrein may also explain the traces of tissue kallikrein 
found in plasma by Rabito et al. (1980, 1982). Apart from their action of increasing 
vascular permeability in the gut, kallikreins rapidly increase the rate of amino acid
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transportation by intestinal cells both in vitro and in situ (Moriwaki et al., 1977a, 
1977b). Kallidin stimulates sodium ion (Na+) and glucose transport in the intestine 
from the mucosal to serosal surfaces (Moriwaki & Fujimori, 1979). Electrophysiolo- 
gical studies in several species have shown that an increase in net ion transport 
occurs across the gut wall following stimulation with kinins, which are more potent 
than a number of other agents (see Cuthbert & Margolius, 1982). Hardcastle et al. 
(1976) first established that the increased potential difference across the rat jejenum 
and colon caused by bradykinin was the result of an increased net chloride ion (Cl-) 
secretion. This has since been confirmed in other tissues and species (see Cuthbert 
& MacVinish, 1989) and was shown to be dependent on calcium (Ca++) (Cuthbert et 
al., 1984). Cuthbert and Margolius (1982) demonstrated that rat glandular kallikrein 
and mellitin, a potent activator of membrane-bound kallikrein, stimulated Cl’ 
secretion. Kinin-stimulated ion secretion from intestinal epithelial cells is stimulated 
more by applicaton of the agonist to the basolateral surface of the cells than to the 
mucosal surface (see Cuthbert & MacVinish, 1989). Valine transport was also 
stimulated more by additon of kallikrein to the serosal surface than to the mucosal 
surface of the tissues (Moriwaki et al., 1977b). These results are in agreement with 
the reported location of the bradykinin receptor sites on the serosal surface of 
intestinal cells (Manning et al., 1982). The influence of kinins on ion transport in 
epithelial cells is not thought to be a direct action. Indomethacin and phospholipasae 
A2 inhibitors block Cl* secretion (Hardcastle et al., 1976; Cuthbert & Margolius, 
1982; Musch et al., 1983). Thus, Cl- secretion is believed to be mediated by 
prostaglandin generation by the epithelial cell, stimulated by kinins (see Cuthbert & 
MacVinish, 1989). However, depending on the species, lipoxygenase products have 
been implicated in place of prostaglandins (Musch et al., 1982, 1983). Likewise, 
epithelial Na+ uptake is thought to be mediated by a secondary factor. In this case, 
an increased cytosolic Ca++ concentration, the major part of which is mediated by 
phospholipase C stimulation and the inositol phosphate pathway, although 
stimulation of kinin receptors may directly affect Ca++ concentration (see Cuthbert 
& MacVinish, 1989).
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The first activity observed for substance R was the contraction of the isolated uterus 
(Gaddum, 1953). The oxytocic action of kallikreins was first noted by Frey et al. in 
1928. Rat tissue kallikreins contract the isolated rat uterus (Beraldo et al., 1966; 
Erdos et al., 1968), whilst having no effect on the uterus preparation from other 
species (Beraldo et al., 1966). In contrast, tissue kallikreins from a number of other 
species are without oxytocic activity on the rat uterus (Beraldo et al., 1966; 
Whalley, 1979). The mechanism of action of the oxytocic activity of rat tissue 
kallikrein has been the subject of a long running dispute as to whether kallikrein 
acts directly itself on the uterine smooth muscle cells or via kinin generation.
In a series of publications Beraldo and his colleagues proposed that this oxytocic 
action of kallikrein was independent of uterine kininogen content, the enzyme acting 
on specific kallikrein receptors on the smooth muscle cells (Beraldo et al., 1966, 
1971, 1975, 1976; Araujo et al., 1970; Siqueira et al., 1970). On the other hand, 
Nustad and Pierce (1974) provided evidence that kinin generation from uterine 
kininogen was responsible for contraction of the smooth muscle. The tachyphylaxis 
which occurs after repeated additions of kallikrein to uterine preparations (Nustad & 
Pierce, 1974; Beraldo et al., 1976) was cited as evidence to the contrary by Beraldo. 
The muscle still contracted, at the end of 8-9 hours of repeated addition of 
kallikrein, to 30-50 times the original dose (Beraldo et al., 1976). An alteration in 
the configuration of the kallikrein receptor, rendering it progressively less reactive 
to kallikrein was suggested to account for the tachyphylaxis rather than a 
progressive depletion of kininogen (Beraldo et al., 1976). Others have supported 
Beraldo’s hypothesis. The oxytocic action of kallikrein was unaffected by either 
carboxypeptidase B or a bradykinin antiserum (Chao et al., 1981). This group could 
detect no kinin in a radioimmunoassay from media in which kallikrein and uterine 
tissue had been incubated, and so concluded that the oxytocic action of kallikrein is 
independent of kinin generation. In contrast, it has recently been demonstrated that 
both caboxypeptidase B and an antibody to bradykinin reduced uterine responses to 
kallikrein (Orce et al., 1989). Furthermore, Figueiredo et al. (1989, 1990) 
demonstrated the dependence upon uterine kininogen of the contraction of the uterus
73
by kallikrein. Whalley (1979) reported that a prototype kinin receptor antagonist 
inhibited the oxytocic activity of trypsin and kallikrein. This has been confirmed 
recently by Orce et al. (1989) and in the present study, using a selective BK2 
bradykinin receptor antagonist. Uterine contractile responses to both urinary 
kallikrein and substance R were inhibited by D-Arg-[Hyp3,Thi5*8,D-Phe7]-bradyk- 
inin. There was no significant difference between the inhibition of responses to 
bradykinin, urinary kallikrein or substance R by this antagonist, suggesting that the 
oxytocic activity of each is mediated by the BK2 bradykinin receptor, and provides 
further evidence of the co-identity of substance R with tissue kallikrein. Thus, it is 
proposed that the oxytocic activity of rat tissue kallikrein and substance R is 
dependent on kinin generation from uterine kininogen.
In conclusion, substance R is a kininogenase enzyme released from the perfused rat 
small intestine which shares immunological and physical characteristics with rat 
tissue kallikrein, but differs in its susceptibility to protease inhibitors. The slight 
differences in molecular weight to other rat tissue kallikreins and perhaps the 
differences in inhibition by SBTI may be due to variations in carbohydrate 
composition. The primary protein structure is probably identical to that determined 
for other rat tissue kallikreins. However, any variation in the carbohydrate content 
of the enzyme may result in subtle changes in the conformation of the molecule 
from that seen in enzymes isolated from other sources. Thus it seems probable that 
any molecular differences are the result of post-translational mechanisms upon the 
protein and not in its primary structure determined by expression of the tissue 
kallikrein gene.
In the future it may be possible to determine the origin of substance R in intestinal 
tissue by immunohistochemical techniques, utilizing polyclonal or monoclonal 
antibodies to tissue kallikrein. It is also hoped to study differences in the inhibitory 
profile of substance R further, and in the near future to sequence the N-terminus of 
the substance R molecule for comparison with other tissue kallikreins. Despite 
having partially characterized substance R, why Gaddum chose the initial “R”
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remains a mystery. Substance P was so-called because the original preparation was 
labelled “P” (von Euler & Gaddum, 1931). Perhaps “R” stood for rat. If, however, 
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T ab le  2.
COMPARISON OF RAT TISSUE KALLIKREIN AND SUBSTANCE R: HYDROLYSIS 
OF THE CHR0M06ENIC SUBSTRATE S -2266




































Brit. J. Pharmacol. (1953), 8, 321.
THE TECHNIQUE OF SUPERFUSION
BY
J. H. GADDUM 
From the Department o f  Pharmacology, University o f  Edinburgh
( r e c e iv e d  Ju n e  5. 1953)
The amount of an active substance required for 
an assay on isolated plain muscle suspended in a 
bath depends upon the volume of the bath, which 
cannot conveniently be made much smaller than 
about 2 ml. A piece of intestine may be suspended 
in air and kept in good condition by a stream 
of a suitable solution running over its surface 
(Finkleman, 1930). This technique may be called 
superfusion, since the fluid runs over the tissue, 
by analogy with perfusion, in which the fluid runs 
through the tissue.
The effect of drugs on such a preparation may 
be tested by injecting them into the stream of 
fluid (Gaddum, Jang, and Kwiatkowski, 1939), 
and such preparations have been used for the assay 
of histamine (Kwiatkowski, 1941).
Greater sensitivity can be obtained by stopping 
the flow for a standard interval of time and applying 
the active solutions undiluted to the surface of 
the muscle. The object of the present paper is to 
describe an apparatus which has been developed 
during the last few years for this purpose and to 
present some results obtained with it.
M e t h o d s
The apparatus is shown in Fig. 1. The muscle is 
suspended in air in the middle o f a wide glass tube 
which is immersed in warm water in a small copper 
bath. This copper bath is attached to a vertical rod 
and the lever is attached to the same rod. The warm 
water is mixed by means o f a  stream o f air which is 
sufficiently violent to cause slight vibration o f the 
whole apparatus and so diminish friction o f  the writing 
point on the drum. The vibration may be controlled 
by finding the appropriate height for the apparatus on 
the vertical bar. The appropriate salt solution is 
contained in a reservoir 20-40 cm. above the bath. 
It runs from this reservoir through a glass tap and a 
glass-wool filter, and is then warmed by passing through 
the water in the copper bath. The rate o f flow is 
controlled by a  resistance which consists o f  a capillary 
tube drawn out to a  fine point and held inside a wider 
glass tube by passing the same rubber tube over both. 
The flow is adjusted to 1-5 ml./min. by altering the 
height o f the reservoir. The superfusion fluid drips 
from a glass tube down the cotton which attaches the
tissue to the lever. The end o f this tube has been 
filed off at an acute angle in order to facilitate the 
administration o f drugs. The height o f the glass tube 
above the tissue must not be too small, or the solution 
may run down one side o f the tissue and allow the 
other side to dry. If  the height is sufficient (>  10 cm.), 
each drop is broken up on reaching the tissue, and 
wetting is even.
Solutions to be tested are contained in small test-tubes 
(12x65 mm.) which are warmed before use by placing 
them in a  suitable holder attached to the copper bath.
From
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Figure 1. The title page from Gaddum’s 1953 paper on the technique of superfusion 










Figure 2. Schematic representation of the interrelationships of the major 
components of the kallikrein-kinin system. The high molecular weight precursor of 
the kinins, kininogen, undergoes limited proteolysis by the serine protease 
kallikrein. This results in liberation of the short chain polypeptide effector kinins 
which act on receptors located on the surface of the target cells. Kinins are acted 
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Figure 3. Interrelationship of the plasma kallikrein-kinin system with the blood 







Small in tes tine
Caecum
Figure 4. Dissection of the rat small intestine. Following laparotomy, two pairs of 
ligatures were tied around the intestine, at duodenal level (Ligature 1) and at the 
ileo-caecal junction (Ligature 2). The superior mesenteric artery was then 
cannulated and all other vessels, with the exception of the hepatic portal vein, were 
tied off. The intestine was sectioned between each pair of ligatures and the whole 
mesenteric bed was removed, care being taken to exclude any pancreatic tissue. The 
vasculature was flushed gently with heparinised Tyrode’s solution before the 









Figure 5. Perfusion of the isolated small intestine of the rat. The dissected intestinal 
preparation was suspended in a covered heated jacket (37°C) and perfused with 
aerated (95% 0 2; 5% C 02) Tyrode’s solution (0.4 ml min*1, peristaltic pump) via 
the mesenteric artery. Perfusate from the hepatic portal vein was collected by means 
of a fraction collector. The oxytocic activity of the fractions of perfusate was 
determined on the superfused isolated rat uterus.
DIALYSIS OF PERFUSATE
FREEZE-DRIED






PERFUSION OF SMALL INTESTINE 
(TYRODE'S SOLUTION, 37°C , 0 .4  m l/m in )
DIALYSIS AND FREEZE-DRYING OF 
ACTIVE FRACTIONS
ASSAY OF FRACTIONS FOR 
OXYTOCIC ACTIVITY
Figure 6. Scheme summarising steps in the purification of substance R from 
intestinal perfusate.
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Figure 7. Measurement of oedema in rabbit skin as represented by the local 
accumulation of 125I-HSA. 125I-HSA is administered via the marginal ear vein, 
together with Evans blue dye as a visual marker, to an anaesthetised rabbit. 
Inflammatory agents are injected intradermally into the clipped dorsal skin. The 
animal is killed after a fixed time by an overdose of barbiturate. A blood sample is 
taken and from this plasma samples are prepared. The skin sites are excised and 
their radioactivity determined in a gamma-counter. Exudate volumes are calculated 




Figure 8. Contractions of the superfused rat isolated uterus. Release of an oxytocic 
substance from rat intestine. A length of rat intestine was introduced into the stream 
of superfusion fluid above a rat uterus. A series of slow and prolonged contractions 
of the uterus were observed. The trace shows the responses of a single uterus over 
several hours. Lengths of small intestine (RI) were suspended above the uterus as 
represented by arrows. A-A, B-B and C-C indicate periods (70, 140, 45 min 
respectively) where the intestine was superfused above the uterus but no activity 
was released. Perfusion of guinea-pig ileum (GPI) elicited a similar response from 
the uterus to that elicited by perfusion of rat ileum.
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Figure 9. Effect of intestinal perfusate on the isolated superfused rat uterus. 










Figure 10. Comparison of the responses of the superfused isolated rat uterus to 
carbachol (CCh), bradykinin (Bk) and intestinal perfusate (IP). The uterine 
contractions to bradykinin and intestinal perfusate were similar, being slower to 
reach a maximum, and of a longer duration than that to carbachol. However, there 
was a latent period of 30-60 sec after the intestinal perfusate had passed over the 
tissue before a response was observed.
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Figure 11. Appearance of oxytocic activity in perfusate from the mesenteric bed. 
The top panel shows contractions of the superfused rat uterus induced by 100 pi 
volumes of intestinal perfusate from samples collected over consecutive 20 min 
periods. No oxytocic activity was detectable during the first 20 min of perfusion, 
but thereafter the samples contained increasing amounts of activity, reaching a 
maximum at 3-4 h. The bottom panel shows the protein concentration of the 
fractions of intestinal perfusate which gradually increased with time. The lower time 
scale refers to the time of collection of the perfusate.
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Figure 12. Effect of thioglycolate treatment on the oxytocic activity of substance R. 
Responses to thioglycolate-treated substance R (ThR, pi) did not differ from those 
of a control sample of substance R (R, pi). The tissue maintained responsive to 
bradykinin (B, ng) throughout the experiment.
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Figure 13. Effect of the proteolytic enzymes trypsin and papain on the oxytocic 
activity of substance R. Oxytocic responses to substance R (R, pi), bradykinin (B, 
ng), substance R incubated with insoluble trypsin (TR, pi) and substance R 
incubated with insoluble papain (PR, pi). The oxytocic activity of substance R was 
not affected by incubation with either of these enzymes.
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Figure 14. Effect of intestinal perfusate, trypsin and urinary kalllikrein on the 
superfused rat isolated uterus, a). A supramaximal dose of intestinal perfusate (R) 
has no effect on the responses to bradykinin (Bk, ng). In contrast, trypsin (T, mg) 
also contracts the uterus, but in addition induces a sensitization of the tissue to 
bradykinin. b). Similar to intestinal perfusate, a supramaximal dose of urinary 
kallikrein (KK) does not induce a sensitization of the uterus to bradykinin.
91
a ) .
V-A ^ v , 
•  •
. 3  . 6Bk  . 3  . 6  . 7 5  CT . 3  . 6  CT
■5 cm
5 m i n
0.1 1.0
Figure 15. Effect of chymotrypsin on the superfused isolated rat uterus, a). 
Alpha-chymotrypsin (CT, mg) contracts the uterus and induces sensitization to 
bradykinin (Bk, ng). b). Delta-chymotrypsin (CT, mg) is more potent than 




















Figure 16. Effect of substance R on blood pressure. Substance R had a dose-related 
hypotensive action in the anaesthetised guinea-pig. A progessive fall in blood 
pressure was obtained with a). 10 pi, b). 20 pi and c). 50 pi of a preparation of 
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Figure 17. The effect of aprotinin on the oxytocic activities of urinary kallikrein 
(KK), substance R (R) and bradykinin (Bk). Aprotinin completely inhibited uterine 
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Figure 18. The effect of soy bean trypsin inhibitor (SBTI) on the oxytocic 
responses of urinary kallikrein (KK), substance R (R) and carbachol (CCh). SBTI 
reversibly inhibited the response to substance R without a significant reduction in 




Figure 19. The effect of the selective BK2 bradykinin receptor antagonist 
D-Arg-[Hyp3,Thi5>8,D-Phe7]-bradykinin on the oxytocic activities of bradykinin (Bk, 
ng), carbachol (CCh, ng), substance R (R, pi) and urinary kallikrein (KK, pi). 
D-Arg-[Hyp3,Thi5’8,D-Phe7]-bradykinin reduces responses to substance R, urinary 
kallikrein and bradykinin but not those to carbachol.
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Figure 20. Effect of incubating plasma with kallikrein or substance R on the 
guinea-pig ileum in the presence of captopril (4.6 x 10'4M). The guinea-pig ileum 
contracted to bradykinin (Bk, ng m l'1) but not to urinary kallikrein (KK) or 
substance R (R) alone and sometimes gave a small contraction to rat plasma (P) 
alone. However, when kallikrein or substance R were added to the organ bath in the 
presence of rat plasma, a slow contraction of the ileum was observed.
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Figure 21. The effect of SBTI on the kininogenase activity of substance R. The 
experiment was carried out in the presence of captopril (4.6 x 10'4M). Addition of 
human plasma kininogen (KGN) alone to guinea-pig isolated ileum elicited no 
contraction. However, when kininogen was present in the organ bath, addition of 
urinary kallikrein (KK), resulted in a slow contraction of the ileum. Substance R (R) 
also induced a slow contraction of the ileum in the presence of kininogen (KGN + 
R). Addition of SBTI to the bath did not markedly affect the response to kininogen 
+ kallikrein. In contrast, the contraction to kininogen + substance R was blocked in 
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Figure 22 . Oedema formation in rabbit skin induced by mixtures of substance 
R+PGE2 ( • ) .  Substance R caused a dose-dependent increase in vascular 
permeability. The response to a boiled sample of substance R+PGE2 ( O ) was 
reduced compared to an unboiled sample. Results are the mean of 6 replicates in a 
single animal.
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Figure 23. Anion-exchange chromatography of crude intestinal perfusate on 
DEAE-Sepharose. The sample was applied at V = 0 and was washed with 100 ml 
Tris buffer (50mM, pH 7.5). Substance R was eluted with a linear salt gradient at 
approximately 0.2M NaCl indicated by the horizontal arrows above the elution 
profile. The absobance of fractions was measured at 280 nm and oxytocic activity 
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Figure 24. Gel-filtration chromatography on Sephacryl S-200 of pooled oxytocic 
fractions previously subjected to ion-exchange chromatography. The sample was 
applied at V = 0 and was eluted with 50mM PBS, pH 7.5. The absorbance was 
measured at 280 nm and the elution profile is shown by the solid line. Oxytocic 
activity of the eluted fractions was determined on the isolated superfused uterus of 
the rat, indicated by the dashed line and is expressed as % maximum contraction per 
pi eluate. Inset: The molecular weight of the substance R peak ( • )  corresponded to 
40 kDa when compared to calibrating proteins (o).
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Figure 25. Comparison of the oxytocic activity (■) and kininogenase activity (Q) of 
fractions eluted from the Sephacryl S-200 cloumn. Kininogenase activity was 
measured by S-2266 hydrolysis (nkat I*1). Oxytocic activity was determined on the 
isolated rat uterus and is expressed as % maximal contraction per pi eluate. The 




Figure 26. Immunodiffusion study of substance R and rat urinary kallikrein. The 
central well (A) contained rabbit anti-rat tissue kallikrein antiserum. The other wells 
contained urinary Kallikrein (B), substance R (C) and a sample from a fraction 
containing no oxytocic activity (D). A strong precipitation band formed between 
urinary kallikrein and the antiserum. A precipitation band also formed between 
substance R and the antiserum but the non-oxytocic sample did not react with 
antiserum.
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Figure 27. SDS-polyacrylamide gel electrophoresis of substance R. Lanes 1 and 4: 
molecular weight markers. Lanes 2 and 3: preparations of substance R. The major 
protein bands in the substance R preparations have approximate molecular weights 
of 62,000, 39,000, 26,000 and 21,000 Daltons. The band indicated ( —) which 
migrated between glyceraldehyde-6-phosphate dehydrogenase (36 kDa) and egg 
albumin (45 KDa) confirms the presence of a protein of approximately 40,000 Da, 
corresponding to the estimated molecular weight of substance R from the peak of 









Figure 28. Western blot analysis of substance R and rat submandibular gland 
kallikrein. Electrophoresis was performed using a linear 7.5-15% gradient gel 
containing 0.1% SDS, and proteins were electrophoretically transferred to a 
nitrocellulose sheet. The blots were incubated with sheep anti-rat tissue kallikrein 
antiserum followed by 125I-labelled rat tissue kallikrein. The antibody-bound protein 
bands were revealed by autoradiography. Lane 1: substance R (39,000 Da), lane 2: 
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Figure 29. Log-logit transformation of tissue kallikrein radioimmunoassay. A serial 
diution of a sample of substance R (A) shows complete parallelism to the standard 
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Figure 30. Summary of the effects of the enzyme inhibitors aprotinin (Trasylol, 100 
KIU m l'1), SBTI (5 x 10-7M), and the BK2 receptor antagonist D-Arg- 
[Hyp3,Thi5>8,D-Phe7]-bradykinin (10 7M) on a), the oxytocic activity of bradykinin 
(Bk), carbachol (CCh), urinary kallikrein (KK) and substance R (R). b). The effects 
of aprotinin (Trasylol, 100 KIU m l1) and SBTI (5 x 10'7M) on the kinin-releasing 
activity of urinary kallikrein and substance R. All results are the mean ± s.e. mean 





Adam, H.M., Hardwick, D.C. and Spencer, K.H.V. (1954). Assay of histamine on 
the isolated guinea-pig ileum by the method of superfusion. Br. J. Pharmacol. 
Chemother., 9, 360-366.
Al-Dhahir, H.A.R. and Zeitlin, IJ . (1983). Bile salts activate glandular kallikrein- 
like activity in rat colon. Adv. Exp. Med. Biol., 156A, 463-467.
Ames, R.G., Moore, D.H. and van Dyke, H.B. (1950). The excretion of posterior 
pituitary antidiuretic hormone in the urine and its detection in the blood. 
Endocrinol., 46, 215-227.
Amundsen, E. (1966). Kinin formation and destruction in fluid produced by a 
strangulated segment of ileum in the rat. In: Hypotensive peptides, ed. Erdos, E. G., 
Back, N. and Sicuteri, F. pp 474-483. Berlin: Springer-Verlag.
Amundsen, E. and Nustad, K. (1965). Kinin-forming and destroying activities of 
cell homogenates. J. Physiol., 179, 479-488.
Amundsen, E., Putter, J., Friberger, P., Knos, M., Larsbraten, M. and Claeson, G. 
(1979). Methods for the determination of glandular kallikrein by means of a 
chromogenic tripeptide substrate. Adv. Exp. Med. Biol., 120A, 83-95.
Araujo, R.L., Dias da Silva, W. and Beraldo, W.T. (1970). Kininogenase and 
oxytocic properties of rat pancreatic juice. Adv. Exp. Med. Biol., 8, 77-80.
Back, N. and Steger, R. (1968). Effect of inhibitors on kinin-releasing activity of 
proteases. Fed. Proc., 27, 96-99.
Bain, W.A. (1932a). Method of demonstrating humoral transmission of effects of 
cardiac vagus stimulation in frog. Q. Jl. Exp. Physiol., 22, 269-274.
Bain, W.A. (1932b). On the mode of action of vasomotor nerves. / .  Physiol., 77, 
3P-4P.
Barabe, J. Drouin, J.-N., Regoli, D. and Park, W.K. (1977). Receptors for 
bradykinin in intestinal and uterine smooth muscle. Can. J. Physiol. Pharmacol., 55, 
1270-1285.
Barab6, J. and Regoli, D. (1988). Kinin antagonists. Methods Enzymol., 163, 
282-292.
Barlas, A., Gao, X. and Greenbaum, L.M. (1987). Isolation of a thiol activated 
T-kininogenase from the rat submandibular gland. FEBS Lett., 218, 266-270.
Baumgarten, C.R., Schwarting, R. and Kunkel, G. (1989). Localization of glandular 
kallikrein in nasal mucosa of allergic and non-allergic individuals. Adv. Exp. Med. 
Biol., 247B, 523-528.
109
Becker, E.L. and Kagen, L. (1964). The permeability globulins of human serum and 
the biochemical mechanism of hereditary angioneurotic edema. Ann. N.Y. Acad. 
Sci., 116, 866-873.
Beraldo, W.T., Araujo, R.L. and Mares-Guia, M. (1966). Oxytocic esterase in rat 
urine. Am. J. Physiol., 211, 975-980.
Beraldo, W.T., Araujo, R.L., Siqueira, G., Rodrigues, J.A.A. and Machado, C.S. 
(1971). Peculiaridades do sistema cinina-cininogenina do rato. Cience Cult. (Sao 
Paulo), 23, 475-480; through Biol. Abstr., (1972), 54, 36662.
Beraldo, W.T., Siqueira, G., Heneine, I.F. and Lauar, N.L. (1975). Peculiarities of 
the oxytocic action of rat kallikrein. Life Sci., 16, 790.
Beraldo, W.T., Lauar, N.L., Siqueira, G., Heneine, I.F. and Catanzaro, O.L. (1976). 
Peculiarities of the oxytocic action of rat urinary kallikrein. In: Chemistry and 
biology o f the kallikrein-kinin system in health and disease, ed. Pisano, J.J. and 
Austen, K.F. pp 375-378. Washington D.C.: Government Printing Office.
Berg, T. (1988). Immuncohemical viewing of kallikrein in tissues. Methods 
Enzymol., 163, 143-159.
Berg-0rstravik, T., Nustad, K. and Brandtzaeg, P. (1980). Localization of glandular 
kallikreins in rat and man. In: Enzymatic release o f vasoactive peptides, ed. Gross, 
F. and Vogel, G. pp 137-147. New York: Raven Press.
Bertaccini, G. (1976). Active polypeptides of non-mammalian origin. Pharmacol. 
Rev., 28, 127-175.
Bertaccini, G. (1982). Peptides: Locally active peptides (“vasoactive peptides”). 
Handb. Exp. Pharmacol., 59/11, 175-200.
Bhoola, K.D., Yi, R.M.M., Morley, J. and Schachter, M. (1961). Kinin-releasing 
enzyme in the accessory sex glands of the guinea-pig. J. Physiol., 159, 34P-35P.
Bhoola, K.D., Yi, R.M.M., Morley, J. and Schachter, M. (1962). Release of kinin by 
an enzyme in the accessory sex glands of the guinea-pig. J. Physiol., 163, 269-280.
Bhoola, K., Lemon, M. And Matthews, R. (1979). Kallikrein in exocrine glands. 
Handb. Exp. Pharmacol., 25 suppl., 289-523.
Boissonnas, R.A. (1962). The synthesis of bradykinin. Biochem. Pharmacol., 10, 
35-38.
Boissonnas, R.A., Guttmann, St., Jaquenoud, P.-A., Pless, J. and Sandrin, E. (1963). 
The synthesis of bradykinin and of related peptides. Ann. N.Y. Acad. Sci., 104, 5-14.
Boschcov, P., Paiva, A.C.M., Paiva, T.B. and Shimuta, S.I. (1984). Further evidence
110
for the existence of two receptor subtypes for bradykinin responsible for the 
diphasic effect in the rat isolated duodenum. Br. J. Pharmacol., 83, 591-600.
ten Cate, J. (1924). Sur la question de Taction humorale du nerf vague. Archs. neerl. 
Physiol., 9, 588-597.
Chao, J., Buse, J., Shimamoto, K. and Margolius, H.S. (1981). Kallikrein-induced 
uterine contraction independent of kinin formation. Proc. Natl. Acad. Sci. USA, 78, 
6154-6157.
Chao, J., Woodley, C., Chao, L. and Margolius, H.S. (1983). Identification of tissue 
kallikrein in brain and in cell-free translation product encoded by brain mRNA. J. 
Biol. Chem., 258, 15173-15178.
Chao, J., Chao, L. and Margolius, H.S. (1984). Isolation of tissue kallikrein in rat 
spleen by monoclonal antibody-affinity chromatography. Biochem. Biophys. Acta, 
801, 244-249.
Chao, J., Chao, L., Woodley, C.M., Gerald, W. and Margolius, H.S. (1986a). Active 
kallikrein, preprokallikrein, and kallikrein-inhibitor complex. Adv. Exp. Med. Biol., 
198A, 181-187.
Chao, J., Tillman, D.M., Wang, M., Margolius, H.S. and Chao, L. (1986b). 
Identification of a new tissue-kallikrein-binding protein. Biochem. J ., 239, 325-331.
Chao, J. and Chao, L. (1987). Identification and expression of kallikrein gene family 
in rat submandibular and prostate glands using monoclonal antibodies as specific 
probes. Biochem. Biophys. Acta, 910, 233-239.
Chao, J., Chao, L., Swain, C.C., Tsai, J. and Margolius, H.S. (1987). Tissue 
kallikrein in rat brain and pituitary: regional distribution and estrogen induction in 
the anterior pituitary. Endocrinol., 120, 475-482.
Chao, J. and Chao, L. (1988). Identification of latent tissue kallikrein, prolactin and 
growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays. 
Mol. Cell. Endocrinol., 55, 21-31.
Chao, J., Chai, K.X., Chen, L.-M., Xion, W., Chao, S., Woodley-Miller, C., Wang, 
L., Lu, H.S. and Chao, L. (1990). Tissue kallikrein-binding protein is a serpin. I. 
Purification, characterization, and distribution in normotensive and spontaneously 
hypertensive rats. J. Biol. Chem., 265, 16394-16401.
Chung, D.W., Fujikawa, K., McMullen, B.A. and Davie, E.W. (1986). Human 
plasma prekallikrein, a zymogen to a serine protease that contains four tandem 
repeats. Biochemistry, 25, 2410-2417.
Cohen-Laroque, E.-S., Beny, J.-L. and Huggel, H. (1990). Microvascular effects of 
bradykinin in the isolated perfused guinea-pig hindbrain: Method and characteriz­
111
ation of a possible third type of bradykinin receptor. Microvasc. Res., 40, 55-62.
Collier, H.O.J. and Shorley, P.G. (1960). Analgesic antipyretic drugs as antagonists 
of bradykinin. Br. J. Pharmacol. Chemother., 15, 601-610.
Colman, R.W. and Bagdasarian, A. (1976). Human kallikrein and prekallikrein. 
Methods Enzymol., 45, 303-322.
Colman, R.W. (1989). Kallikrein-kinin system in infectious diseases. Adv. Exp. 
Med. Biol., 247A, 153-157.
Cuthbert, A.W. and Margolius, H.S. (1982). Kinins stimulate net chloride secretion 
by the rat colon. Br. J. Pharmacol., 75, 587-598.
Cuthbert, A.W., Halushka, P.V., Margolius, H.S. and Spayne, J.A. (1984). Role of 
calcium ions in kinin-induced chloride secretion. Br. J. Pharmacol., 82, 587-595.
Cuthbert, A.W. and MacVinish, L J. (1989). Diversisty of kinin effects on 
transporting epithelia. Adv. Exp. Med. Biol., 247A, 105-111.
Dorer, F.E., Kahn, J.R., Lentz, K.E., Levine, M. and Skeggs, L.T. (1974a). 
Hydrolysis of bradykinin by angiotensin converting enzyme. Circ. Res., 34, 
824-827.
Dorer, F.E., Ryan, J.W. and Stewart, J.M. (1974b). Hydrolysis of bradykinin and its 
higher homologues by angiotensin converting enzyme. Biochem. J., 141, 915-917.
Douglas, G.J., Williams, K.I. and Flower, R.J. (1988). What is Gaddum’s 
“substance R”? Br. J. Pharmacol, 94, 37IP.
Douglas, G.J., Williams, K.I. and Flower, R J. (1989). Further characterisation of 
Gaddum’s ‘substance R’. Br. J. Pharmacol., 96, 282P.
Douglas, G.J., Williams, K.I. and Flower, R.J. (1991). Characterization of 
Gaddum’s substance R. Br. J. Pharmacol., 102, 926-930.
van Dyke, H.B., Chow, B.F., Greep, R.O. and Rothen, A. (1942). The isolation of a 
protein from the pars neuralis of the ox pituitary with constant oxytocic pressor and 
diuresis-inhibiting activities. J. Pharmacol. Exp. Ther., 74, 190-209.
Edery, H. (1964). Potentiation of the action of bradykinin on smooth muscle by 
chymotrypsin, chymotrypsinogen and trypsin. Br. J. Pharmacol. Chemother., 22, 
371-379.
Edery, H. (1965). Further studies of the sensitization of smooth muscle to the action 
of plasma kinins by proteolytic enzymes. Br. J. Pharmacol. Chemother., 24, 
485-496.
112
Edery, H. and Grunfeld, Y. (1969). Sensitization of smooth muscle to plasma 
kinins: effects of enzymes and peptides on various preparations. Br. J. Pharmacol., 
35, 51-61.
Elliott, D.F. (1970). The discovery and characterization of bradykinin. Handb. Exp. 
Pharmacol., 25, 7-13.
Elliott, D.F., Lewis, G.P. and Horton, E.W. (1960). The structure of bradykinin - a 
plasma kinin from ox blood. Biochem. Biophys. Res. Comm., 3, 87-91.
Erdos, E.G. (1970). Preface. Handb. Exp. Pharmacol., 25, v-vi.
Erdos, E.G. (1979). Kininases. Handb. Exp. Pharmacol., 25 suppl., 427-487.
Erdos, E.G. and Sloane. E.M. (1962). An enzyme in human blood that inactivates 
bradykinin and kallidins. Biochem. Pharmacol., 11, 585-592.
Erdos, E.G., Renfrew, A.G., Sloane, E.M. and Wohler, J.R. (1963). Enzymatic 
studies on bradykinin and similar peptides. Ann. N.Y. Acad. Sci., 104, 222-234.
Erdos, E.G., Back, N. and Sicuteri, F. (editors) (1966). Hypotensive peptides. Berlin: 
Springer-verlag.
Erdos, E.G., Tague, L.L. and Miwa, I. (1968). Kallikrein in the granules of the 
submaxillary gland. Biochem. Pharmacol., 17, 667-674.
von Euler, U.S. (1966). In memorium. In: Erdos, E.G. et al. (editors). Hypotensive 
peptides, ed. Erdos, E. G., Back, N. and Sicuteri, F. pp xxii-xxiv. Berlin: 
Springer-Verlag.
von Euler, U.S. and Gaddum, J.H. (1931). An unidentified depressor substance in 
certain tissue extracts. J. Physiol., 72, 74-87.
Farmer, S.G., Burch, R.M., Meeker, S.A. and Wilkins, D.E. (1989). Evidence for a 
pulmonary B3 bradykinin receptor. Mol. Pharmacol., 36, 1-8.
Fatsch, S., Hulten, L., Johnson, B.J., Nordgren, S. and Zeitlin, I.J. (1978). 
Mobilization of colonic kallikrein following pelvic nerve stimulation in the 
atropinized cat. J. Physiol., 285, 471-478.
Feldberg, W. (1967). John Henry Gaddum. Biogr. Mem. Fellows Roy. Soc., 13, 
57-77.
Feldberg, W. and Gaddum, J.H. (1934). The chemical transmitter at synapses in a 
sympathetic ganglion. J. Physiol., 81, 305-319.
113
Ferreira, S. and Vane, J.R. (1967). The disappearance of bradykinin and eledoisin in 
the circulation and vascular beds of the cat. Br. J. Pharmacol. Chemother., 30, 
417-424.
Ferreira, S. and de Souza Costa, F. (1976). A laminar flow superfusion technique 
with much increased sensitivity for the detection of smooth muscle-stimulating 
substances. Eur. J. Pharmacol., 39, 379-381.
Fielder, F. (1979). Enzymology of glandular kallikreins. Handb. Exp. Pharmacol., 
25 suppl., 103-161.
Fielder, v.F. and Werle, E. (1967). Vorkommen zweier Kallikreinogene im 
Schweinepankreas und Automation der Kallikrein - und Kallikreinogenbestimmung. 
Hoppe-Seyler’s Z. Physiol. Chem., 348, 1087-1089.
Figueiredo, A.F.S., Salgado, A.H.I., Siqueira, G.R.T. and Beraldo, W.T. (1989). 
Kallikrein-induced rat uterus contraction is dependent on kinin release. Adv. Exp. 
Med. Biol., 247A, 563-566.
Figueiredo, A.F.S., Salgado, A.H.I., Siqueira, G.R.T., Velloso, C.R. and Beraldo, 
W.T. (1990). Rat uterine contraction by kallikrein and its dependence on uterine 
kininogen. Biochem. Pharmacol., 39, 763-767
Figueroa, C.D. and Bhoola, K.D. (1989). The discovery of a tissue kallikrein in 
human neutrophils. Br. J. Pharmacol., 97, 439P.
Figueroa, C.D., Maclver, A.G., Dieppe, P., Mackenzie, J.C. and Bhoola, K.D. 
(1989). Presence of immunoreactive tissue kallikrein in human polymorphonuclear 
(PMN) leukocytes. Adv. Exp. Med. Biol., 247B, 207-210.
Fink, E., Geiger, R., Witte, J., Biedermann, S., Seifert, J. and Fritz, H. (1980). 
Biochemical, pharmacological, and functional aspects of glandular kallikreins. In: 
Enzymatic release o f vasoactive peptides, ed. Gross, F. and Vogel, G. pp 101-113. 
New York: Raven Press.
Fink, E. and Schill, W.-B. (1983). Tissue kallikrein in human seminal plasma. Adv. 
Exp. Med. B iol, 156B, 1175-1180.
Fink, E., Feng, X.-C. and Richter, E. (1989). Studies on the intestinal absorption of 
tissue kallikrein. Adv. Exp. Med. Biol., 247B, 663-668.
Finkleman, B. (1930). On the nature of inhibition in the intestine. J. Physiol., 70, 
145-157.
Flower, R.J. (1984). Macrocortin and the antiphospholipase proteins. Adv. Inflamm. 
Res., 8, 1-34.
Flower, R.J. and Blackwell, G.J. (1979). Anti-inflammatory steroids induce
114
biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin 
generation. Nature, 278, 456-459.
Forssmann, W.-G. (1980). Distribution of vasoactive peptides in the gastrointestinal 
tract and autonomic nervous system. In: Enzymatic release o f vasoactive peptides. 
ed. Gross, F. and Vogel, G. pp 171-189. New York: Raven Press.
Frankish, N.H. and Zeitlin, I.J. (1977a). The assay of tissue kallikrein in rat 
intestine. Br. J. Pharmacol., 59, 517P.
Frankish, N.H. and Zeitlin, I.J. (1977b). Kallikrein release from rat duodenum 
stimulated by bile acids and other factors. J. Physiol., 273, 60P-61P.
Frankish, N.H. and Zeitlin, I.J. (1980). The effect of diet on tissue levels of 
kinin-forming enzyme in blood-free rat gastrointestinal tract. J. Physiol., 298, 
361-370.
Frey, E.K. (1926). Zusammenhange zwischen Herzarbeit und Nierentatigkeit. Arch. 
Klin. Chir., 142, 633-669.
Frey, E.K. and Kraut, H. (1928). Ein neues Kreislaufhormon und seine Wirkung. 
Naunyn-Schmiedeberg’s Arch. Exp. Path. Pharmak., 133, 1-56; through Physiol. 
Abstr., (1929-30), 14, 2028.
Frey, E.K., Kraut, H. and Schultz, F. (1930). Uber eine neue innersekretorische 
Funktion des Pankreas. V. Mittelung: Uber ein Kreislaufhormon. Naunyn- 
Schmiedeberg’s Arch. Exp. Path. Pharmak., 158, 334; through Physiol. Abstr., 
(1931-32), 16, 1018.
Friberger, A.B., Aurell, L. and Claeson, G. (1981). Chromogenic substrates for 
kallikreins and related enzymes. Agents Actions Suppl., 9, 83-90.
Fritz, H. Fink, E. and Truscheit, E. (1979). Kallikrein inhibitors. Fed. Proc., 38, 
2753-2759.
Fritz, H., Dietze, G., Fiedler, F. and Haberland, G.L. (1981). Preface to ‘Recent 
progress on kinins’. Agents Actions Suppl., 9, 5.
Fujikawa, K., Chung, D.W., Hendrickson, L.E. and Davie, E.W. (1986). Amino acid 
sequence of human factor XI, a blood coagulation factor with four tandem repeats 
that are highly homologous with plasma prekallikrein. Biochemistry, 25, 2417-2424.
Fujimori, H., Levison, P.R. and Schachter, M. (1986a). Purification and partial 
characterization of cat colon and submandibular gland kallikreins. Adv. Exp. Med. 
Biol., 198A, 211-218.
Fujimori, H., Levison, P.R. and Schachter, M. (1986b). Purification and partial 
characterization of cat pancreatic and urinary kallikreins - comparison with other cat
115
tissue kallikreins and related proteases. Adv. Exp. Med. Biol., 198A, 219-229.
Fukushima, D., Kitamura, N. and Nakashini, S. (1985). Nucleotide sequence of 
cloned cDNA for human pancreatic kallikrein. Biochemistry, 24, 8037-8043.
Gaddum, J.H. (1953). The technique of superfusion. Br. J. Pharmacol. Chemother., 
8, 321-326.
Gaddum, J.H. (editor) (1955). Polypeptides which stimulate plain muscle. 
Edinburgh: E & S Livingstone.
Gaddum, J.H. (1955). The pharmacological analysis of tissue extracts. In: 
Polypeptides which stimulate plain muscle, ed. Gaddum, J.H. pp 1-6. Edinburgh: E 
& S Livingstone.
Gaddum, J.H., Jang, C.S. and Kwiatkowski, H. (1939). The effect on the intestine of 
the substance liberated by adrenergic nerves in a rabbit’s ear. J. Physiol., 96, 
104-108.
Gaddum, J.H. and Horton, E.W. (1959). The extraction of human urinary kinin 
(substance Z). Br. J. Pharmacol. Chemother., 14, 117-124.
Gaddum, J.H. and Guth, P.S. (1960). A comparison of the kallikrein-kinin system in 
sheep and dogs. Br. J. Pharmacol. Chemother., 15, 181-184.
Garrett, J.R., Harrison, J.D., Kidd, A., Kyriacou, K. and Smith, R.E. (1982). 
Kallikrein-like activity in human salivary glands and colon, including mast cells. J. 
Physiol., 334, 78P.
Gautvik, K.M., Berg-Oerstradvik, T. and Nustad, K. (1976). Role of the 
kallikrein-kinin system in glandular secretion. In: Chemistry and biology o f the 
kallikrein-kinin system in health and disease, ed. Pisano, J.J. and Austen, K.F. pp 
335-357. Washington D.C.: Government Printing Office.
Gautvik, K.M., 0rstradvik, T.B. and Svindahl, K. (1980). Release of glandular 
kallikrein. In: Enzymatic release o f vasoactive peptides, ed. Gross, F. and Vogel, G. 
pp 287-298. New York: Raven Press.
Geiger, R., Feifel, G. and Haberland, G.L. (1977). A precursor of kinins in human 
gastric mucus. In: Kininogenases: Kallikrein 4. ed. Haberland, G.L., Rohen, J.W. 
and Suzuki, T. pp 73-77. Stuttgart-New York: F.K. Schauttauer.
Gerald, W.L., Chao, J. and Chao, L. (1986). Immunological identification of rat 
tissue kallikrein cDNA and characterization of the kallikrein gene family. Biochem. 
Biophys. Acta, 866, 1-14.
Gilfoil, T.M. and Kelly, C.A. (1966). Mechanism of action of chymotrypsin on 
plain muscle. Br. J. Pharmacol. Chemother., 27, 120-130.
116
Greenbaum, L.M. (1979). Kininogenases of blood cells. (Alternate kinin generating 
system). Handb. Exp. Pharm., 25 suppl., 91-102.
Greenbaum, L.M., Semente, G., Prakash, A. and Roffman, S. (1978). Leukokinins; 
their pharmacological properties and role in pathology of fluid (ascites) accumul­
ation). Agents actions, 8, 80-84.
Greenbaum, L.M. (1984). T-kinin and T-kininogen - an historical overview. Adv. 
Exp. Med. Biol., 198A, 55-59.
Greenbaum, L.M. and Okamoto, H. (1988). T-kinin and T-kininogen. Methods 
Enzymol., 163, 272-282.
Gryglewski, R.J., Moncada, S. and Palmer, R.MJ. (1986). Bioassay of prostacyclin 
and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial 
cells. Br. J. Pharmacol., 87, 685-694.
Guimaraes, J.A., Borges, D.A., Prado, E.S. and Prado, J.L. (1973). Kinin-converting 
aminopeptidase from human serum. Biochem. Pharmacol., 22, 3157-3172.
Gutman, N., Moreau, T., Alhenc-Gelas, F., Baussant, T., El Moujahed, A., Akpona, 
S. and Gauthier, F. (1988). T-kinin release from T-kininogen by rat-submaxillary- 
gland endopeptidase K. Eur. J. Biochem., 171, 577-582.
Habermann, E. (1966). Enzymatic kinin release from kininogen and from 
low-molecular compounds. In: Hypotensive peptides, ed. Erdos, E. G., Back, N. and 
Sicuteri, F. pp 116-128. Berlin: Springer-Verlag.
Hamberg, U. (1978). Current and past nomenclature of the kininogen-kinin system. 
Agents Actions, 8, 165-166.
Han, Y.N., Komiya, S., Iwanaga, S. and Suzuki, T. (1975). Studies on the primary 
structure of bovine high-molecular-weight kininogen. Amino acid sequence of a 
fragment (“histidine-rich peptide”) released by plasma kallikrein. J. Biochem. 
(Tokyo), 77, 55-68.
Hardcastle, J., Hardcastle, P.T., Flower, R.J. and Sanford, P.A. (1978). The effect of 
bradykinin on the electrical activity of rat jejenum. Experientia, 34, 617-618.
Harpel, P.C., Mosesson, M.W. and Cooper, N.R. (1975). Studies on the structure 
and function of alpha-2-macroglobulin and Ci inactivator. In: Proteases and 
biological control, ed. Reich, E., Rifkin, D.B. and Shaw, E. pp 387-404. Cold 
Spring Harbor Laboratory.
Heimark, R.L. and Davie, E.W. (1981). Bovine and human plasma prekallikrein. 
Methods Enzymol., 80, 157-172.
117
Hirata, Y., Takata, S. and Takaichi, S. (1989). Specific binding sites for bradykinin 
and its degradation process in cultured rat vascular smooth muscle cells. Adv. Exp. 
Med. Biol., 247A, 415-420.
Hojima, Y., Moriwaki, C. and Moriya, H. (1975). Isolation of dog, rat and hog 
pancreatic kallikreins by preparative disc electrophoresis and their properties. Chem. 
Pharm. Bull., 23, 1128-1136.
Holmstedt, B. and Liljestrand, G. (1981). Readings in pharmacology. 2nd edition. 
New York: Raven Press, pp 225-227.
Horton, E.W. (1959). Human urinary kinin excretion. Br. J. Pharmacol. Chemother., 
14, 125-132.
Innis, R.B., Manning, D.C., Stewart, J.M. and Snyder, S.H. (1981). [3H]Bradykinin 
receptor binding in mammalian tissue membranes. Proc. Natl. Acad. Sci. USA., 78, 
2630-2634.
Jacobsen, S. (1966a). Substrates for plasma kinin-forming enzymes in human, dog 
and rabbit plasmas. Br. J. Pharmacol. Chemother., 26, 403-411.
Jacobsen, S. (1966b). Substrates for kinin-forming enzymes in rat and guinea-pig 
plasma. Br. J. Pharmacol. Chemother., 28, 64-72.
Jendrassik, I. (1924). Humorale Ubertragbarkeit von Nervenreizen beim Warmblii- 
ter. Biochem. Z., 144, 520-535.
Johnson, A.R. (1979). Effects of kinins on organ systems. Handb. Exp. Pharmacol., 
25 suppl., 357-399.
Jose, P.J., Forrest, M.J. and Williams, T. J. (1981). Human C5a des Arg increases 
vascular permeability. J. Immunol., 127, 2376-2380.
Kagen, L.J., Leddy, J.S. and Becker, E.L. (1963). The presence of two permeability 
globulins in human serum. J. Clin. Invest., 42, 1353-1361.
Kaplan, A.P. and Silverberg, M. (1988). Mediators of inflammation: An overview. 
Methods Enzymol., 163, 3-23.
Kaplan, A.P., Silverberg, M., Ghebrehiwet, B., Atkins, P. and Zweiman, B. (1989). 
The kallikrein-kinin system in inflammation. Adv. Exp. Med. Biol., 247A, 125-136.
Kato, H., Nagasawa, S. and Iwanaga, S. (1981). HMW and LMW kininogens. 
Methods Enzymol., 80, 172-198.
Kimura, M., Sueyoshi, T., Morita, T., Tanaka, K. and Iwanaga, S. (1989). 
Omitho-kininogen and ornitho-kinin: isolation, characterization and chemical 
structure. Adv. Exp. Med. Biol., 247A, 359-367.
118
Kizuki, K., Shimamoto, Y., Ikekita, M. and Moriya, H. (1986). An inactive form of 
kallikrein in human urine. Adv. Exp. Med. Biol., 198A, 329-337.
Kraut, H., Frey, E.K. and Bauer, E. (1928). Uber ein neues Kreislaufhormon. II. 
Mitteilung. Z. Physiol. Chemie, 175, 97-114; through Biol. Abstr., (1929), 3, 1414; 
Physiol. Abstr., (1928-29), 13, 2599.
Kraut, H., Frey, E.K. and Werle, E. (1930a). Der Nachweis eines Kreislaufhormons 
in der Pankreadriise. Z. Physiol. Chemie, 189, 97-106: through Physiol. Abstr., 
(1930-31), 15, 3178.
Kraut, H., Frey, E.K. and Werle, E. (1930b). Uber die Inaktivierung des Kallikreins. 
Z. Physiol. Chemie, 192, 1-21; through Physiol. Abstr., (1931-32), 16, 529.
Kwiatkowski, H. (1941). Observations on the relation of histamine to reactive 
hyperaemia. J. Physiol., 100, 147-158.
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature (London), 227, 680-665.
Lembeck, F., Griesbacher, T., Eckhadt, M., Henke, S., Breiphohl, G. and Knolle, J. 
(1991). New, long-acting, potent bradykinin antagonists. Br. J. Pharmacol., 102, 
297-304.
Loewi, O. (1921). Uber humorale ubertragbarkeit der herznervenwirkung. Pfleugers 
Arch. Ges. Physiol., 189, 239-242.
Lowry, O.H., Rosenbrough, N.J., Farr, A.L. and Randall, R.J. (1951). Protein 
measurement with the Folin phenol reagents. J. Biol. Chem., 193, 265-275.
Lu, H.S., Lin, F.-K., Chao, L. and Chao, J. (1989). Human urinary kallikrein. 
Complete amino acid sequence and sites of glycosylation. Int. J. Peptide Protein 
Res., 33, 237-249.
MacDonald, R.J., Margolius, H.S. and Erdos, E.G. (1988). Molecular biology of 
tissue kallikrein. Biochem. J., 253, 313-321.
Macintosh, F.C. (1986). Notes. In: Gaddum, J.H. Vasodilator substances o f the 
tissues. 50th Anniversary edition. 1986. Cambridge: Cambridge University Press. 
Originally published in German as "Gefasserweiternde Stoff der Gewebe”. 1936. 
Leipzig, pp 210-217.
Magnus, R. (1904). Verusche am uberlebenden Diinndarm von Saugethieren. Erste 
Mitth. Pfliigers Arch. Ges. Physiol., 102, 123-151.
Mandle, R.J., Colman, R.W. and Kaplan, A.P. (1976). Identification of prekallikrein 
and high-molecular-weight kininogen as a complex in human plasma. Proc. Natl. 
Acad. Sci. U.S.A., 73, 4179-4183.
119
Mandle, R., Jr. and Kaplan, A.P. (1977). Hageman factor substrates. Human plasma 
kallikrein: Mechanism of activation in Hageman factor-dependent fibrinolysis. J. 
Biol. Chem., 252, 6097-6104.
Manning, D.C., Snyder, S.H., Kachur, J.F., Miller, R.J. and Field, M. (1982). 
Bradykinin receptor-mediated chloride secretion in intestinal function. Nature, 299,
256-259.
Manning, D.C. and Snyder, S.H. (1986). 3H-bradykinin binding site localization in 
guinea-pig urinary system. Adv. Exp. Med. Biol., 198A, 563-569.
Marceau, F., Ussier, A., Regoli, D. and Giroud, J.P. (1983). Pharmacology of 
kinins: their relevance to tissue injury and inflammation. Gen. Pharmacol., 14,
209-229.
Margolius, H.S. (1989). Tissue kallikreins and kinins: Roles in human disease and 
target for new drug development. Adv. Exp. Med. Biol., 247A, 1-6.
Marin-Grez, M., Schaechtelin, G. and Hermann, K. (1982). Kininogenase activity in 
rat uterus homogenates. Hoppe-Seyler’s Z. Physiol. Chem., 363, 1359-1364.
Mathias, A.P. and Schachter, M. (1958). The chromatographic behaviour of wasp 
venom kinin, kallidin and bradykinin. Br. J. Pharmacol. Chemother., 13, 326-329.
Miwa, I., Erdos, E.G. and Seki, T. (1969). Seperation of peptide components of 
urinary kinin (substance Z). Proc. Soc. Exp. Biol. Med., 131, 768-772.
Moncada, S., Gryglewski, R.J., Bunting, S. and Vane, J.R. (1976). An enzyme 
isolated from arteries transforms prostaglandin endoperoxides to an unstable 
substance that inhibits platelet aggregation. Nature, 263, 663-665.
Morichi, S., Sako, E., Hasewaga, E., Suyama, T. and Moriya, H. (1984). Large scale 
purification and characterization of human urinary kallikrein. Chem. Pharm. Bull., 
32, 1152-1162.
Moriwaki, C. and Fujimori, H. (1979). Effect of kallikrein-kinin system on ion 
transport across rat small intestine. Adv. Exp. Med. Biol., 120A, 461-471.
Moriwaki, C., Fujimori, H., Moriya, H. and Kizuki, K. (1977a). Studies on 
kallikreins. IV. Enhancement of valine transport across the rat small intestine. 
Chem. Pharm. Bull., 25, 1174-1178.
Moriwaki, C., Fujimori, H. and Toyono, Y. (1977b). Intestinal kallikrein and the 
influence of kinin on the intestinal transport. In: Kininogenases: Kallikrein 4. ed. 
Haberland, G.L., Rohen, J.W. and Suzuki, T. pp 283-290. Stuttgart-New York: F.K. 
Schauttauer.
Moriya, H., Ikekita, M. and Kizuki, K. (1983). Some aspects of carbohydrate
120
contents in glandular kallikrein. Adv. Exp. Med. Biol., 156A, 309-316.
Movat, H.Z. (1978). The kinin system: Its relationship to blood coagulation, 
fibrinolysis and the formed elelments of the blood. Rev. Physiol. Biochem. 
Pharmacol., 84, 143-202.
Movat, H.Z. (1979). The plasma kallikrein-kinin system and its interrelationship 
with other components of blood. Handb. Exp. Pharmacol., 25 suppl., 1-89.
Mulholland, F., Ashford, A. and Baily, G.S. (1986). Initial observations of a rat 
kallikrein-like enzyme associated with the plasma membranes of rat adipocytes. 
Adv. Exp. Med. Biol., 198A, 41-46.
Miiller-Esterl, W. and Fritz, H. (1984). Human kininogens and their function in the 
kallikrein-kinin systems. Adv. Exp. Med. Biol., 167, 41-62.
Miiller-Esterl, W., Iwanaga, S. and Nakanishi, S. (1986). Kininogens revisited. 
Trends Biochem. Sci., 11, 336-339.
Musch, M.W., Miller, R.J., Field, M. and Siegel, M. (1982). Stimulation of colonic 
secretion by lipoxygenase metabolites of arachidonic acid. Science, 217, 1255-1256.
Musch, M.W., Kachur, J.F., Miller, R.J., Field, M. and Stoff, J.S. (1983). 
Bradykinin-stimulated electrolyte secretion in rabbit and guinea-pig intestine. 
Involvement of arachidonic acid metabolites. J. Clin. Invest., 71, 1073-1083.
Nasjletti, A. and Malik, K.U. (1980). Interrelationship of the renal kallikrein-kinin 
and prostaglandin systems. In: Enzymatic release o f vasoactive peptides, ed. Gross, 
F. and Vogel, G. pp 323-333. New York: Raven Press.
Nolly, H. and Lama, M.C. (1982). 'Vascular kallikrein’: a kallikrein-like enzyme 
present in vascular tissue of the rat. Clin. Sci., 63, 249s-251s.
Nolly, H., Scicli, A.G., Scicli, G. and Carretero, O.A. (1985). Characterization of a 
kininogenase from rat vascular tissue resembling tissue kallikrein. Circ. Res., 56, 
816-821.
Nolly, H., Scicli, A.G., Scicli, G., Lama, M.C., Guercio, A.M. and Carretero, O.A. 
(1986). Kininogenase from rat vascular tissue. Adv. Exp. Med. Biol., 198A, 11-17.
Nustad, K. and Pierce, J.V. (1974). Purification of rat urinary kallikreins and their 
specific antibody. Biochemistry, 13, 2312-2319.
Nustad, K., Gautvik, K.M. and Pierce, J.V. (1976). Glandular kallikreins: 
Purification, characterization, and biosynthesis. In: Chemistry and biology o f the 
kallikrein-kinin system in health and disease, ed. Pisano, JJ . and Austen, K.F. pp 
77-92. Washington D.C.: Government Printing Office.
121
Nustad, K., Johansen, L., 0stravik, T.B. and Pierce, J.V. (1980). Submandibular and 
kidney kallikreins: Biochemistry, origin, and function. In: Enzymatic release of 
vasoactive peptides, ed. Gross, F. and Vogel, G. pp 89-98. New York: Raven Press.
Odya, C.E., Goodfriend, T.L. and Pena, C. (1980). Bradykinin receptor-like binding 
studied with iodinated analogues. Biochem. Pharmacol., 29, 175-185.
Okamoto, H. and Greenbaum, L.M. (1983). Isolation and structure of T-kinin. 
Biochem. Biophys. Res. Comm., 112, 621-628.
Okamoto, H. and Greenbaum, L.M. (1984). Isolation and properties of two rat 
plasma T-kininogens. Adv. Exp. Med. Biol., 198A, 69-75.
Orce, C.G., Carretero, O.A., Scicli, G. and Scicli, A.G. (1989). Kinins contribute to 
the contractile effects of rat glandular kallikrein on the isolated rat uterus. J. 
Pharmacol. Exp. Ther., 249, 470-475.
Overlack, A., Scicli, A.G. and Carretero, O.A. (1983). Intestinal absorption of 
glandular kallikrein in the rat. Am. J. Physiol., 244, G689-G694.
Oxford English Dictionary. (1989). Prepared by Simpson, J.A. and Weiner, E.S.C.. 
2nd edition. Oxford: Clarendon Press.
Pemow, B. (1983). Substance P. Pharmacol. Revs., 35, 85-141.
Piper, P.J. and Vane, J.R. (1969). Release of additional factors in anaphylaxis and 
its antagonism by anti-inflammatory drugs. Nature (London), 233, 29-35.
Pisano, J.J. (1970). Kinins of non-mammalian origin. Handb. Exp. Pharmacol., 25, 
589-595.
Pisano, J.J. (1975). Chemistry and biology of the kallikrein-kinin system. In: 
Proteases and biological control, ed. Reich, E., Rifkin, D.B. and Shaw, E. pp 
199-222. Cold Spring Harbor Laboratory.
Pisano, J.J. (1979). Kinins in nature. Handb. Exp. Pharmacol., 25 suppl., 273-285.
Polivka, E., Maier, M. and Binder, B.R. (1981). Purification and characterization of 
a kallikrein-like kininogenase from pig pituitary glands. Agents Actions Suppl., 9, 
153-156.
Rabito, S.F., Scicli, A.G. and Carretero, O.A. (1980). Immunoreactive glandular 
kallikrein in plasma. In: Enzymatic release o f vasoactive peptides, ed. Gross, F. and 
Vogel, G. pp 247-256. New York: Raven Press.
Rabito, S.F., Scicli, A.G., Kher, V. and Carretero, O.A. (1982). Immunoreactive 
glandular kallikrein in rat plasma: a radioimmunoassay for its determination. Am. J. 
Physiol., 242, H602-H610.
122
Regoli, D., Barabe, J. and Park, W.K. (1977). Receptors for bradykinin in rabbit 
aortae. Can. J. Physiol. Pharmacol., 55, 855-867.
Regoli, D., Marceau, F. and Barabe, J. (1978). De novo formation of vascular 
receptors for bradykinin. Can. J. Physiol. Pharmacol., 56, 674-677.
Regoli, D. and Barabe, J. (1980). Pharmacology of bradykinin and related kinins. 
Pharmacol. Rev., 32, 1-46.
Regoli, D. and Barabe, J. (1988). Kinin receptors. Methods Enzymol., 163, 210-230.
Regoli, D., Drapeau, G., Rovero, P., D’Orleans-Juste, P. and Barabe, J. (1986a). The 
actions of kinin antagonists on Bj and B2 receptor systems. Eur. J. Pharmacol., 123, 
61-65.
Regoli, D., Drapeau, G., Rovero, P., Dion, S., Rhaleb, N.-E., Barabe, J., 
D ’Orleans-Juste, P. and Ward, P. (1986b). Conversion of kinins and their 
antagonists into Bj receptor activators or blockers in isolated vessels. Eur. J. 
Pharmacol., 127, 219-224.
Regoli, D., Rhaleb, N.-E., Dion, S. and Drapeau, G. (1990). New selective receptor 
antagonists and bradykinin B2 receptor characterization. Trends Pharmacol. Sci., 11, 
156-161.
Rocha e Silva, M. (1939). The pharmacology of trypsin. Arquivos do Instituto 
Biologico, 10, 93-128.
Rocha e Silva, M. (1960). Biochemistry and pharmacology of bradykinin. In: 
Polypeptides which affect smooth muscles and blood vessels, ed. Schachter, M. pp
210-231. London: Pergamon Press.
Rocha e Silva, M. (1975). Bradykinin and bradykininogen. Introductory remarks. 
Life Sci., 16, 782.
Rocha e Silva, M. (1976a). Past, present and future of kinins. Introductory remarks. 
Adv. Exp. Med. Biol., 70, 1-3
Rocha e Silva, M. (1976b). Bradykinin and bradykininogen - introductory remarks. 
In: Chemistry and biology o f the kallikrein-kinin system in health and disease, ed. 
Pisano, J.J. and Austen, K.F. pp 7-15. Washington D.C.: Government Printing 
Office.
Rocha e Silva, M., Beraldo, W.T. and Rosenfeld, G. (1949). Bradykinin, a 
hypotensive and smooth muscle stimulating factor released from plasma globulin by 
snake venoms and trypsin. Am. J. Physiol., 156, 261-273.
Roffman, S. and Greenbaum, L.M. (1979). Properties of leukokininogen isolated 
from human neoplastic ascites. Biochem. Pharmacol., 28, 1043-1050.
123
Roscher, A.A., Maganiello, V.C., Jalsema, C.L. and Moss, J. (1983). Receptors for 
bradykinin in intact cultured human fibroblasts: Identification and characterization 
by direct binding study. J. Clin. Invest. 72, 626-635.
Sakamoto, W., Satoh, F., Nagasawa, S., Handa, H., Suzuki, S., Uehara, S. and 
Hirayama, A. (1989). A novel kinin, Met-Ile-Ser-Bradykinin (Met-T-kinin) is 
released from T-kininogen by an acid protease of granulatomous tissues in rats. Adv. 
Exp. Med. Biol., 247B, 103-108.
Schachter, M. (editor) (1960). Polypeptides which affect smooth muscles and blood 
vessels. London: Pergamon Press.
Schachter, M. (1969). Kallikreins and kinins. Physiol. Rev., 49, 509-547.
Schachter, M. (1979). Biological and physiological considerations arising from 
cellular localization and other recent observations on kallikreins. Adv. Exp. Med. 
Biol., 120B, 249-254.
Schachter, M. (1980a). Kallikreins (kininogenases) - A group of serine proteases 
with bioregulatory actions. Pharmacol. Rev., 31, 1-17.
Schachter, M. (1980b). Kallikrein localization and its significance. In: Enzymatic 
release o f vasoactive peptides, ed. Gross, F. and Vogel, G. pp 151-160. New York: 
Raven Press.
Schachter, M. and Thain, E.M. (1954). Chemical and pharmacological properties of 
the potent, slow contracting substance (kinin) in wasp venom. Br. J. Pharmacol. 
Chemother., 9, 352-359.
Schachter, M., Peret, W., Billing, A.G. and Wheeler, G.D. (1983). Immunological 
localization of the protease, kallikrein, in the colon. J. Histochem. Cytochem., 28, 
1255-1260.
Schachter, M., Peret, M.W., Moriwaki, C., Wheeler, G.D., Matthews, R.W., Mehta, 
J.G. and Labedz, T. (1986). The varied localization and functional significance of 
kallikrein-like enzymes in salivary glands, pancreas, colon, sex glands and 
spermatozoa, including evidence for the presence of nerve growth factor (NGF) in 
bull sperm acrosome. Adv. Exp. Med. Biol., 198A, 1-10.
Schachter, M., Uchida, Y., Longridge, D.J., Labedz, T., Whalley, E.T., Vavrek, R J. 
and Stewart, J.M. (1987). New synthetic antagonists of bradykinin. Br. J. 
Pharmacol., 92, 851-855.
Schroder, E. (1970). Structure-activity relationships of kinins. Handb. Exp. 
Pharmacol., 25, 324-350.
Scicli, G., Nolly, H., Carretero, O.A. and Scicli, A.G. (1989). Glandular 
kallikrein-like enzyme in adrenal glands. Adv. Exp. Med. Biol., 247B, 217-222.
124
Sealy, J.E (1980). Prorenin activation by renal and plasma kallikreins. In: 
Enzymatic release o f vasoactive peptides, ed. Gross, F. and Vogel, G. pp 117-133. 
New York: Raven Press.
Seki, T. Nakajima, T. and Erdos, E.G. (1972). Colon kallikrein, its relationship to 
the plasma enzyme. Biochem. Pharmacol., 21, 1227-1235.
Shimamoto, K., Tanaka, S., Nakao, T., And, T., Nakahashi, Y., Sakuma, M. and 
Miyahara, M. (1979). Measurement of urinary kallikrein activity by kinin 
radioimmunoassay. Jap. Circ. 43, 147-152.
Shimojo, N., Chao, J., Chao, L., Margolius, H.S. and Mayfield, R.K. (1987). 
Identification and characterization of a tissue kallikrein in rat skeletal muscles. 
Biochem. J., 243, 773-778.
Silverberg, M. and Kaplan, A.P. (1988). Prekallikrein. Methods Enzymol., 163, 
85-95.
Siqueira, G., Dias da Silva, W. and Beraldo, W.T. (1970). A kinin-like forming 
enzyme in saliva presenting a potent oxytocic activity. Adv. Exp. Med. Biol., 8, 
137-140.
Spragg, J. (1983). Characterization of purified human latent kallikrein. Adv. Exp. 
Med. Biol., 156A, 393-398.
Spragg, J. (1988). Latent kallikrein from human urine. Methods Enzymol., 163, 
96-102.
Stewart, J.M. (1979). Chemistry and biologic activity of peptides related to 
bradykinin. Handb. Exp. Pharmacol., 25, 227-272.
Sugo, T., Ikari, N., Iwanaga, S. and Fuji, S. (1980). Functional sites of bovine high 
molecular weight kininogen as a co-factor in kaolin mediated activation of factor 
XII (Hageman factor). Biochemistry, 19, 3215-3220.
Takaoka, M., Okamura, H., Iwamoto, T. and Morimoto, S. (1986). Purification of 
inactive kallikrein from rat urine. Adv. Exp. Med. Biol., 198A, 339-345.
Terragno, N.A. and Terragno, A. (1979). Release of vasoactive substances by 
kinins. Handb. Exp. Pharmacol., 25 suppl., 401-426.
Trautschold, I., Werle, E. and Zickgraf-Rudel, G. (1967). Trasylol. Biochem. 
Pharmacol., 16, 59-72.
Tschesche, H., Mair, G., Godec, G., Fielder, F., Ehret, W., Hirschauer, C., Lemon, 
M., Fritz, H., Schmidt-Kastner, G. and Kutzbach, C. (1979). The primary structure 
of porcine glandular kallikrein. Adv. Exp. Med. Biol., 120A, 245-260.
125
Uchida, K., Kushiro, H., Hitomi, Y., Niinobe, M. and Fujii, S. (1979). Rat stomach 
kallikrein: Its purification and properties. Adv. Exp. Med. Biol., 120A, 291-303.
Uchida, K., Kushiro, H., Hitomi, Y., Niinobe, M. and Fujii, S. (1981). Rat thyroid 
gland kallikrein: Its purification and properties. Agents Actions Suppl., 9, 167-172.
Uetsuji, S., Yamamura, M., Yamamoto, M., Uchida, K., Kushiro, H., Kodama, J. 
and Fujii, S. (1981). Human stomach kallikrein. Agents Actions Suppl., 9, 137-142.
Vane, J.R. (1957). A sensitive method for the assay of 5-hydoxytryptamine. Br. J. 
Pharmacol. Chemother., 12, 344-349.
Vane, J.R. (1958). The blood-bathed isolated organ: a method of testing the 
circulating blood for active substances. J. Physiol., 143, 75P-76P.
Vane, J.R. (1964). The use of isolated organs for detecting active substances in the 
circulating blood. Br. J. Pharmacol. Chemother., 23, 360-373.
Vane, J.R. (1966). The estimation of catecholamines by biological assay. 
Pharmacol. Revs., 18, 317-324.
Vane, J.R. (1969). The release and fate of vaso-active hormones in the circulation. 
Br. J. Pharmacol., 35, 209-242.
Vane, J.R. (1983). Adventures and excursions in bioassay - the stepping stones to 
prostacyclin. Postgrad. Med. J., 59, 743-758.
Vio, C.P., Silva, R.H. and Powers, C.A. (1989). Immunoctochemical identification 
of glandular kallikreins in the rat anterior pituitary. Adv. Exp. Med. Biol., 247B, 
183-188.
Vogel, R. (1979). Kallikrein inhibitors. Handb. Exp. Pharmacol., 25 suppl., 
163-225.
Vogel, R. and Werle, E. (1970). Kallikrein inhibitors. Handb. Exp. Pharmacol., 25, 
213-249.
Vogt, W. (1966). The presence of two separate kinin-forming systems in human and 
other plasma. In: Hypotensive peptides, ed. Erdos, E. G., Back, N. and Sicuteri, F. 
pp 184-192. Berlin: Springer-Verlag.
Vogt, M. (1970). John Henry Gaddum, 1900-1965. Rev. Physiol. Biochem. 
Pharmacol., 82, 1-5.
Walker, J.M. (1967). Oxytocin. In: Hormones in blood. Volume 1. ed. Gray, C.H. 
and Bacharach, A.L. pp 129-144. 2nd edition. London: Academic Press.
126
Ward, P.E. and Margolius, H.S. (1979). Renal and urinary kallikreins. Handb. Exp. 
Pharmacol., 25 suppl., 525-548.
Webster, M.E. (1966). Report of the committee on nomenclature for hypotensive 
peptides. In: Hypotensive peptides, ed. Erdos, E. G., Back, N. and Sicuteri, F. pp 
648-653. Berlin: Springer-Verlag.
Webster, M.E. (1970a). Kallikreins in glandular tissues. Handb. Exp. Pharmacol., 
25, 131-155.
Webster, M.E. (1970b). Recommendations for the nomenclature and units. Handb. 
Exp. Pharmacol., 25, 659-665.
Webster, M.E. and Pierce, J.V. (1963). The nature of the kallidins released from 
human plasma by kallikreins and other enzymes. Ann. N.Y. Acad. Sci., 104, 91-105.
Werle, E. (1936a). Uber die Wirkung einiger Kreislaufstoffe beim Huhn und uber 
eine neue Kreislaufaktive Substanz aus Hiihnerkot. Klin. Wschr., 15, 164-167; 
through Physiol. Abstr., (1936-37), 21, 2623.
Werle, E. (1936b). Uber Kallikrein aus Blut. Biochem. Z., 287, 235-261; through 
Physiol. Abstr., (1937-38), 22, 216.
Werle, E. (1936c). Die Wirkung des Kallikrein (Padutin) auf den isolierten Darm. 
Klin. Wschr., 15, 848-849; through Physiol. Abstr., (1936-37), 21, 2623.
Werle, E. (1937). Uber die Wirkung des kallikreins auf den Darm und uber eine 
darmkontrahierende Substanz. Biochem. Z., 281, 217-233.
Werle, E. (1955). The chemistry and pharmacology of kallikrein and kallidin. In: 
Polypeptides which stimulate plain muscle, ed. Gaddum, J.H. pp 20-27. Edinburgh: 
E&S Livingstone.
Werle, E. (1970). Discovery of the most important kallikreins and kallikrein 
inhibitors. Handb. Exp. Pharmacol., 25, 1-6.
Werle, E. (1975). A short history of the kallikrein-kinin system. Life Sci., 16, 
781-782.
Werle, E. (1976). A short history of the kallikrein-kinin system. In: Chemistry and 
biology o f the kallikrein-kinin system in health and disease, ed. Pisano, J.J. and 
Austen, K.F. pp 1-6. Washington D.C.: Government Printing Office.
Werle, E. and Hurter, J. (1936). Uber Omitho-kallikrein. I. Mitteilung uber 
kreislaufaktive Substanzen der Vogel. Biochem. Z., 285, 175-191; through Physiol. 
Abstr., (1936-37), 21, 3238.
127
Werle, E. and von Roden, P. (1936). Uber das Vorkommen von Kallikrein in den 
Speicheldriisen und im Mundspeichel. Biochem. Z., 286, 213-219; through Physiol. 
Abstr., (1937-38), 22, 2805.
Werle, E., Gotze, W. and Keppler, A. (1936). Uber die Wirkung des Kallikreins auf 
den isolierten Darm und liber eine neue darmkontrahierenden Substanz. Biochem. Z., 
289, 217-233; through Physiol. Abstr., (1937-38), 22, 3998.
Werle, E. and Berek, U. (1948). Zur kenntnis des kallikreins. Agnew. Chem., 60(A), 
53.
Werle, E. and Berek, U. (1950). Uber kallidin. Biochem. Z., 320, 136-145.
Werle, E. and Maier, L. (1952). Uber die chemische und pharmakologische 
unterscheidung von kallikrein verschiedener herkunft. Biochem. Z., 323, 279-283.
Werle, E. and Vogel, R. (1961). Uber die Freisetzung einer Kallikreinartigen 
Substanz aus Extraken verschiedener Organe. Arch. Int. Pharmacodyn., 131,
257-261.
Werle, E. and Trautschold, I. (1963). Kallikrein, kallidin, kallikrein inhibitors. Ann. 
N.Y. Acad. Sci., 104, 117-129.
Werle, E., Hochstrausser, K. and Trautschold, I. (1966). Studies of bovine plasma 
kininogen, omitho-kallikrein, and ornitho-kinin. In: Hypotensive peptides, ed. 
Erdos, E. G., Back, N. and Sicuteri, F. pp 105-115. Berlin: Springer-Verlag.
Whalley, E.T. (1979). Action of kallikrein and trypsin on isolated rat uterus. Acta 
Endocr. Suppl., 225, 118.
Williams, T J. (1979). Prostaglandin E2, prostaglandin I2 and the vascular changes 
in inflammation. Br. J. Pharmacol., 65, 517-524.
Woodbury, R.G., Gruzenski, G.M. and Lagunoff, D. (1978). Immunofluorescent 
localization of a serine protease in rat small intestine. Proc. Natl. Acad. Sci. USA, 
75, 2785-2789.
Woodley, C.M., Chao, J., Margolius, H.S. and Chao, L. (1985). Specific 
identification of tissue kallikrein in exocrine tissues and in cell-free translation 
products with monoclonal antibodies. Biochem. J., 231, 721-728.
Yakada, Y, Skidgel, R.A. and Erdos, E.G. (1985). Purification of human urinary 
prokallikrein. Identification of the site of activation by the metalloproteinase 
thermolysin. Biochem. J., 232, 851-858.
Yanaihara, N., Okaru, Y., Mochizuki, T., Yanihara, C., Iwanaga,T. and Fujita, T. 
(1983). Comparative immunochemical characterization of various kallikreins. Adv. 
Exp. Med. Biol., 156A, 661-670.
128
Yang, H.Y.T. and Erdos, E.G. (1967). Second kininase in blood plasma. Nature 
(London), 215, 1402-1403.
Zeitlin, I.J. (1971). Pharmacological characteristics of kinin-forming activity in rat 
intestinal tissue. Br. J. Pharmacol., 42, 648P-649P.
Zeitlin, I.J. (1972). Rat intestinal kallikrein. Adv. Exp. Med. Biol., 21, 289-296.
Zeitlin, I.J., Singh, Y.N., Lembeck, F. and Theiler, M. (1976). The molecular weight 
of plasma and intestinal kallikreins in rats. Naunyn-Schmiedeberg’s Arch. 
Pharmacol., 293, 159-161.
Zeitlin, I.J., Al-Dhahir, H.A.R., Cook, S., Currie, A. and Donovan, K. (1986). Bile 
acids and the intestinal kallikrein-kinin system. Adv. Exp. Med. Biol., 198A, 47-53.
129
APPENDIX
Publication: Characterization of Gaddum's substance R 
British Journal o f  Pharmacology (1991), 102, 926-930
130
Br. J. Pharmacol. (1991), 102, 926-930 ©  Macmillan Press Ltd, 1991
Characterization of Gaddum’s substance R
XG J. Douglas, K.I. Williams & 2R.J. Flower
Pharmacology Group, School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY
1 When the isolated small intestine of the rat is perfused via the mesenteric artery, an oxytocic principle 
(Gaddum’s substance R) is released which is detectable in the perfusate after 30min and is present in 
samples collected 8 h later.
2 The oxytocic activity of substance R is lost after boiling but is unaffected by treatment with thioglycol- 
ate. Furthermore, atropine, methysergide and indomethacin failed to antagonize uterine contractions to 
substance R.
3 Neither substance R nor urinary kallikrein alone induce a contraction of the guinea-pig isolated ileum. 
However, in the presence of kininogen both substance R and urinary kallikrein produce a slow and 
prolonged contraction of the guinea-pig ileum.
4 The oxytocic and kininogenase properties of both substance R and urinary kallikrein are inhibited by 
Trasylol.
5 Soy bean trypsin inhibitor (SBTI) selectively inhibited both the oxytocic and the kininogenase activ­
ities of substance R but not those of urinary kallikrein.
6 Gel filtration of substance R resolved a single peak of oxytocic activity with an estimated molecular 
weight of 40 kDa.
7 We conclude that substance R is a kininogenase enzyme which may be distinguished from plasma 
kallikrein by its molecular weight and from urinary kallikrein by its susceptibility to SBTI. The exact 
nature of this enzyme remains to be elucidated.
Keywords: Substance R; kallikrein; perfused small intestine; kininogenase
Introduction
In 1953 Gaddum published a highly cited paper in which he 
described for the first time, the superfusion technique. Less 
well-known is that in this paper Gaddum also reported the 
production by the perfused rat intestine of a factor with oxy­
tocic activity. The results he obtained suggested that this 
factor was a protein. We have recently confirmed these obser­
vations (Douglas et a i, 1988). Furthermore, we observed that 
the spectrum of pharmacological actions of ‘substance R’ was 
similar, but not identical, to those of a tissue kallikrein.
Methods
Collection o f  substance R
Male Wistar rats (200-300 g) were first anaesthetized with 
ether, and heparin (1000 u) was administered by a tail vein to 
prevent clotting during the perfusion. Following laparotomy 
the small intestine was ligated at the duodenal level, distal to 
the pancreas and also at the ileo-caecal junction. The superior 
mesenteric artery was cannulated and all other vessels, with 
the exception of the hepatic portal vein, were tied off. The 
intestine was sectioned anterior to the duodenal ligature and 
distal to the caecal ligature. The intact mesenteric bed was 
then removed, care being taken to exclude all pancreatic 
tissue, suspended in a heated jacket and perfused with oxygen­
ated Tyrode solution (37°C, 0.4 ml min-1 ) through the mesen­
teric artery. Effluent from the hepatic portal vein was either 
collected for consecutive 20 min periods over 6 h and aliquots 
of each fraction were assayed for oxytocic activity, or, after a 
30min equilibration period, perfusate, collected over 6h, was 
pooled, lyophylized and stored at — 20°C. For preparative 
purposes pooled perfusates from three experiments were used.
1 Author for correspondence.
2 Present address: Departm ent of Biochemical Pharmacology, St Bar­
tholomew’s Hospital Medical College, Charterhouse Square, London 
EC1M 6BQ.
The pooled perfusates from three such preparations were 
then dialysed overnight against 10 volumes of ammonium 
bicarbonate (50 m M , pH 7.8). The high molecular weight 
residue was freeze-dried and stored at — 20°C. The lyo­
phylized perfusate from nine intestinal preparations was 
redissolved in 6 ml of Trisbuffer (50 m M , pH 7.5) and filtered 
before application to the ion-exchange column.
A ssay o f  oxytocic activity
Segments of stilboestrol-primed rat uterus superfused with de 
Jalon’s solution (30°C, 5 ml min-1 ) were used for the assay of 
oxytocic activity of samples. Volumes of between 10 and 
150 /zl were injected into the stream of superfusion fluid above 
the tissue.
Assay o f  kinin-releasing activity
The kinin-releasing activity of substance R and kallikrein was 
assayed on the guinea-pig isolated ileum. In these experiments 
a 2cm length of ileum was suspended in an 8 ml organ bath 
and bathed in oxygenated Tyrode solution containing captop- 
ril (100/^gml- 1 at 37°C). Bradykinin was used as a standard.
Ion-exchange chromatography
Ion-exchange chromatography of the soluble intestinal extract 
was performed by use of DEAE-Sepharose. The sample was 
applied to the column (2.6 x 30cm), equilibrated in Tris buffer 
(50 m M , pH 7.5). Fractions of 5 ml were eluted at a flow rate of 
0.4 ml min - 1 by a linear salt gradient of 0-1 m  sodium chloride 
and assayed for oxytocic activity before the absorbance at 
280 nm was measured. Fractions containing oxytocic activity 
were then pooled, dialysed against 50 volumes of ammonium 
bicarbonate (50 m M , pH 7.8) for 12-18 h and lyophilized.
Gel filtra tion
Gel filtration of the oxytocic principle was carried out rou­
tinely on a calibrated Sephacryl S-300 column (2.6 x 90cm). 
The column was equilibrated with phosphate-buffered saline
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(50 m M , pH 7.5 (PBS) and 5 ml of soluble intestinal extract was 
applied to the column. The sample was eluted at a flow rate of 
0.4 ml min _1 and 5 ml fractions were collected. Fractions were 
then assayed for oxytocic activity and the absorbance at 
280 nm measured.
Estimation of the molecular weight of the oxytocic principle 
was made on a Sephacryl S-200 column (2.6 x  90 cm), cali­
brated with molecular weight markers, under the conditions 
described above and the fraction containing the peak oxytocic 
activity was determined by assay on the superfused isolated 
uterus of the rat.
U rinary kallikrein
Initially, crude preparations of rat urinary kallikrein were 
made by desalting rat urine on a Sephadex G-25 (PD-10) 
column equilibrated with PBS. Later, for comparative pur­
poses, rat urinary kallikrein was prepared from urine collected 
overnight from male Wistar rats. The urine from individual 
rats was pooled and filtered before an overnight dialysis 
against PBS. The dialysed sample was then stored at — 20°C. 
A partially purified preparation or urinary kallikrein was 
obtained by the same preparative and assay techniques 
employed in the isolation of substance R.
M aterials
Reagents and drugs were obtained from the following sources: 
aprotinin (Trasylol), (Bayer UK Ltd); H-D-Val-L-Leu-L-Arg-p- 
nitroanilide dichloride (S-2266), (Kabi Vitrum), D-Arg-[Hyp3, 
Thi5,8, D-Phe7]-bradykinin, (Novabiochem); PD-10 columns, 
Sephacryl S-200, Sephacryl S-300 and DEAE-Sepharose, 
(Pharmacia Ltd); methysergide hydrogen maleate, (Sandoz 
UK Ltd), atropine sulphate, bradykinin, carbamylcholine, st­
and <5-chymotrypsin, diethylstilboestrol, heparin sulphate, 
indomethacin, soy bean trypsin inhibitor (SBTI), thioglycolic 
acid, Trizma base, Trizma hydrochloride, and trypsin, 
(Sigma); captopril, (Squibb). Human plasma kininogen was 
kindly donated by Dr K.D. Bhoola, University of Bristol.
Statistical analysis
Data are expressed as mean + s.e.mean. Statistical significance 
was computed by the paired t test or analysis of variance 
(ANOVAR) where appropriate.
ity was not inhibited by addition of atropine (1 0 '6m), methy­
sergide (5.7 x  1 0 '7 m) or indomethacin (1 x  10“5 m) to the 
superfusate. Samples of perfusate possessing substantial oxy­
tocic activity were inactive when tested on the isolated super- 
fused guinea-pig ileum or rat fundic strip preparations. The 
perfusate lost oxytocic activity on heating but was unaffected 
by treatment with thioglycolate which inactivates oxytocin 
(Ames et al., 1950). The material was stable when frozen at 
— 20°C for at least 8 weeks.
Trypsin and chymotrypsin contract the superfused rat 
uterus in a similar way to substance R (Gaddum, 1953). 
Gaddum (1953) found that a preparation of substance R was 
more active, weight for weight, on the rat uterus than crys­
talline preparations of trypsin or chymotrypsin. It has since 
been shown that both trypsin and chymotrypsin sensitize 
certain smooth muscle preparations to bradykinin (Aarsen, 
1968; Edery & Grumfeld, 1969). In the present study it was 
found that trypsin, a-chymotrypsin and <5-chymotrypsin 
induced sensitization to bradykinin of both the superfused rat 
uterus and guinea-pig ileum. However, in each of three experi­
ments, substance R and urinary kallikrein failed to induce sen­
sitization to bradykinin in either of these preparations.
To investigate further the similarity between substance R 
and tissue kallikrein, the effect of inhibitors of kallikrein on 
the oxytocic activities of substance R and urinary kallikrein 
were studied. Addition of the dual plasma and tissue kalli­
krein inhibitor aprotinin (Trasylol, 50-100K iu m l'1), to the 
fluid superfusing the isolated uterus completely inhibited the 
activity of both substance R and urinary kallikrein in six 
experiments (Figure 2). However, the plasma kallikrein inhibi­
tor, soy bean trypsin inhibitor (SBTI, 100//g m l'1), completely 
inhibited the action of substance R on the isolated uterus 
(99.4 ±  0.3%) whereas the oxytocic activity of urinary kalli­
krein was only reduced by 12.6 ±  2.5% (n = 6) (Figure 3). A 
reduction of 9.9 ±  1.8% and 3.0 ±  0.8% was seen in response 
to bradykinin and carbachol respectively (n =  4). The inhibi­
tion of the oxytocic activity of substance R by SBTI was sig­
nificant (P < 0.01, ANOVAR).
Both urinary kallikrein and substance R were found to con­
tract the guinea-pig isolated ileum in the presence of crude 
human plasma kininogen. Use of the selective bradykinin 
receptor antagonist, D-Arg-[Hyp3,Thi5,8,D-Phe7]-bradykinin 
(Regoli et al., 1986; Schachter et al., 1987) inhibited the con­
tractions induced by substance R plus kininogen indicating 
that the generated factor was a kinin. The kinin releasing 
activity was assayed on the guinea-pig isolated ileum in the
Results
The effluent from perfused rat small intestines was found to 
contract the superfused rat uterus in a dose-dependent 
manner. Contractions were delayed in onset (30 s) when com­
pared to those produced by carbachol or bradykinin. When 
consecutive fractions of perfusate were collected, at least 
30 min elapsed before oxytocic activity was detectable (Figure 
1). However, oxytocic activity was released in increasing 
amounts thereafter, reaching a maximum concentration at 
3-4 h, which was sustained for a further 2-3 h. Protein concen­
tration, estimated by the Lowry-Folin method (Lowry et al., 
1951), remained between l-2m gm l” 1 throughout the period 
of perfusion with no correlation between protein concentra­
tion and oxytocic activity.
The characteristics of the oxytocic principle isolated are 
very similar to those described by Gaddum (1953) for sub­
stance R. As Gaddum himself observed, these properties are 
similar to those of (then recently described) kallikrein. To 
compare the activities of the two substances further, we used 
crude preparations of rat urinary kallikrein as a source of 
tissue kallikrein, and compared its properties with those of 
substance R.
The oxytocic principle from the intestinal perfusate was 
non-dialysable (mol. wt. cut off 10-15 kDa) and oxytocic activ­
5 min
i---------------1
 1------------ 1---------- 1------------ 1-----------1
1 2 3 4 5
Time (h)
F ig u re  1 Appearance of oxytocic activity in perfusate from the mes­
enteric bed. The contractions of the superfused rat uterus induced by 
100/^1 aliquots of intestinal perfusate from samples collected over con­
secutive 20 min periods. No oxytocic activity was detectable during 
the first 20 min of perfusion, but thereafter the samples contained 
increasing amounts of activity, reaching a maximum concentration at 
3-4 h. The lower time scale refers to the time of collection of the per­
fusate.
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5 m in
1 cm
W  V V
UK R BK UK R BK 
 Aprotinin 100 u m l -1
F ig u re  2 The effect of aprotinin on the oxytocic activities of urinary 
kallikrein (UK), substance R (R) and bradykinin (BK). Aprotinin com­
pletely inhibited uterine contraction to both kallikrein and substance 
R but did not affect responses to bradykinin.
5 min
1 cm
J  V J  VJV 
UK R CCh UK R CCh 
— SBTI 100 (xg ml
UK R CCh
Figu re  3 The effect of soy bean trypsin inhibitor (SBTI) on the oxy­
tocic activities of urinary kallikrein (UK), substance R (R) and car­
bachol (CCh). SBTI reversibly inhibited the response to substance R 
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Figure 4 The kininogenase activity of substance R. (a) Addition of 
substance R (R) alone to guinea-pig isolated ileum elicited no 
response. However, when kininogen (K) was added, followed by sub­
stance R, a slow contraction was seen which was blocked by the pre­
sence of soy bean trypsin inhibitor (SBTI). (b) Urinary kallikrein (UK) 
induced no effect unless kininogen was also present. The contraction 




















Elution v o lu m e  (ml)
Figure 5 Ion-exchange chromatography of crude intestinal perfusate 
on DEAE-Sepharose. The sample was applied at V =  0 and was 
washed with 100 ml Tris buffer (50 mM, pH 7.5). Substance R was 
eluted with a linear salt gradient at approximately 0.2 m NaCl indi­
cated by the solid bar above the elution profile. The absorbance of 
fractions was measured at 280 nm and oxytocic activity determined on 
the superfused rat uterus.
presence of captopril (4.6 x 10_4m). The ileum was unrespon­
sive to either kallikrein, substance R, or kininogen alone 
(Figure 4a and b). However, in the presence of kininogen, 
addition of kallikrein or substance R to the bath resulted in 
kinin liberation (Figure 4a). Aprotinin (lOOKiuml-1) com­
pletely inhibited the kinin-releasing activity of both urinary 
kallikrein and substance R (n = 3). In contrast, SBTI 
(1 0 0 /tg m l1) produced a small inhibition of the kinin liber­
ation by urinary kallikrein of 13.2 + 6.3% but significantly 
(P < 0.001, paired t test) reduced the release of kinin by sub­
stance R by 80.4 +  5.0% (n =  6) (Figure 4b).
When the selective BK2 bradykinin receptor antagonist 
D-Arg-[Hyp3,Thi5,8,D-Phe7]-bradykinin was added to the 
superfusate (1 x  10~7 m), oxytocic responses to bradykinin, 
kallikrein and substance R were reduced by 63.8 ±  10.7%, 
69.5 ±  11.7%, 85.9 +  8.6%, respectively (P < 0.01, ANOVAR) 
(n = 8). Responses to carbachol were not reduced in the pre­
sence of the antagonist.
Chromatography of crude intestinal perfusate preparations 
on DEAE-sepharose resulted in elution of a single peak of 
activity with approximately 0.2 m NaCl (Figure 5). When the 
active ion-exchange fractions were applied to the Sephacryl 
S-200 column, a single peak of oxytocic activity was resolved 
with a molecular weight of approximately 40kDa (Figure 6). 
There was no detectable oxytocic activity in fractions either 
side of this peak. Preliminary studies with SDS-PAGE 
confirm this estimate of molecular weight. Urinary kallikrein 
was found to have very similar chromatographic properties to 
substance R.
The kininogenase activity of fractions eluted from the Seph­
acryl column was determined by hydrolysis of the chromo- 
genic substrate S-2266 using the endpoint method. A single 
peak of kininogenase activity was found which coincided with 
that of oxytocic activity.
Discussion
Perfusion of the rat isolated small intestine resulted in the lib­
eration of a non-dialysable oxytocic principle which Gaddum
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Figu re  6 Gel filtration on Sephacryl S-200 of pooled oxytocic frac­
tions previously subjected to ion-exchange chromatography. The 
sample was applied at V =  0 and was eluted with 50 mM PBS, pH 7.5. 
The absorbance of fractions was measured at 280 nm and the elution 
profile is shown by the solid line. Oxytocic activity of the eluted frac­
tions was determined on the isolated superfused uterus of the rat, indi­
cated by the dashed line, and is expressed as % maximum contraction 
per n\ eluate. The molecular weight of the substance R peak (# )  cor­
responded to 40 kD when compared to calibrating proteins (O)-
(1953) named substance R. Release of substance R from the 
perfused intestine increased with time from 20 min to approx­
imately 3h after which the oxytocic activity of samples col­
lected remained high and fairly constant. Contraction of the 
rat uterus by substance R was unaffected by atropine, methy- 
sergide or by treatment with thioglycolate. However, boiling 
samples of substance R for 3-4 min resulted in a substantial 
loss of activity. These results are in agreement with the obser­
vations of Gaddum (1953).
Substance R and tissue kallikrein share a number of proper­
ties, as Gaddum himself remarked (1953). Our results with the 
guinea-pig isolated ileum support this, as kallikrein and sub­
stance R only induce contraction of the ileum when kininogen 
is also present, resulting in the generation of a kinin.
The polyvalent protease inhibitor, aprotonin (Trautschold 
et al., 1967) was found to inhibit the oxytocic responses of the
rat uterus to both substance R and urinary kallikrein. 
However, SBTI, which selectively inhibits plasma kallikrein 
(Werle & Maier, 1952; Back & Steger, 1968) blocked 
responses of the uterus to substance R without affecting those 
to urinary kallikrein. The release of kinin from kininogen by 
substance R is likewise inhibited by SBTI and aprotinin, 
whereas kinin release by urinary kallikrein was inhibited by 
the latter only. These results suggest that substance R pos­
sesses kininogenase activity but is unlikely to be a tissue kalli­
krein. An attempt was therefore made to purify and further 
characterise substance R.
Gel filtration chromatography of the oxytocic principle 
obtained from ion exchange chromatography of crude intesti­
nal perfusate resolved a single peak of biological activity with 
a molecular weight corresponding to approximately 40 kDa. 
Preliminary experiments with SDS-PAGE confirm this esti­
mate. As plasma kallikreins have been reported to possess a 
molecular mass of over 100 kDa (see Movat, 1979; Schachter, 
1980) it is unlikely that substance R is a plasma kallikrein. 
The site of release of substance R from the perfused intestine is 
at present unknown. The presence of kininogenase in rat 
vascular tissues has previously been reported (Nolly & Lama, 
1982; Nolly et al., 1985; 1986). However, when the arterial 
vasculature of the mesentery alone was perfused, none of the 
20 min fractions collected over 6 h contained oxytocic activity. 
The kininogenase reported by Nolly and colleagues was not 
inhibited by SBTI. It thus seems probable that substance R is 
released from the intestinal tissue during perfusion, rather 
than the arterial vasculature (unpublished data). The physio­
logical significance of substance R in the gut is not fully 
understood but is the subject of further investigation.
It has recently been demonstrated that contraction of the 
rat isolated uterus by glandular kallikrein is dependent on the 
presence of kininogen within the uterine tissue (Figueiredo et 
al., 1990). This supports the evidence presented by Orce et al. 
(1989) who suggested that the oxytocic activity of glandular 
kallikrein is mediated, at least in part, by kinins generated 
from uterine kininogen. In the present study uterine contrac­
tile responses to both urinary kallikrein and substance R were 
inhibited by the kinin antagonist D-Arg-[Hyp3,Thi5,8,D- 
Phe7]-bradykinin. There was no significant difference between 
the inhibition of responses to bradykinin, urinary kallikrein or 
substance R by this antagonist, suggesting that the oxytocic 
activity of each is mediated by the BK2 kinin receptor. It is 
proposed that substance R shares with glandular kallikrein 
the same mechanism in the contraction of the rat isolated 
uterus.
We conclude that substance R is a proteolytic enzyme with 
a molecular weight of approximately 40kDa which is bio­
chemically related to the tissue kallikrein family of enzymes 
but has an anomalous sensitivity to SBTI. The reasons for this 
discrepancy require further elucidation.
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